A 46 base pair enhancer sequence within the locus activating region is required for induced expression of the gamma - globin gene during erythroid differentiation .
 - Gold: []
 - Pred: []

The locus activating region ( LAR ) , contained within 30 kb of chromatin flanking the human beta - globin gene cluster , has recently been shown to be essential for high level beta - globin gene expression .
 - Gold: []
 - Pred: []

To determine the effect of fragments containing LAR sequences on globin gene expression , mRNA from a marked gamma - globin gene linked to LAR fragments was assayed in stably transfected K562 erythroleukemia cells .
 - Gold: []
 - Pred: []

DNaseI hypersensitive site II ( HS II ) , located 10 . 9 kb upstream of the epsilon - globin gene , was required for high level gamma - globin gene expression .
 - Gold: []
 - Pred: []

We also showed that a 46 bp enhancer element within HS II was necessary and sufficient for the increased gamma - globin gene expression observed with hemin induced erythroid maturation of K562 cells .
 - Gold: []
 - Pred: []

These results localize a distant regulatory element important for activation of globin genes during human erythroid cell maturation .
 - Gold: []
 - Pred: []

Structural and functional cross - talk between a distant enhancer and the epsilon - globin gene promoter shows interdependence of the two elements in chromatin . Structural and functional cross - talk between a distant enhancer and the epsilon - globin gene promoter shows interdependence of the two elements in chromatin .
 - Gold: []
 - Pred: []

We investigated the requirements for enhancer - promoter communication by using the human beta - globin locus control region ( LCR ) DNase I - hypersensitive site 2 ( HS2 ) enhancer and the epsilon - globin gene in chromatinized minichromosomes in erythroid cells . We investigated the requirements for enhancer - promoter communication by using the human beta - globin locus control region ( LCR ) DNase I - hypersensitive site 2 ( HS2 ) enhancer and the epsilon - globin gene in chromatinized minichromosomes in erythroid cells .
 - Gold: []
 - Pred: []

Activation of globin genes during development is accompanied by localized alterations of chromatin structure , and CACCC binding factors and GATA - 1 , which interact with both globin promoters and the LCR , are believed to be critical for globin gene transcription activation .
 - Gold: []
 - Pred: []

We found that an HS2 element mutated in its GATA motif failed to remodel the epsilon - globin promoter or activate transcription yet HS2 nuclease accessibility did not change . We found that an HS2 element mutated in its GATA motif failed to remodel the epsilon - globin promoter or activate transcription yet HS2 nuclease accessibility did not change .
 - Gold: []
 - Pred: []

Accessibility and transcription were reduced at promoters with mutated GATA - 1 or CACCC sites . Accessibility and transcription were reduced at promoters with mutated GATA - 1 or CACCC sites .
 - Gold: []
 - Pred: []

Strikingly , these mutations also resulted in reduced accessibility at HS2 .
 - Gold: []
 - Pred: []

In the absence of a globin gene , HS2 is similarly resistant to nuclease digestion .
 - Gold: []
 - Pred: []

In contrast to observations in Saccharomyces cerevisiae , HS2 - dependent promoter remodeling was diminished when we mutated the TATA box , crippling transcription .
 - Gold: []
 - Pred: []

This mutation also reduced HS2 accessibility .
 - Gold: []
 - Pred: []

The results indicate that the epsilon - globin promoter and HS2 interact both structurally and functionally and that both upstream activators and the basal transcription apparatus contribute to the interaction . The results indicate that the epsilon - globin promoter and HS2 interact both structurally and functionally and that both upstream activators and the basal transcription apparatus contribute to the interaction .
 - Gold: []
 - Pred: []

Further , at least in this instance , transcription activation and promoter remodeling by a distant enhancer are not separable .
 - Gold: []
 - Pred: []

Smad3 activates the Sox9 - dependent transcription on chromatin . Transforming growth factor ( TGF ) - beta has an essential role for the Sry - type high - mobility - group box ( Sox ) - regulated chondrogenesis .
 - Gold: []
 - Pred: []

Chondrogenic differentiation is also controlled by chromatin - mediated transcription .
 - Gold: []
 - Pred: []

We have previously reported that TGF - beta - regulated Smad3 induces chondrogenesis through the activation of Sox9 - dependent transcription .
 - Gold: []
 - Pred: []

However , the cross - talk between TGF - beta signal and Sox9 on chromatin - mediated transcription has not been elucidated .
 - Gold: []
 - Pred: []

In the present study , we investigated the activity of Smad3 , Sox9 , and coactivator p300 using an in vitro chromatin assembly model .
 - Gold: []
 - Pred: []

Luciferase reporter assays revealed that Smad3 stimulated the Sox9 - mediated transcription in a TGF - beta - dependent manner .
 - Gold: []
 - Pred: []

Recombinant Sox9 associated with phosphorylated Smad3 / 4 and recognized the enhancer region of type II collagen gene . Recombinant Sox9 associated with phosphorylated Smad3 / 4 and recognized the enhancer region of type II collagen gene .
 - Gold: []
 - Pred: []

In vitro transcription and S1 nuclease assays showed that Smad3 and p300 cooperatively activated the Sox9 - dependent transcription on chromatin template .
 - Gold: []
 - Pred: []

The combination treatment of phosphorylated Smad3 , Sox9 , and p300 were necessary for the activation of chromatin - mediated transcription .
 - Gold: []
 - Pred: []

These findings suggest that TGF - beta signal Smad3 plays a key role for chromatin remodeling to induce chondrogenesis via its association with Sox9 .
 - Gold: []
 - Pred: []

Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis . Pax5 is an essential regulator of B cell identity and function . Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis . Pax5 is an essential regulator of B cell identity and function .
 - Gold: []
 - Pred: []

Here , we used transgenesis and deletion mapping to identify a potent enhancer in intron 5 of the Pax5 locus . Here , we used transgenesis and deletion mapping to identify a potent enhancer in intron 5 of the Pax5 locus .
 - Gold: []
 - Pred: []

This enhancer in combination with the promoter region was sufficient to recapitulate the B lymphoid expression of Pax5 .
 - Gold: []
 - Pred: []

The enhancer was silenced by DNA methylation in embryonic stem cells , but became activated in multipotent hematopoietic progenitors .
 - Gold: []
 - Pred: []

It contained functional binding sites for the transcription factors PU . 1 , IRF4 , IRF8 , and NF - kappaB , suggesting that these regulators contribute to sequential enhancer activation in hematopoietic progenitors and during B cell development . It contained functional binding sites for the transcription factors PU . 1 , IRF4 , IRF8 , and NF - kappaB , suggesting that these regulators contribute to sequential enhancer activation in hematopoietic progenitors and during B cell development .
 - Gold: []
 - Pred: []

In O O
contrast O O
, O O
the O O
promoter O O
region O O
was O O
repressed O O
by O O
Polycomb O O
group O O
proteins O O
in O O
non O O
- O O
B O O
cells O O
and O O
was O O
activated O O
only O O
at O O
the O O
onset O O
of O O
pro O O
- O O
B O O
cell O O
development O O
through O O
induction O O
of O O
chromatin O O
remodeling O O
by O O
the O O
transcription O O
factor O O
EBF1 O O
. O O

These O O
experiments O O
demonstrate O O
a O O
stepwise O O
activation O O
of O O
Pax5 O O
in O O
early O O
lymphopoiesis O O
and O O
provide O O
mechanistic O O
insights O O
into O O
the O O
process O O
of O O
B O O
cell O O
commitment O O
. O O

The O O
human O O
urocortin O O
2 O O
gene O O
is O O
regulated O O
by O O
hypoxia B-Disease B-Disease
: O O
identification O O
of O O
a O O
hypoxia B-Disease B-Disease
- O O
responsive O O
element O O
in O O
the O O
3 O O
' O O
- O O
flanking O O
region O O
. O O
Ucn2 O O
( O O
urocortin O O
2 O O
) O O
has O O
been O O
shown O O
to O O
exert O O
potent O O
beneficial O O
effects O O
in O O
the O O
cardiovascular O O
system O O
, O O
including O O
inhibition O O
of O O
apoptosis O O
, O O
improvement O O
of O O
cardiomyocyte O O
contractility O O
and O O
decrease O O
of O O
oxidative O O
stress O O
. O O
The O O
human O O
urocortin O O
2 O O
gene O O
is O O
regulated O O
by O O
hypoxia B-Disease B-Disease
: O O
identification O O
of O O
a O O
hypoxia B-Disease B-Disease
- O O
responsive O O
element O O
in O O
the O O
3 O O
' O O
- O O
flanking O O
region O O
. O O
Ucn2 O O
( O O
urocortin O O
2 O O
) O O
has O O
been O O
shown O O
to O O
exert O O
potent O O
beneficial O O
effects O O
in O O
the O O
cardiovascular O O
system O O
, O O
including O O
inhibition O O
of O O
apoptosis O O
, O O
improvement O O
of O O
cardiomyocyte O O
contractility O O
and O O
decrease O O
of O O
oxidative O O
stress O O
. O O

The O O
mechanisms O O
that O O
contribute O O
to O O
the O O
regulation O O
of O O
hUcn2 O O
( O O
human O O
Ucn2 O O
) O O
expression O O
in O O
cardiovascular B-Disease B-Disease
pathologies I-Disease I-Disease
are O O
not O O
known O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
analysed O O
the O O
mechanism O O
by O O
which O O
hypoxia B-Disease B-Disease
, O O
a O O
major O O
stimulus O O
in O O
ischaemic B-Disease B-Disease
heart I-Disease I-Disease
disease I-Disease I-Disease
, O O
regulates O O
Ucn2 O O
gene O O
expression O O
. O O
Hypoxia B-Disease B-Disease
and O O
CPX O O
( O O
ciclopirox O O
olamine O O
) O O
, O O
which O O
prevents O O
proteolytic O O
degradation O O
of O O
HIF O O
( O O
hypoxia B-Disease O
- O O
inducible O O
factor O O
) O O
, O O
significantly O O
increased O O
hUcn2 O O
mRNA O O
levels O O
in O O
TE O O
- O O
671 O O
cells O O
. O O

Gene O O
silencing O O
of O O
endogenous O O
HIF1alpha O O
abolishes O O
this O O
increase O O
. O O
Hypoxia B-Disease B-Disease
and O O
CPX O O
activated O O
a O O
luciferase O O
- O O
linked O O
fragment O O
of O O
the O O
3 O O
' O O
FLR O O
( O O
3 O O
' O O
- O O
flanking O O
region O O
) O O
of O O
the O O
hUcn2 O O
gene O O
containing O O
two O O
putative O O
HREs O O
( O O
hypoxia O B-Disease
- O O
response O O
elements O O
) O O
, O O
HRE1 O O
and O O
HRE2 O O
. O O

Site O O
- O O
directed O O
mutagenesis O O
experiments O O
demonstrated O O
that O O
HRE1 O O
is O O
required O O
for O O
HIF1alpha O O
- O O
dependent O O
luciferase O O
activation O O
. O O

This O O
activation O O
was O O
conserved O O
in O O
constructs O O
with O O
the O O
3 O O
' O O
FLR O O
fragment O O
placed O O
upstream O O
of O O
the O O
luciferase O O
gene O O
, O O
indicating O O
an O O
enhancer O O
function O O
for O O
HRE1 O O
. O O
This O O
activation O O
was O O
conserved O O
in O O
constructs O O
with O O
the O O
3 O O
' O O
FLR O O
fragment O O
placed O O
upstream O O
of O O
the O O
luciferase O O
gene O O
, O O
indicating O O
an O O
enhancer O O
function O O
for O O
HRE1 O O
. O O

Competition O O
assays O O
revealed O O
direct O O
binding O O
between O O
HRE1 O O
and O O
HIF1alpha O O
. O O

Regulation O O
of O O
Ucn2 O O
by O O
hypoxia B-Disease B-Disease
was O O
confirmed O O
in O O
rat O O
neonatal O O
cardiomyocytes O O
and O O
in O O
cardiac O O
- O O
derived O O
H9c2 O O
cells O O
transfected O O
with O O
constructs O O
of O O
the O O
3 O O
' O O
FLR O O
of O O
the O O
hUcn2 O O
gene O O
. O O

In O O
conclusion O O
, O O
our O O
study O O
demonstrates O O
that O O
hypoxia B-Disease B-Disease
induces O O
hUcn2 O O
expression O O
via O O
a O O
specific O O
HRE O O
in O O
the O O
3 O O
' O O
FLR O O
of O O
the O O
hUcn2 O O
gene O O
, O O
which O O
interacts O O
with O O
the O O
transcription O O
factor O O
HIF1alpha O O
. O O
Hypoxia B-Disease B-Disease
- O O
mediated O O
stimulation O O
of O O
cardioprotective O O
Ucn2 O O
may O O
help O O
to O O
preserve O O
cardiac O O
function O O
and O O
prevent O O
apoptosis O O
in O O
ischaemic B-Disease O
conditions I-Disease O
in O O
the O O
heart O O
. O O
In O O
conclusion O O
, O O
our O O
study O O
demonstrates O O
that O O
hypoxia B-Disease B-Disease
induces O O
hUcn2 O O
expression O O
via O O
a O O
specific O O
HRE O O
in O O
the O O
3 O O
' O O
FLR O O
of O O
the O O
hUcn2 O O
gene O O
, O O
which O O
interacts O O
with O O
the O O
transcription O O
factor O O
HIF1alpha O O
. O O
Hypoxia B-Disease B-Disease
- O O
mediated O O
stimulation O O
of O O
cardioprotective O O
Ucn2 O O
may O O
help O O
to O O
preserve O O
cardiac O O
function O O
and O O
prevent O O
apoptosis O O
in O O
ischaemic B-Disease O
conditions I-Disease O
in O O
the O O
heart O O
. O O

Glucocorticoid O O
receptor O O
activates O O
poised O O
FKBP51 O O
locus O O
through O O
long O O
- O O
distance O O
interactions O O
. O O

Recent O O
studies O O
have O O
identified O O
FKBP51 O O
( O O
FK506 O O
- O O
binding O O
protein O O
51 O O
) O O
as O O
a O O
sensitive O O
biomarker O O
of O O
corticosteroid O O
responsiveness O O
in O O
vivo O O
. O O

In O O
this O O
work O O
, O O
we O O
have O O
elucidated O O
the O O
molecular O O
mechanisms O O
underlying O O
the O O
induction O O
of O O
FKBP51 O O
by O O
the O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
in O O
human O O
A549 O O
lung O O
cancer O O
cells O O
showing O O
robust O O
accumulation O O
of O O
FKBP51 O O
mRNA O O
in O O
response O O
to O O
dexamethasone O O
exposure O O
. O O

Our O O
quantitative O O
chromatin O O
immunoprecipitation O O
scans O O
and O O
enhancer O O
activity O O
analyses O O
indicate O O
that O O
activation O O
of O O
the O O
FKBP51 O O
locus O O
by O O
glucocorticoids O O
in O O
vivo O O
is O O
triggered O O
by O O
the O O
loading O O
of O O
GR O O
to O O
enhancers O O
at O O
about O O
34 O O
kb O O
5 O O
' O O
and O O
about O O
87 O O
kb O O
3 O O
' O O
of O O
the O O
transcription O O
start O O
site O O
. O O

Interestingly O O
, O O
the O O
region O O
encompassing O O
these O O
enhancers O O
is O O
bordered O O
by O O
CCCTC O O
- O O
binding O O
factor O O
- O O
and O O
cohesin O O
- O O
binding O O
sites O O
. O O
Interestingly O O
, O O
the O O
region O O
encompassing O O
these O O
enhancers O O
is O O
bordered O O
by O O
CCCTC O O
- O O
binding O O
factor O O
- O O
and O O
cohesin O O
- O O
binding O O
sites O O
. O O

Dexamethasone O O
treatment O O
also O O
decreased O O
the O O
histone O O
density O O
at O O
several O O
regions O O
of O O
the O O
gene O O
, O O
which O O
was O O
paralleled O O
with O O
the O O
occupancy O O
of O O
SWI O O
/ O O
SNF O O
chromatin O O
remodeling O O
complexes O O
within O O
the O O
locus O O
. O O

Moreover O O
, O O
silencing O O
of O O
BRM O O
subunit O O
of O O
the O O
SWI O O
/ O O
SNF O O
complex O O
blunted O O
the O O
glucocorticoid O O
induction O O
of O O
the O O
locus O O
. O O

The O O
proximal O O
promoter O O
region O O
along O O
with O O
the O O
major O O
intronic O O
enhancer O O
at O O
approximately O O
87 O O
kb O O
, O O
at O O
which O O
the O O
GR O O
binding O O
peaked O O
, O O
had O O
elevated O O
levels O O
of O O
histone O O
3 O O
acetylation O O
and O O
H3K4 O O
trimethylation O O
, O O
whereas O O
H3K36 O O
trimethylation O O
more O O
generally O O
marked O O
the O O
gene O O
body O O
and O O
reflected O O
the O O
occupancy O O
of O O
RNA O O
polymerase O O
II O O
. O O

The O O
occurrence O O
of O O
these O O
active O O
chromatin O O
marks O O
within O O
the O O
FKBP51 O O
locus O O
before O O
glucocorticoid O O
exposure O O
suggests O O
that O O
it O O
is O O
poised O O
for O O
transcription O O
in O O
A549 O O
cells O O
. O O

Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
the O O
holo O O
- O O
GR O O
is O O
capable O O
of O O
activating O O
transcription O O
and O O
evoking O O
changes O O
in O O
chromatin O O
structure O O
through O O
distant O O
- O O
acting O O
enhancers O O
. O O

Conserved O O
regulatory O O
motifs O O
in O O
osteogenic O O
gene O O
promoters O O
integrate O O
cooperative O O
effects O O
of O O
canonical O O
Wnt O O
and O O
BMP O O
pathways O O
. O O
Osteoblast O O
differentiation O O
depends O O
on O O
the O O
coordinated O O
network O O
of O O
evolutionary O O
conserved O O
transcription O O
factors O O
during O O
bone O O
formation O O
and O O
homeostasis O O
. O O

Evidence O O
indicates O O
that O O
bone O O
morphogenetic O O
protein O O
( O O
BMP O O
) O O
and O O
Wnt O O
proteins O O
regulate O O
several O O
steps O O
of O O
skeletal O O
development O O
. O O

Here O O
, O O
we O O
provide O O
a O O
molecular O O
description O O
of O O
the O O
cooperative O O
effects O O
of O O
BMP O O
and O O
Wnt O O
canonical O O
pathway O O
on O O
the O O
expression O O
of O O
the O O
early O O
osteogenic O O
genes O O
Dlx5 O O
, O O
Msx2 O O
, O O
and O O
Runx2 O O
in O O
C2C12 O O
cells O O
, O O
primary O O
cultures O O
of O O
bone O O
marrow O O
- O O
mesenchymal O O
stem O O
cells O O
, O O
and O O
organotypic O O
calvarial O O
cultures O O
. O O

Coordinated O O
regulation O O
of O O
these O O
genes O O
leads O O
to O O
the O O
cooperative O O
activation O O
of O O
their O O
downstream O O
osteogenic O O
target O O
gene O O
osterix O O
. O O

Induction O O
of O O
these O O
genes O O
is O O
mediated O O
through O O
enhancer O O
regions O O
with O O
an O O
evolutionary O O
conserved O O
structure O O
encompassing O O
both O O
Smad O O
and O O
TCF O O
/ O O
LEF1 O O
DNA O O
- O O
binding O O
sites O O
. O O

Formation O O
of O O
a O O
cooperative O O
complex O O
is O O
mediated O O
through O O
DNA O O
binding O O
of O O
Smads O O
and O O
TCF4 O O
/ O O
beta O O
- O O
catenin O O
to O O
their O O
cognate O O
sequences O O
, O O
as O O
well O O
as O O
protein O O
- O O
protein O O
interactions O O
between O O
them O O
. O O

The O O
formation O O
of O O
these O O
cooperative O O
transcriptional O O
complexes O O
results O O
in O O
a O O
more O O
efficient O O
recruitment O O
of O O
coactivators O O
such O O
as O O
p300 O O
. O O

We O O
propose O O
that O O
evolutionary O O
conserved O O
regulatory O O
regions O O
in O O
specific O O
osteogenic O O
master O O
genes O O
are O O
key O O
integrative O O
modules O O
during O O
osteogenesis O O
. O O

Mechanisms O O
by O O
which O O
interleukin O O
- O O
6 O O
regulates O O
prostate O O
- O O
specific O O
antigen O O
gene O O
expression O O
in O O
prostate O O
LNCaP O O
carcinoma O O
cells O O
. O O
Interleukin O O
- O O
6 O O
( O O
IL O O
- O O
6 O O
) O O
is O O
involved O O
in O O
regulation O O
of O O
cell O O
growth O O
and O O
survival O O
of O O
prostate O O
carcinoma O O
cells O O
. O O

Previous O O
studies O O
suggest O O
that O O
IL O O
- O O
6 O O
promotes O O
prostate B-Disease B-Disease
cancer I-Disease I-Disease
progression O O
through O O
the O O
induction O O
of O O
an O O
androgen O O
- O O
independent O O
response O O
. O O

In O O
this O O
study O O
, O O
we O O
evaluated O O
the O O
mechanisms O O
by O O
which O O
IL O O
- O O
6 O O
regulates O O
the O O
gene O O
expression O O
of O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
in O O
human O O
prostate O O
LNCaP O O
carcinoma O O
cells O O
. O O

( O O
3 O O
) O O
H O O
- O O
thymidine O O
incorporation O O
assays O O
revealed O O
that O O
IL O O
- O O
6 O O
treatment O O
inhibited O O
the O O
proliferation O O
of O O
LNCaP O O
cells O O
. O O

Results O O
of O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
and O O
immunoblot O O
assays O O
indicated O O
that O O
IL O O
- O O
6 O O
treatment O O
enhanced O O
PSA O O
gene O O
expression O O
. O O

Similar O O
results O O
were O O
found O O
in O O
LNCaP O O
cells O O
that O O
had O O
been O O
engineered O O
to O O
stably O O
overexpress O O
IL O O
- O O
6 O O
. O O

Although O O
forced O O
overexpression O O
of O O
c O O
- O O
Myc O O
- O O
associated O O
zinc O O
finger O O
protein O O
( O O
MAZ O O
) O O
induced O O
PSA O O
promoter O O
activity O O
, O O
mutation O O
of O O
the O O
MAZ O O
response O O
elements O O
had O O
little O O
effect O O
on O O
IL O O
- O O
6 O O
- O O
induced O O
PSA O O
promoter O O
activity O O
. O O
Although O O
forced O O
overexpression O O
of O O
c O O
- O O
Myc O O
- O O
associated O O
zinc O O
finger O O
protein O O
( O O
MAZ O O
) O O
induced O O
PSA O O
promoter O O
activity O O
, O O
mutation O O
of O O
the O O
MAZ O O
response O O
elements O O
had O O
little O O
effect O O
on O O
IL O O
- O O
6 O O
- O O
induced O O
PSA O O
promoter O O
activity O O
. O O

Results O O
from O O
5 O O
' O O
- O O
deletion O O
reporter O O
assays O O
revealed O O
that O O
the O O
effects O O
of O O
IL O O
- O O
6 O O
appear O O
to O O
be O O
mediated O O
via O O
an O O
androgen O O
enhancer O O
region O O
( O O
24801 O O
to O O
23933 O O
) O O
, O O
which O O
is O O
dependent O O
on O O
the O O
signal O O
transducer O O
and O O
activator O O
of O O
the O O
transcription O O
3 O O
( O O
STAT3 O O
) O O
pathway O O
, O O
and O O
a O O
region O O
located O O
at O O
2193 O O
to O O
241 O O
base O O
pairs O O
upstream O O
of O O
the O O
translational O O
initiation O O
site O O
of O O
the O O
human O O
PSA O O
gene O O
, O O
which O O
did O O
not O O
respond O O
to O O
androgen O O
or O O
STAT3 O O
. O O

Results O O
of O O
reporter O O
assays O O
, O O
immunoblot O O
assays O O
, O O
and O O
ELISA O O
revealed O O
that O O
the O O
heat O O
shock O O
protein O O
90 O O
( O O
Hsp90 O O
) O O
inhibitors O O
17 O O
- O O
allyamino O O
- O O
17 O O
- O O
demethoxygeldanamycin O O
and O O
geldanamycin O O
blocked O O
IL O O
- O O
6 O O
- O O
induced O O
PSA O O
gene O O
expression O O
. O O

Those O O
results O O
suggest O O
that O O
IL O O
- O O
6 O O
upregulates O O
PSA O O
gene O O
expression O O
and O O
that O O
Hsp90 O O
plays O O
a O O
novel O O
role O O
in O O
the O O
activation O O
of O O
IL O O
- O O
6 O O
on O O
PSA O O
gene O O
expression O O
in O O
an O O
androgen O O
- O O
independent O O
manner O O
. O O

Mechanisms O O
of O O
bone O O
morphogenetic O O
protein O O
2 O O
( O O
BMP2 O O
) O O
stimulated O O
inhibitor O O
of O O
DNA O O
binding O O
3 O O
( O O
Id3 O O
) O O
transcription O O
. O O
Bone O O
morphogenetic O O
protein O O
2 O O
( O O
BMP2 O O
) O O
stimulates O O
expression O O
of O O
the O O
inhibitors O O
of O O
DNA O O
binding O O
( O O
Id O O
) O O
1 O O
, O O
2 O O
, O O
and O O
3 O O
in O O
a O O
variety O O
of O O
cell O O
types O O
. O O

Here O O
, O O
we O O
examined O O
mechanisms O O
mediating O O
BMP2 O O
- O O
stimulated O O
Id3 O O
transcription O O
in O O
murine O O
gonadotropes O O
. O O

Using O O
a O O
combination O O
of O O
quantitative O O
RT O O
- O O
PCR O O
, O O
promoter O O
- O O
reporter O O
analyses O O
, O O
over O O
- O O
expression O O
, O O
and O O
RNA O O
interference O O
approaches O O
, O O
we O O
demonstrate O O
that O O
BMP2 O O
signals O O
via O O
the O O
BMPR2 O O
and O O
BMPR1A O O
( O O
ALK3 O O
) O O
receptors O O
and O O
intracellular O O
signaling O O
proteins O O
SMADs O O
1 O O
and O O
5 O O
to O O
stimulate O O
Id3 O O
transcription O O
. O O

We O O
further O O
define O O
a O O
novel O O
6 O O
- O O
bp O O
cis O O
- O O
element O O
mediating O O
BMP2 O O
- O O
and O O
SMAD O O
- O O
dependent O O
transcription O O
, O O
though O O
this O O
site O O
does O O
not O O
appear O O
to O O
bind O O
SMADs O O
directly O O
. O O
We O O
further O O
define O O
a O O
novel O O
6 O O
- O O
bp O O
cis O O
- O O
element O O
mediating O O
BMP2 O O
- O O
and O O
SMAD O O
- O O
dependent O O
transcription O O
, O O
though O O
this O O
site O O
does O O
not O O
appear O O
to O O
bind O O
SMADs O O
directly O O
. O O

A O O
specific O O
DNA O O
binding O O
protein O O
complex O O
binds O O
to O O
this O O
element O O
, O O
but O O
its O O
constituent O O
protein O O
( O O
s O O
) O O
remain O O
undetermined O O
. O O

Recently O O
, O O
a O O
more O O
distal O O
enhancer O O
was O O
shown O O
to O O
mediate O O
BMP4 O O
- O O
induction O O
of O O
the O O
human O O
ID3 O O
gene O O
in O O
ovarian O O
cancer O O
cells O O
. O O

This O O
enhancer O O
is O O
conserved O O
in O O
the O O
murine O O
gene O O
and O O
we O O
demonstrate O O
its O O
role O O
in O O
BMP2 O O
- O O
induced O O
Id3 O O
promoter O O
activity O O
in O O
gonadotropes O O
. O O
This O O
enhancer O O
is O O
conserved O O
in O O
the O O
murine O O
gene O O
and O O
we O O
demonstrate O O
its O O
role O O
in O O
BMP2 O O
- O O
induced O O
Id3 O O
promoter O O
activity O O
in O O
gonadotropes O O
. O O

Conversely O O
, O O
the O O
proximal O O
cis O O
- O O
element O O
defined O O
here O O
is O O
also O O
conserved O O
in O O
human O O
ID3 O O
and O O
we O O
demonstrate O O
its O O
functional O O
role O O
in O O
BMP2 O O
- O O
induction O O
of O O
ID3 O O
transcription O O
. O O

Finally O O
, O O
we O O
show O O
that O O
the O O
two O O
regulatory O O
elements O O
also O O
mediate O O
BMP2 O O
- O O
induction O O
of O O
Id3 O O
promoter O O
activity O O
in O O
murine O O
fibroblasts O O
. O O
Finally O O
, O O
we O O
show O O
that O O
the O O
two O O
regulatory O O
elements O O
also O O
mediate O O
BMP2 O O
- O O
induction O O
of O O
Id3 O O
promoter O O
activity O O
in O O
murine O O
fibroblasts O O
. O O

Collectively O O
, O O
we O O
have O O
defined O O
a O O
general O O
mechanism O O
whereby O O
BMP2 O O
regulates O O
Id3 O O
/ O O
ID3 O O
transcription O O
in O O
different O O
cell O O
types O O
and O O
in O O
different O O
species O O
. O O

The O O
Pou5f1 O O
/ O O
Pou3f O O
- O O
dependent O O
but O O
SoxB O O
- O O
independent O O
regulation O O
of O O
conserved O O
enhancer O O
N2 O O
initiates O O
Sox2 O O
expression O O
during O O
epiblast O O
to O O
neural O O
plate O O
stages O O
in O O
vertebrates O O
. O O

The O O
transcription O O
factor O O
Sox2 O O
is O O
a O O
core O O
component O O
of O O
the O O
pluripotency O O
control O O
circuits O O
in O O
the O O
early O O
embryo O O
, O O
and O O
later O O
controls O O
many O O
aspects O O
of O O
neural O O
development O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
Sox2 O O
expression O O
in O O
the O O
epiblast O O
( O O
mouse O O
blastoderm O O
) O O
and O O
anterior O O
neural O O
plate O O
( O O
ANP O O
) O O
is O O
determined O O
by O O
the O O
upstream O O
enhancer O O
N2 O O
. O O

The O O
mouse O O
enhancer O O
N2 O O
exhibits O O
strong O O
activity O O
in O O
mouse O O
ES O O
cells O O
, O O
epiblast O O
and O O
ANP O O
, O O
and O O
is O O
regulated O O
correctly O O
in O O
chicken O O
and O O
zebrafish O O
embryos O O
. O O

Targeted O O
deletion O O
of O O
this O O
enhancer O O
in O O
mouse O O
embryos O O
caused O O
a O O
large O O
reduction O O
of O O
Sox2 O O
expression O O
to O O
10 O O
% O O
of O O
that O O
of O O
wild O O
- O O
type O O
levels O O
in O O
epiblast O O
and O O
ANP O O
. O O

However O O
, O O
this O O
was O O
tolerated O O
by O O
mouse O O
embryo O O
, O O
probably O O
due O O
to O O
functional O O
compensation O O
by O O
Sox3 O O
. O O

The O O
activity O O
of O O
enhancer O O
N2 O O
depends O O
on O O
phylogenetically O O
conserved O O
bipartite O O
POU O O
factor O O
- O O
binding O O
motifs O O
in O O
a O O
73 O O
- O O
bp O O
core O O
sequence O O
that O O
function O O
synergistically O O
, O O
but O O
this O O
activation O O
does O O
not O O
involve O O
Sox2 O O
. O O

The O O
major O O
POU O O
factor O O
expressed O O
at O O
the O O
epiblastic O O
stage O O
is O O
Pou5f1 O O
( O O
Oct3 O O
/ O O
4 O O
) O O
, O O
while O O
those O O
in O O
the O O
anterior O O
neural O O
plate O O
are O O
Pou3f O O
factors O O
( O O
Oct6 O O
, O O
Brn2 O O
etc O O
. O O
) O O
. O O

These O O
factors O O
are O O
gradually O O
exchanged O O
during O O
the O O
transition O O
from O O
epiblast O O
to O O
ANP O O
stages O O
in O O
mouse O O
embryos O O
and O O
epiblast O O
stem O O
cells O O
( O O
EpiSC O O
) O O
. O O

Consistently O O
, O O
enhancer O O
N2 O O
activity O O
changes O O
from O O
full O O
Pou5f1 O O
dependence O O
to O O
Pou3f O O
dependence O O
during O O
the O O
development O O
of O O
neural O O
plate O O
cells O O
( O O
NPC O O
) O O
from O O
EpiSC O O
, O O
as O O
assessed O O
by O O
specific O O
POU O O
factor O O
knockdown O O
in O O
these O O
cells O O
. O O
Zebrafish O O
mutant O O
embryos O O
completely O O
devoid O O
of O O
Pou5f1 O O
activity O O
failed O O
to O O
activate O O
enhancer O O
N2 O O
and O O
to O O
express O O
Sox2 O O
in O O
the O O
blastoderm O O
and O O
ANP O O
, O O
and O O
these O O
defects O O
were O O
rescued O O
by O O
exogenous O O
supply O O
of O O
pou5f1 O O
. O O

Previously O O
, O O
Pou5f1 O O
- O O
Sox2 O O
synergism O O
- O O
dependent O O
Sox2 O O
activation O O
through O O
enhancer O O
SRR2 O O
in O O
ES O O
cells O O
has O O
been O O
highlighted O O
, O O
but O O
this O O
mechanism O O
is O O
limited O O
to O O
ES O O
cells O O
and O O
amniotes O O
. O O

In O O
contrast O O
, O O
the O O
enhancer O O
N2 O O
- O O
mediated O O
, O O
POU O O
factor O O
- O O
dependent O O
activation O O
of O O
Sox2 O O
, O O
without O O
involvement O O
of O O
Sox2 O O
, O O
is O O
a O O
phylogenetically O O
conserved O O
core O O
mechanism O O
that O O
functions O O
in O O
gene O O
regulatory O O
networks O O
at O O
early O O
embryonic O O
stages O O
. O O

cAMP O O
target O O
sequences O O
enhCRE O O
and O O
CNRE O O
sense O O
low O O
- O O
salt O O
intake O O
to O O
increase O O
human O O
renin O O
gene O O
expression O O
in O O
vivo O O
. O O

This O O
study O O
aimed O O
to O O
assess O O
the O O
role O O
of O O
cAMP O O
target O O
sequences O O
enhancer O O
cAMP O O
response O O
element O O
( O O
enhCRE O O
) O O
and O O
cAMP O O
and O O
overlapping O O
negative O O
response O O
element O O
( O O
CNRE O O
) O O
in O O
the O O
control O O
of O O
human O O
renin O O
gene O O
( O O
REN O O
) O O
in O O
vivo O O
. O O
enhCRE O O
and O O
CNRE O O
were O O
silenced O O
by O O
mutations O O
in O O
a O O
12 O O
. O O
2 O O
- O O
kb O O
human O O
renin O O
promoter O O
fused O O
to O O
LacZ O O
reporter O O
gene O O
. O O
This O O
study O O
aimed O O
to O O
assess O O
the O O
role O O
of O O
cAMP O O
target O O
sequences O O
enhancer O O
cAMP O O
response O O
element O O
( O O
enhCRE O O
) O O
and O O
cAMP O O
and O O
overlapping O O
negative O O
response O O
element O O
( O O
CNRE O O
) O O
in O O
the O O
control O O
of O O
human O O
renin O O
gene O O
( O O
REN O O
) O O
in O O
vivo O O
. O O
enhCRE O O
and O O
CNRE O O
were O O
silenced O O
by O O
mutations O O
in O O
a O O
12 O O
. O O
2 O O
- O O
kb O O
human O O
renin O O
promoter O O
fused O O
to O O
LacZ O O
reporter O O
gene O O
. O O

This O O
construct O O
was O O
used O O
to O O
generate O O
transgenic O O
mice O O
( O O
RENMut O O
- O O
LacZ O O
) O O
. O O

The O O
expression O O
of O O
the O O
transgene O O
was O O
correctly O O
targeted O O
to O O
the O O
juxtaglomerular O O
portions O O
of O O
renal O O
afferent O O
arterioles O O
which O O
express O O
endogenous O O
mouse O O
renin O O
. O O

Therefore O O
, O O
enhCRE O O
and O O
CNRE O O
do O O
not O O
seem O O
to O O
be O O
relevant O O
for O O
the O O
control O O
of O O
the O O
cell O O
- O O
specific O O
expression O O
of O O
the O O
human O O
renin O O
gene O O
. O O

The O O
beta O O
- O O
adrenoreceptor O O
agonist O O
isoproterenol O O
( O O
10 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
for O O
2 O O
days O O
) O O
stimulated O O
the O O
endogenous O O
renin O O
, O O
but O O
not O O
the O O
LacZ O O
mRNA O O
expression O O
. O O

Treatment O O
of O O
RENMut O O
- O O
LacZ O O
mice O O
with O O
the O O
angiotensin O O
converting O O
enzyme O O
inhibitor O O
( O O
enalapril O O
10 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
for O O
7 O O
days O O
) O O
or O O
their O O
crossing O O
to O O
angiotensin O O
receptor O O
type O O
1a O O
knockout O O
mice O O
led O O
to O O
increased O O
renin O O
and O O
LacZ O O
mRNA O O
levels O O
. O O
Renin O O
expression O O
was O O
upregulated O O
by O O
low O O
- O O
salt O O
diet O O
( O O
0 O O
. O O
03 O O
% O O
NaCl O O
, O O
for O O
10 O O
days O O
) O O
and O O
downregulated O O
by O O
high O O
- O O
salt O O
diet O O
( O O
4 O O
% O O
NaCl O O
, O O
for O O
10 O O
days O O
) O O
. O O

In O O
contrast O O
, O O
low O O
- O O
salt O O
diet O O
did O O
not O O
influence O O
, O O
while O O
high O O
- O O
salt O O
diet O O
inhibited O O
the O O
expression O O
of O O
LacZ O O
. O O

In O O
summary O O
, O O
enhCRE O O
and O O
CNRE O O
appear O O
to O O
be O O
necessary O O
for O O
the O O
transactivation O O
of O O
the O O
human O O
renin O O
gene O O
through O O
beta O O
- O O
adrenoreceptors O O
and O O
by O O
low O O
- O O
salt O O
diet O O
. O O

Our O O
data O O
also O O
suggest O O
that O O
different O O
intracellular O O
mechanisms O O
mediate O O
the O O
effect O O
of O O
low O O
- O O
and O O
high O O
- O O
salt O O
intake O O
on O O
renin O O
expression O O
in O O
vivo O O
. O O

Nkx2 O O
- O O
5 O O
represses O O
Gata1 O O
gene O O
expression O O
and O O
modulates O O
the O O
cellular O O
fate O O
of O O
cardiac O O
progenitors O O
during O O
embryogenesis O O
. O O

BACKGROUND O O
: O O
Recent O O
studies O O
suggest O O
that O O
the O O
hematopoietic O O
and O O
cardiac O O
lineages O O
have O O
close O O
ontogenic O O
origins O O
, O O
and O O
that O O
an O O
early O O
mesodermal O O
cell O O
population O O
has O O
the O O
potential O O
to O O
differentiate O O
into O O
both O O
lineages O O
. O O

Studies O O
also O O
suggest O O
that O O
specification O O
of O O
these O O
lineages O O
is O O
inversely O O
regulated O O
. O O

However O O
, O O
the O O
transcriptional O O
networks O O
that O O
govern O O
the O O
cell O O
fate O O
specification O O
of O O
these O O
progenitors O O
are O O
incompletely O O
defined O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Here O O
, O O
we O O
show O O
that O O
Nkx2 O O
- O O
5 O O
regulates O O
the O O
hematopoietic O O
/ O O
erythroid O O
fate O O
of O O
the O O
mesoderm O O
precursors O O
early O O
during O O
cardiac O O
morphogenesis O O
. O O

Using O O
transgenic O O
technologies O O
to O O
isolate O O
Nkx2 O O
- O O
5 O O
expressing O O
cells O O
, O O
we O O
observed O O
an O O
induction O O
of O O
the O O
erythroid O O
molecular O O
program O O
, O O
including O O
Gata1 O O
, O O
in O O
the O O
Nkx2 O O
- O O
5 O O
- O O
null O O
embryos O O
. O O

We O O
further O O
observed O O
that O O
overexpression O O
of O O
Nkx2 O O
- O O
5 O O
with O O
an O O
Nkx2 O O
- O O
5 O O
- O O
inducible O O
embryonic O O
stem O O
cell O O
system O O
significantly O O
repressed O O
Gata1 O O
gene O O
expression O O
and O O
suppressed O O
the O O
hematopoietic O O
/ O O
erythroid O O
potential O O
, O O
but O O
not O O
the O O
endothelial O O
potential O O
, O O
of O O
the O O
embryonic O O
stem O O
cells O O
. O O

This O O
suppression O O
was O O
cell O O
- O O
autonomous O O
, O O
and O O
was O O
partially O O
rescued O O
by O O
overexpressing O O
Gata1 O O
. O O

In O O
addition O O
, O O
we O O
demonstrated O O
that O O
Nkx2 O O
- O O
5 O O
binds O O
to O O
the O O
Gata1 O O
gene O O
enhancer O O
and O O
represses O O
the O O
transcriptional O O
activity O O
of O O
the O O
Gata1 O O
gene O O
. O O
In O O
addition O O
, O O
we O O
demonstrated O O
that O O
Nkx2 O O
- O O
5 O O
binds O O
to O O
the O O
Gata1 O O
gene O O
enhancer O O
and O O
represses O O
the O O
transcriptional O O
activity O O
of O O
the O O
Gata1 O O
gene O O
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
demonstrate O O
that O O
the O O
hematopoietic O O
/ O O
erythroid O O
cell O O
fate O O
is O O
suppressed O O
via O O
Nkx2 O O
- O O
5 O O
during O O
mesodermal O O
fate O O
determination O O
, O O
and O O
that O O
the O O
Gata1 O O
gene O O
is O O
one O O
of O O
the O O
targets O O
that O O
are O O
suppressed O O
by O O
Nkx2 O O
- O O
5 O O
. O O

Genome O O
- O O
wide O O
approaches O O
reveal O O
functional O O
interleukin O O
- O O
4 O O
- O O
inducible O O
STAT6 O O
binding O O
to O O
the O O
vascular O O
cell O O
adhesion O O
molecule O O
1 O O
promoter O O
. O O
Endothelial O O
cell O O
activation O O
and O O
dysfunction O O
underlie O O
many O O
vascular B-Disease B-Disease
disorders I-Disease I-Disease
, O O
including O O
atherosclerosis B-Disease B-Disease
and O O
inflammation B-Disease B-Disease
. O O
Genome O O
- O O
wide O O
approaches O O
reveal O O
functional O O
interleukin O O
- O O
4 O O
- O O
inducible O O
STAT6 O O
binding O O
to O O
the O O
vascular O O
cell O O
adhesion O O
molecule O O
1 O O
promoter O O
. O O
Endothelial O O
cell O O
activation O O
and O O
dysfunction O O
underlie O O
many O O
vascular B-Disease B-Disease
disorders I-Disease I-Disease
, O O
including O O
atherosclerosis B-Disease B-Disease
and O O
inflammation B-Disease B-Disease
. O O

Here O O
, O O
we O O
show O O
that O O
interleukin O O
- O O
4 O O
( O O
IL O O
- O O
4 O O
) O O
markedly O O
induced O O
vascular O O
cell O O
adhesion O O
molecule O O
1 O O
( O O
VCAM O O
- O O
1 O O
) O O
, O O
both O O
in O O
cultured O O
endothelial O O
cells O O
and O O
in O O
the O O
intact O O
endothelium O O
in O O
mice O O
. O O

Combined O O
treatment O O
with O O
IL O O
- O O
4 O O
and O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
resulted O O
in O O
further O O
, O O
sustained O O
induction O O
of O O
VCAM O O
- O O
1 O O
expression O O
. O O
IL O O
- O O
4 O O
- O O
mediated O O
induction O O
of O O
VCAM O O
- O O
1 O O
and O O
secondary O O
monocyte O O
adhesion O O
was O O
predominantly O O
regulated O O
by O O
the O O
transcription O O
factor O O
STAT6 O O
. O O

Genome O O
- O O
wide O O
survey O O
of O O
IL O O
- O O
4 O O
- O O
mediated O O
STAT6 O O
binding O O
from O O
sequential O O
chromatin O O
- O O
immunoprecipitation O O
with O O
deep O O
sequencing O O
( O O
chromatin O O
immunoprecipitation O O
sequencing O O
[ O O
ChIP O O
- O O
seq O O
] O O
) O O
in O O
endothelial O O
cells O O
revealed O O
regions O O
of O O
transient O O
and O O
sustained O O
transcription O O
factor O O
binding O O
. O O

Through O O
the O O
combination O O
of O O
DNA O O
microarrays O O
and O O
ChIP O O
- O O
seq O O
at O O
the O O
same O O
time O O
points O O
, O O
the O O
majority O O
of O O
IL O O
- O O
4 O O
- O O
responsive O O
genes O O
were O O
shown O O
to O O
be O O
STAT6 O O
dependent O O
and O O
associated O O
with O O
direct O O
STAT6 O O
binding O O
to O O
their O O
promoter O O
. O O
IL O O
- O O
4 O O
- O O
mediated O O
stable O O
binding O O
of O O
STAT6 O O
led O O
to O O
sustained O O
target O O
gene O O
expression O O
. O O

Moreover O O
, O O
our O O
strategy O O
led O O
to O O
the O O
identification O O
of O O
a O O
novel O O
functionally O O
important O O
STAT6 O O
binding O O
site O O
within O O
16 O O
kb O O
upstream O O
of O O
the O O
VCAM O O
- O O
1 O O
gene O O
. O O
Moreover O O
, O O
our O O
strategy O O
led O O
to O O
the O O
identification O O
of O O
a O O
novel O O
functionally O O
important O O
STAT6 O O
binding O O
site O O
within O O
16 O O
kb O O
upstream O O
of O O
the O O
VCAM O O
- O O
1 O O
gene O O
. O O

Taken O O
together O O
, O O
these O O
findings O O
support O O
a O O
critical O O
role O O
for O O
STAT6 O O
in O O
mediating O O
IL O O
- O O
4 O O
signal O O
transduction O O
in O O
endothelial O O
cells O O
. O O

Identification O O
of O O
a O O
novel O O
IL O O
- O O
4 O O
- O O
mediated O O
VCAM O O
- O O
1 O O
enhancer O O
may O O
provide O O
a O O
foundation O O
for O O
targeted O O
therapy O O
in O O
vascular B-Disease B-Disease
disease I-Disease I-Disease
. O O
Identification O O
of O O
a O O
novel O O
IL O O
- O O
4 O O
- O O
mediated O O
VCAM O O
- O O
1 O O
enhancer O O
may O O
provide O O
a O O
foundation O O
for O O
targeted O O
therapy O O
in O O
vascular B-Disease B-Disease
disease I-Disease I-Disease
. O O

A O O
distal O O
enhancer O O
in O O
Il12b O O
is O O
the O O
target O O
of O O
transcriptional O O
repression O O
by O O
the O O
STAT3 O O
pathway O O
and O O
requires O O
the O O
basic O O
leucine O O
zipper O O
( O O
B O O
- O O
ZIP O O
) O O
protein O O
NFIL3 O O
. O O
A O O
distal O O
enhancer O O
in O O
Il12b O O
is O O
the O O
target O O
of O O
transcriptional O O
repression O O
by O O
the O O
STAT3 O O
pathway O O
and O O
requires O O
the O O
basic O O
leucine O O
zipper O O
( O O
B O O
- O O
ZIP O O
) O O
protein O O
NFIL3 O O
. O O

Deregulated O O
IL O O
- O O
12 O O
and O O
IL O O
- O O
23 O O
production O O
from O O
activated O O
myeloid O O
lineage O O
cells O O
is O O
a O O
key O O
driver O O
of O O
numerous O O
T O O
cell O O
- O O
dependent O O
autoimmune B-Disease O
and O O
inflammatory B-Disease B-Disease
diseases I-Disease I-Disease
. O O

IL O O
- O O
12 O O
and O O
IL O O
- O O
23 O O
share O O
a O O
common O O
p40 O O
subunit O O
encoded O O
by O O
Il12b O O
, O O
which O O
is O O
negatively O O
regulated O O
at O O
the O O
transcriptional O O
level O O
by O O
the O O
STAT3 O O
( O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
) O O
- O O
activating O O
anti O O
- O O
inflammatory O O
cytokine O O
IL O O
- O O
10 O O
. O O

We O O
found O O
that O O
IL O O
- O O
10 O O
targets O O
an O O
enhancer O O
10 O O
kb O O
upstream O O
of O O
the O O
Il12b O O
transcriptional O O
start O O
site O O
. O O
We O O
found O O
that O O
IL O O
- O O
10 O O
targets O O
an O O
enhancer O O
10 O O
kb O O
upstream O O
of O O
the O O
Il12b O O
transcriptional O O
start O O
site O O
. O O

Within O O
the O O
enhancer O O
, O O
a O O
single O O
10 O O
- O O
bp O O
site O O
is O O
required O O
for O O
the O O
inhibitory O O
effects O O
of O O
IL O O
- O O
10 O O
and O O
is O O
bound O O
by O O
NFIL3 O O
( O O
nuclear O O
factor O O
, O O
interleukin O O
3 O O
- O O
regulated O O
) O O
, O O
a O O
B O O
- O O
ZIP O O
transcription O O
factor O O
. O O
Myeloid O O
cells O O
lacking O O
NFIL3 O O
produce O O
excessive O O
IL O O
- O O
12p40 O O
and O O
increased O O
IL O O
- O O
12p70 O O
. O O

Thus O O
, O O
the O O
STAT3 O O
- O O
dependent O O
expression O O
of O O
NFIL3 O O
is O O
a O O
key O O
component O O
of O O
a O O
negative O O
feedback O O
pathway O O
in O O
myeloid O O
cells O O
that O O
suppresses O O
proinflammatory O O
responses O O
. O O

Enhancer O O
- O O
blocking O O
activity O O
is O O
associated O O
with O O
hypersensitive O O
site O O
V O O
sequences O O
in O O
the O O
human O O
growth O O
hormone O O
locus O O
control O O
region O O
. O O

Activation O O
of O O
the O O
human O O
growth O O
hormone O O
gene O O
( O O
hGH O O
- O O
N O O
) O O
is O O
linked O O
to O O
a O O
locus O O
control O O
region O O
( O O
LCR O O
) O O
containing O O
four O O
( O O
I O O
- O O
III O O
, O O
V O O
) O O
hypersensitive O O
sites O O
( O O
HS O O
) O O
. O O
Pit O O
- O O
1 O O
binding O O
to O O
HS O O
I O O
/ O O
II O O
is O O
required O O
for O O
efficient O O
pituitary O O
expression O O
. O O

However O O
, O O
inclusion O O
of O O
HS O O
III O O
and O O
V O O
, O O
located O O
about O O
28 O O
and O O
32 O O
kb O O
upstream O O
of O O
the O O
hGH O O
- O O
N O O
gene O O
, O O
respectively O O
, O O
is O O
also O O
required O O
for O O
consistent O O
hGH O O
- O O
N O O
expression O O
levels O O
in O O
vivo O O
. O O

HS O O
V O O
is O O
referred O O
to O O
as O O
a O O
boundary O O
for O O
the O O
hGH O O
LCR O O
, O O
but O O
no O O
specific O O
enhancer O O
blocking O O
or O O
barrier O O
function O O
is O O
reported O O
. O O

We O O
examined O O
a O O
547 O O
bp O O
fragment O O
containing O O
HS O O
V O O
sequences O O
( O O
nucleotides O O
- O O
32 O O
, O O
718 O O
/ O O
- O O
32 O O
, O O
172 O O
relative O O
to O O
hGH O O
- O O
N O O
) O O
for O O
enhancer O O
- O O
blocking O O
activity O O
using O O
a O O
well O O
- O O
established O O
transient O O
gene O O
transfer O O
system O O
and O O
assessed O O
these O O
sequences O O
for O O
CCCTC O O
binding O O
factor O O
( O O
CTCF O O
) O O
, O O
which O O
is O O
linked O O
to O O
enhancer O O
- O O
blocking O O
activity O O
. O O

The O O
547 O O
bp O O
HS O O
V O O
fragment O O
decreased O O
enhancer O O
activity O O
with O O
a O O
reverse O O
- O O
orientation O O
preference O O
when O O
inserted O O
between O O
HS O O
III O O
enhancer O O
sequences O O
and O O
a O O
minimal O O
thymidine O O
kinase O O
promoter O O
( O O
TKp O O
) O O
. O O
The O O
547 O O
bp O O
HS O O
V O O
fragment O O
decreased O O
enhancer O O
activity O O
with O O
a O O
reverse O O
- O O
orientation O O
preference O O
when O O
inserted O O
between O O
HS O O
III O O
enhancer O O
sequences O O
and O O
a O O
minimal O O
thymidine O O
kinase O O
promoter O O
( O O
TKp O O
) O O
. O O

These O O
sequences O O
are O O
associated O O
with O O
CTCF O O
in O O
human O O
pituitary O O
and O O
nonpituitary O O
chromatin O O
. O O

Enhancer O O
- O O
blocking O O
activity O O
with O O
an O O
orientation O O
preference O O
was O O
further O O
localized O O
to O O
a O O
45 O O
bp O O
sub O O
- O O
fragment O O
, O O
with O O
evidence O O
of O O
CTCF O O
and O O
upstream O O
binding O O
factor O O
1 O O
( O O
USF1 O O
) O O
binding O O
; O O
USF1 O O
is O O
linked O O
more O O
closely O O
with O O
barrier O O
function O O
. O O

The O O
presence O O
of O O
yin O O
and O O
yang O O
1 O O
( O O
Yy1 O O
) O O
that O O
cooperates O O
with O O
CTCF O O
in O O
the O O
regulation O O
of O O
X O O
- O O
chromosome O O
inactivation O O
was O O
also O O
seen O O
. O O

A O O
decrease O O
in O O
CTCF O O
and O O
Yy1 O O
RNA O O
levels O O
was O O
associated O O
with O O
a O O
significant O O
reduction O O
in O O
enhancer O O
- O O
blocking O O
activity O O
. O O

Assessment O O
of O O
CpG O O
- O O
dinucleotides O O
in O O
the O O
TKp O O
indicates O O
that O O
the O O
presence O O
of O O
HS O O
V O O
sequences O O
are O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
CpG O O
- O O
dinucleotide O O
methylation O O
of O O
the O O
GC O O
box O O
region O O
. O O

These O O
data O O
support O O
association O O
of O O
CTCF O O
and O O
enhancer O O
- O O
blocking O O
activity O O
with O O
HS O O
V O O
that O O
is O O
consistent O O
with O O
a O O
role O O
as O O
a O O
( O O
LCR O O
) O O
boundary O O
element O O
and O O
also O O
implicates O O
Yy1 O O
in O O
this O O
process O O
. O O

NEUROG3 O O
is O O
a O O
critical O O
downstream O O
effector O O
for O O
STAT3 O O
- O O
regulated O O
differentiation O O
of O O
mammalian O O
stem O O
and O O
progenitor O O
spermatogonia O O
. O O

Spermatogenesis O O
relies O O
on O O
coordinated O O
differentiation O O
of O O
stem O O
and O O
progenitor O O
spermatogonia O O
, O O
and O O
the O O
transcription O O
factor O O
STAT3 O O
is O O
essential O O
for O O
this O O
process O O
in O O
mammals O O
. O O

Here O O
we O O
studied O O
the O O
THY1 O O
+ O O
spermatogonial O O
population O O
in O O
mouse O O
testes O O
, O O
which O O
contains O O
spermatogonial O O
stem O O
cells O O
( O O
SSC O O
) O O
and O O
non O O
- O O
stem O O
cell O O
progenitor O O
spermatogonia O O
, O O
to O O
further O O
define O O
the O O
downstream O O
mechanism O O
regulating O O
differentiation O O
. O O

Transcript O O
abundance O O
for O O
the O O
bHLH O O
transcription O O
factor O O
Neurog3 O O
was O O
found O O
to O O
be O O
significantly O O
reduced O O
upon O O
transient O O
inhibition O O
of O O
STAT3 O O
signaling O O
in O O
these O O
cells O O
and O O
exposure O O
to O O
GDNF O O
, O O
a O O
key O O
growth O O
factor O O
regulating O O
self O O
- O O
renewal O O
of O O
SSCs O O
, O O
suppressed O O
activation O O
of O O
STAT3 O O
and O O
in O O
accordance O O
Neurog3 O O
gene O O
expression O O
. O O

Moreover O O
, O O
STAT3 O O
was O O
found O O
to O O
bind O O
the O O
distal O O
Neurog3 O O
promoter O O
/ O O
enhancer O O
region O O
in O O
THY1 O O
+ O O
spermatogonia O O
and O O
regulate O O
transcription O O
. O O
Moreover O O
, O O
STAT3 O O
was O O
found O O
to O O
bind O O
the O O
distal O O
Neurog3 O O
promoter O O
/ O O
enhancer O O
region O O
in O O
THY1 O O
+ O O
spermatogonia O O
and O O
regulate O O
transcription O O
. O O

Transient O O
inhibition O O
of O O
Neurog3 O O
expression O O
in O O
cultures O O
of O O
proliferating O O
THY1 O O
+ O O
spermatogonia O O
increased O O
stem O O
cell O O
content O O
after O O
several O O
self O O
- O O
renewal O O
cycles O O
without O O
effecting O O
overall O O
proliferation O O
of O O
the O O
cells O O
, O O
indicating O O
impaired O O
differentiation O O
of O O
SSCs O O
to O O
produce O O
progenitor O O
spermatogonia O O
. O O

Furthermore O O
, O O
cultured O O
THY1 O O
+ O O
spermatogonia O O
with O O
induced O O
deficiency O O
of O O
Neurog3 O O
were O O
found O O
to O O
be O O
incapable O O
of O O
differentiation O O
in O O
vivo O O
following O O
transplantation O O
into O O
testes O O
of O O
recipient O O
mice O O
. O O

Collectively O O
, O O
these O O
results O O
establish O O
a O O
mechanism O O
by O O
which O O
activation O O
of O O
STAT3 O O
regulates O O
the O O
expression O O
of O O
NEUROG3 O O
to O O
subsequently O O
drive O O
differentiation O O
of O O
SSC O O
and O O
progenitor O O
spermatogonia O O
in O O
the O O
mammalian O O
germline O O
. O O

Enhancer O O
transcripts O O
mark O O
active O O
estrogen O O
receptor O O
binding O O
sites O O
. O O

We O O
have O O
integrated O O
and O O
analyzed O O
a O O
large O O
number O O
of O O
data O O
sets O O
from O O
a O O
variety O O
of O O
genomic O O
assays O O
using O O
a O O
novel O O
computational O O
pipeline O O
to O O
provide O O
a O O
global O O
view O O
of O O
estrogen O O
receptor O O
1 O O
( O O
ESR1 O O
; O O
a O O
. O O
k O O
. O O
a O O
. O O
ERalpha O O
) O O
enhancers O O
in O O
MCF O O
- O O
7 O O
human O O
breast O O
cancer O O
cells O O
. O O
We O O
have O O
integrated O O
and O O
analyzed O O
a O O
large O O
number O O
of O O
data O O
sets O O
from O O
a O O
variety O O
of O O
genomic O O
assays O O
using O O
a O O
novel O O
computational O O
pipeline O O
to O O
provide O O
a O O
global O O
view O O
of O O
estrogen O O
receptor O O
1 O O
( O O
ESR1 O O
; O O
a O O
. O O
k O O
. O O
a O O
. O O
ERalpha O O
) O O
enhancers O O
in O O
MCF O O
- O O
7 O O
human O O
breast O O
cancer O O
cells O O
. O O

Using O O
this O O
approach O O
, O O
we O O
have O O
defined O O
a O O
class O O
of O O
primary O O
transcripts O O
( O O
eRNAs O O
) O O
that O O
are O O
transcribed O O
uni O O
- O O
or O O
bidirectionally O O
from O O
estrogen O O
receptor O O
binding O O
sites O O
( O O
ERBSs O O
) O O
with O O
an O O
average O O
transcription O O
unit O O
length O O
of O O
~ O O
3 O O
- O O
5 O O
kb O O
. O O
Using O O
this O O
approach O O
, O O
we O O
have O O
defined O O
a O O
class O O
of O O
primary O O
transcripts O O
( O O
eRNAs O O
) O O
that O O
are O O
transcribed O O
uni O O
- O O
or O O
bidirectionally O O
from O O
estrogen O O
receptor O O
binding O O
sites O O
( O O
ERBSs O O
) O O
with O O
an O O
average O O
transcription O O
unit O O
length O O
of O O
~ O O
3 O O
- O O
5 O O
kb O O
. O O

The O O
majority O O
are O O
up O O
- O O
regulated O O
by O O
short O O
treatments O O
with O O
estradiol O O
( O O
i O O
. O O
e O O
. O O
, O O
10 O O
, O O
25 O O
, O O
or O O
40 O O
min O O
) O O
with O O
kinetics O O
that O O
precede O O
or O O
match O O
the O O
induction O O
of O O
the O O
target O O
genes O O
. O O

The O O
production O O
of O O
eRNAs O O
at O O
ERBSs O O
is O O
strongly O O
correlated O O
with O O
the O O
enrichment O O
of O O
a O O
number O O
of O O
genomic O O
features O O
that O O
are O O
associated O O
with O O
enhancers O O
( O O
e O O
. O O
g O O
. O O
, O O
H3K4me1 O O
, O O
H3K27ac O O
, O O
EP300 O O
/ O O
CREBBP O O
, O O
RNA O O
polymerase O O
II O O
, O O
open O O
chromatin O O
architecture O O
) O O
, O O
as O O
well O O
as O O
enhancer O O
looping O O
to O O
target O O
gene O O
promoters O O
. O O

In O O
the O O
absence O O
of O O
eRNA O O
production O O
, O O
strong O O
enrichment O O
of O O
these O O
features O O
is O O
not O O
observed O O
, O O
even O O
though O O
ESR1 O O
binding O O
is O O
evident O O
. O O

We O O
find O O
that O O
flavopiridol O O
, O O
a O O
CDK9 O O
inhibitor O O
that O O
blocks O O
transcription O O
elongation O O
, O O
inhibits O O
eRNA O O
production O O
but O O
does O O
not O O
affect O O
other O O
molecular O O
indicators O O
of O O
enhancer O O
activity O O
, O O
suggesting O O
that O O
eRNA O O
production O O
occurs O O
after O O
the O O
assembly O O
of O O
active O O
enhancers O O
. O O

Finally O O
, O O
we O O
show O O
that O O
an O O
enhancer O O
transcription O O
" O O
signature O O
" O O
based O O
on O O
GRO O O
- O O
seq O O
data O O
can O O
be O O
used O O
for O O
de O O
novo O O
enhancer O O
prediction O O
across O O
cell O O
types O O
. O O

Together O O
, O O
our O O
studies O O
shed O O
new O O
light O O
on O O
the O O
activity O O
of O O
ESR1 O O
at O O
its O O
enhancer O O
sites O O
and O O
provide O O
new O O
insights O O
about O O
enhancer O O
function O O
. O O
Together O O
, O O
our O O
studies O O
shed O O
new O O
light O O
on O O
the O O
activity O O
of O O
ESR1 O O
at O O
its O O
enhancer O O
sites O O
and O O
provide O O
new O O
insights O O
about O O
enhancer O O
function O O
. O O

Mesp1 O O
patterns O O
mesoderm O O
into O O
cardiac O O
, O O
hematopoietic O O
, O O
or O O
skeletal O O
myogenic O O
progenitors O O
in O O
a O O
context O O
- O O
dependent O O
manner O O
. O O
Mesp1 O O
is O O
regarded O O
as O O
the O O
master O O
regulator O O
of O O
cardiovascular O O
development O O
, O O
initiating O O
the O O
cardiac O O
transcription O O
factor O O
cascade O O
to O O
direct O O
the O O
generation O O
of O O
cardiac O O
mesoderm O O
. O O

To O O
define O O
the O O
early O O
embryonic O O
cell O O
population O O
that O O
responds O O
to O O
Mesp1 O O
, O O
we O O
performed O O
pulse O O
inductions O O
of O O
gene O O
expression O O
over O O
tight O O
temporal O O
windows O O
following O O
embryonic O O
stem O O
cell O O
differentiation O O
. O O

Remarkably O O
, O O
instead O O
of O O
promoting O O
cardiac O O
differentiation O O
in O O
the O O
initial O O
wave O O
of O O
mesoderm O O
, O O
Mesp1 O O
binds O O
to O O
the O O
Tal1 O O
( O O
Scl O O
) O O
+ O O
40 O O
kb O O
enhancer O O
and O O
generates O O
Flk O O
- O O
1 O O
+ O O
precursors O O
expressing O O
Etv2 O O
( O O
ER71 O O
) O O
and O O
Tal1 O O
that O O
undergo O O
hematopoietic O O
differentiation O O
. O O
Remarkably O O
, O O
instead O O
of O O
promoting O O
cardiac O O
differentiation O O
in O O
the O O
initial O O
wave O O
of O O
mesoderm O O
, O O
Mesp1 O O
binds O O
to O O
the O O
Tal1 O O
( O O
Scl O O
) O O
+ O O
40 O O
kb O O
enhancer O O
and O O
generates O O
Flk O O
- O O
1 O O
+ O O
precursors O O
expressing O O
Etv2 O O
( O O
ER71 O O
) O O
and O O
Tal1 O O
that O O
undergo O O
hematopoietic O O
differentiation O O
. O O

The O O
second O O
wave O O
of O O
mesoderm O O
responds O O
to O O
Mesp1 O O
by O O
differentiating O O
into O O
PDGFRalpha O O
+ O O
precursors O O
that O O
undergo O O
cardiac O O
differentiation O O
. O O

Furthermore O O
, O O
in O O
the O O
absence O O
of O O
serum O O
- O O
derived O O
factors O O
, O O
Mesp1 O O
promotes O O
skeletal O O
myogenic O O
differentiation O O
. O O

Lineage O O
tracing O O
revealed O O
that O O
the O O
majority O O
of O O
yolk O O
sac O O
and O O
many O O
adult O O
hematopoietic O O
cells O O
derive O O
from O O
Mesp1 O O
+ O O
precursors O O
. O O

Thus O O
, O O
Mesp1 O O
is O O
a O O
context O O
- O O
dependent O O
determination O O
factor O O
, O O
integrating O O
the O O
stage O O
of O O
differentiation O O
and O O
the O O
signaling O O
environment O O
to O O
specify O O
different O O
lineage O O
outcomes O O
. O O

eRNAs O O
promote O O
transcription O O
by O O
establishing O O
chromatin O O
accessibility O O
at O O
defined O O
genomic O O
loci O O
. O O

Transcription O O
factors O O
and O O
DNA O O
regulatory O O
binding O O
motifs O O
are O O
fundamental O O
components O O
of O O
the O O
gene O O
regulatory O O
network O O
. O O

Here O O
, O O
by O O
using O O
genome O O
- O O
wide O O
binding O O
profiling O O
, O O
we O O
show O O
extensive O O
occupancy O O
of O O
transcription O O
factors O O
of O O
myogenesis O O
( O O
MyoD O O
and O O
Myogenin O O
) O O
at O O
extragenic O O
enhancer O O
regions O O
coinciding O O
with O O
RNA O O
synthesis O O
( O O
i O O
. O O
e O O
. O O
, O O
eRNA O O
) O O
. O O

In O O
particular O O
, O O
multiple O O
regions O O
were O O
transcribed O O
to O O
eRNA O O
within O O
the O O
regulatory O O
region O O
of O O
MYOD1 O O
, O O
including O O
previously O O
characterized O O
distal O O
regulatory O O
regions O O
( O O
DRR O O
) O O
and O O
core O O
enhancer O O
( O O
CE O O
) O O
. O O

While O O
( O O
CE O O
) O O
RNA O O
enhanced O O
RNA O O
polymerase O O
II O O
( O O
Pol O O
II O O
) O O
occupancy O O
and O O
transcription O O
at O O
MYOD1 O O
, O O
( O O
DRR O O
) O O
RNA O O
acted O O
to O O
activate O O
the O O
downstream O O
myogenic O O
genes O O
. O O

The O O
deployment O O
of O O
transcriptional O O
machinery O O
to O O
appropriate O O
loci O O
is O O
contingent O O
on O O
chromatin O O
accessibility O O
, O O
a O O
rate O O
- O O
limiting O O
step O O
preceding O O
Pol O O
II O O
assembly O O
. O O

By O O
nuclease O O
sensitivity O O
assay O O
, O O
we O O
found O O
that O O
eRNAs O O
regulate O O
genomic O O
access O O
of O O
the O O
transcriptional O O
complex O O
to O O
defined O O
regulatory O O
regions O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
eRNAs O O
contribute O O
to O O
establishing O O
a O O
cell O O
- O O
type O O
- O O
specific O O
transcriptional O O
circuitry O O
by O O
directing O O
chromatin O O
- O O
remodeling O O
events O O
. O O

The O O
transcription O O
factors O O
Sox10 O O
and O O
Myrf O O
define O O
an O O
essential O O
regulatory O O
network O O
module O O
in O O
differentiating O O
oligodendrocytes O O
. O O

Myelin O O
is O O
essential O O
for O O
rapid O O
saltatory O O
conduction O O
and O O
is O O
produced O O
by O O
Schwann O O
cells O O
in O O
the O O
peripheral O O
nervous O O
system O O
and O O
oligodendrocytes O O
in O O
the O O
central O O
nervous O O
system O O
. O O

In O O
both O O
cell O O
types O O
the O O
transcription O O
factor O O
Sox10 O O
is O O
an O O
essential O O
component O O
of O O
the O O
myelin O O
- O O
specific O O
regulatory O O
network O O
. O O

Here O O
we O O
identify O O
Myrf O O
as O O
an O O
oligodendrocyte O O
- O O
specific O O
target O O
of O O
Sox10 O O
and O O
map O O
a O O
Sox10 O O
responsive O O
enhancer O O
to O O
an O O
evolutionarily O O
conserved O O
element O O
in O O
intron O O
1 O O
of O O
the O O
Myrf O O
gene O O
. O O
Here O O
we O O
identify O O
Myrf O O
as O O
an O O
oligodendrocyte O O
- O O
specific O O
target O O
of O O
Sox10 O O
and O O
map O O
a O O
Sox10 O O
responsive O O
enhancer O O
to O O
an O O
evolutionarily O O
conserved O O
element O O
in O O
intron O O
1 O O
of O O
the O O
Myrf O O
gene O O
. O O

Once O O
induced O O
, O O
Myrf O O
cooperates O O
with O O
Sox10 O O
to O O
implement O O
the O O
myelination O O
program O O
as O O
evident O O
from O O
the O O
physical O O
interaction O O
between O O
both O O
proteins O O
and O O
the O O
synergistic O O
activation O O
of O O
several O O
myelin O O
- O O
specific O O
genes O O
. O O

This O O
is O O
strongly O O
reminiscent O O
of O O
the O O
situation O O
in O O
Schwann O O
cells O O
where O O
Sox10 O O
first O O
induces O O
and O O
then O O
cooperates O O
with O O
Krox20 O O
during O O
myelination O O
. O O

Our O O
analyses O O
indicate O O
that O O
the O O
regulatory O O
network O O
for O O
myelination O O
in O O
oligodendrocytes O O
is O O
organized O O
along O O
similar O O
general O O
principles O O
as O O
the O O
one O O
in O O
Schwann O O
cells O O
, O O
but O O
is O O
differentially O O
implemented O O
. O O

Role O O
of O O
SWI O O
/ O O
SNF O O
in O O
acute B-Disease B-Disease
leukemia I-Disease I-Disease
maintenance O O
and O O
enhancer O O
- O O
mediated O O
Myc O O
regulation O O
. O O
Cancer O O
cells O O
frequently O O
depend O O
on O O
chromatin O O
regulatory O O
activities O O
to O O
maintain O O
a O O
malignant O O
phenotype O O
. O O

Here O O
, O O
we O O
show O O
that O O
leukemia O O
cells O O
require O O
the O O
mammalian O O
SWI O O
/ O O
SNF O O
chromatin O O
remodeling O O
complex O O
for O O
their O O
survival O O
and O O
aberrant O O
self O O
- O O
renewal O O
potential O O
. O O

While O O
Brg1 O O
, O O
an O O
ATPase O O
subunit O O
of O O
SWI O O
/ O O
SNF O O
, O O
is O O
known O O
to O O
suppress O O
tumor B-Disease B-Disease
formation O O
in O O
several O O
cell O O
types O O
, O O
we O O
found O O
that O O
leukemia B-Disease O
cells O O
instead O O
rely O O
on O O
Brg1 O O
to O O
support O O
their O O
oncogenic O O
transcriptional O O
program O O
, O O
which O O
includes O O
Myc O O
as O O
one O O
of O O
its O O
key O O
targets O O
. O O

To O O
account O O
for O O
this O O
context O O
- O O
specific O O
function O O
, O O
we O O
identify O O
a O O
cluster O O
of O O
lineage O O
- O O
specific O O
enhancers O O
located O O
1 O O
. O O
7 O O
Mb O O
downstream O O
from O O
Myc O O
that O O
are O O
occupied O O
by O O
SWI O O
/ O O
SNF O O
as O O
well O O
as O O
the O O
BET O O
protein O O
Brd4 O O
. O O
Brg1 O O
is O O
required O O
at O O
these O O
distal O O
elements O O
to O O
maintain O O
transcription O O
factor O O
occupancy O O
and O O
for O O
long O O
- O O
range O O
chromatin O O
looping O O
interactions O O
with O O
the O O
Myc O O
promoter O O
. O O
To O O
account O O
for O O
this O O
context O O
- O O
specific O O
function O O
, O O
we O O
identify O O
a O O
cluster O O
of O O
lineage O O
- O O
specific O O
enhancers O O
located O O
1 O O
. O O
7 O O
Mb O O
downstream O O
from O O
Myc O O
that O O
are O O
occupied O O
by O O
SWI O O
/ O O
SNF O O
as O O
well O O
as O O
the O O
BET O O
protein O O
Brd4 O O
. O O
Brg1 O O
is O O
required O O
at O O
these O O
distal O O
elements O O
to O O
maintain O O
transcription O O
factor O O
occupancy O O
and O O
for O O
long O O
- O O
range O O
chromatin O O
looping O O
interactions O O
with O O
the O O
Myc O O
promoter O O
. O O

Notably O O
, O O
these O O
distal O O
Myc O O
enhancers O O
coincide O O
with O O
a O O
region O O
that O O
is O O
focally O O
amplified O O
in O O
~ O O
3 O O
% O O
of O O
acute B-Disease B-Disease
myeloid I-Disease I-Disease
leukemias I-Disease I-Disease
. O O

Together O O
, O O
these O O
findings O O
define O O
a O O
leukemia B-Disease B-Disease
maintenance O O
function O O
for O O
SWI O O
/ O O
SNF O O
that O O
is O O
linked O O
to O O
enhancer O O
- O O
mediated O O
gene O O
regulation O O
, O O
providing O O
general O O
insights O O
into O O
how O O
cancer O O
cells O O
exploit O O
transcriptional O O
coactivators O O
to O O
maintain O O
oncogenic O O
gene O O
expression O O
programs O O
. O O

Switch O O
enhancers O O
interpret O O
TGF O O
- O O
beta O O
and O O
Hippo O O
signaling O O
to O O
control O O
cell O O
fate O O
in O O
human O O
embryonic O O
stem O O
cells O O
. O O

A O O
small O O
toolkit O O
of O O
morphogens O O
is O O
used O O
repeatedly O O
to O O
direct O O
development O O
, O O
raising O O
the O O
question O O
of O O
how O O
context O O
dictates O O
interpretation O O
of O O
the O O
same O O
cue O O
. O O

One O O
example O O
is O O
the O O
transforming O O
growth O O
factor O O
beta O O
( O O
TGF O O
- O O
beta O O
) O O
pathway O O
that O O
in O O
human O O
embryonic O O
stem O O
cells O O
fulfills O O
two O O
opposite O O
functions O O
: O O
pluripotency O O
maintenance O O
and O O
mesendoderm O O
( O O
ME O O
) O O
specification O O
. O O

Using O O
proteomics O O
coupled O O
to O O
analysis O O
of O O
genome O O
occupancy O O
, O O
we O O
uncover O O
a O O
regulatory O O
complex O O
composed O O
of O O
transcriptional O O
effectors O O
of O O
the O O
Hippo O O
pathway O O
( O O
TAZ O O
/ O O
YAP O O
/ O O
TEAD O O
) O O
, O O
the O O
TGF O O
- O O
beta O O
pathway O O
( O O
SMAD2 O O
/ O O
3 O O
) O O
, O O
and O O
the O O
pluripotency O O
regulator O O
OCT4 O O
( O O
TSO O O
) O O
. O O

TSO O O
collaborates O O
with O O
NuRD O O
repressor O O
complexes O O
to O O
buffer O O
pluripotency O O
gene O O
expression O O
while O O
suppressing O O
ME O O
genes O O
. O O

Importantly O O
, O O
the O O
SMAD O O
DNA O O
binding O O
partner O O
FOXH1 O O
, O O
a O O
major O O
specifier O O
of O O
ME O O
, O O
is O O
found O O
near O O
TSO O O
elements O O
, O O
and O O
upon O O
fate O O
specification O O
we O O
show O O
that O O
TSO O O
is O O
disrupted O O
with O O
subsequent O O
SMAD O O
- O O
FOXH1 O O
induction O O
of O O
ME O O
. O O

These O O
studies O O
define O O
switch O O
- O O
enhancer O O
elements O O
and O O
provide O O
a O O
framework O O
to O O
understand O O
how O O
cellular O O
context O O
dictates O O
interpretation O O
of O O
the O O
same O O
morphogen O O
signal O O
in O O
development O O
. O O

Genetic O O
determinants O O
of O O
neuroglobin O O
transcription O O
. O O
Neuroglobin O O
( O O
NGB O O
) O O
is O O
a O O
neuron O O
- O O
specific O O
vertebrate O O
globin O O
shown O O
to O O
protect O O
against O O
hypoxia B-Disease B-Disease
, O O
ischemia B-Disease B-Disease
, O O
oxidative O O
stress O O
and O O
the O O
toxic O O
effects O O
of O O
Amyloid O O
- O O
beta O O
. O O

Following O O
on O O
our O O
and O O
others O O
' O O
results O O
highlighting O O
the O O
importance O O
of O O
NGB O O
expression O O
in O O
disease O O
, O O
we O O
searched O O
for O O
genetic O O
determinants O O
of O O
its O O
expression O O
. O O

We O O
found O O
that O O
a O O
microRNA O O
expressed O O
with O O
the O O
NGB O O
transcript O O
shows O O
significant O O
target O O
enrichments O O
in O O
the O O
angiogenesis O O
pathway O O
and O O
the O O
Alzheimer B-Disease B-Disease
disease I-Disease I-Disease
/ O O
presenilin O O
pathway O O
. O O

Using O O
reporter O O
constructs O O
we O O
identified O O
potential O O
promoter O O
/ O O
enhancer O O
elements O O
between O O
the O O
transcription O O
start O O
site O O
and O O
1 O O
, O O
142 O O
bp O O
upstream O O
. O O

Using O O
184 O O
post O O
- O O
mortem O O
temporal O O
lobe O O
samples O O
we O O
replicated O O
the O O
reported O O
negative O O
effect O O
of O O
age O O
, O O
and O O
after O O
genotyping O O
tagging O O
SNPs O O
we O O
found O O
one O O
( O O
rs981471 O O
) O O
showing O O
a O O
significant O O
correlation O O
with O O
the O O
gene O O
' O O
s O O
expression O O
and O O
another O O
( O O
rs8014408 O O
) O O
showing O O
an O O
interaction O O
with O O
age O O
, O O
the O O
rare O O
C O O
allele O O
being O O
correlated O O
with O O
higher O O
expression O O
and O O
faster O O
decline O O
. O O

The O O
two O O
SNPs O O
are O O
towards O O
the O O
3 O O
' O O
end O O
of O O
NGB O O
within O O
the O O
same O O
LD O O
block O O
, O O
52 O O
Kb O O
apart O O
and O O
modestly O O
correlated O O
( O O
r O O
( O O
2 O O
) O O
= O O
0 O O
. O O
5 O O
) O O
. O O

Next O O
generation O O
sequencing O O
of O O
the O O
same O O
184 O O
temporal O O
lobe O O
samples O O
and O O
79 O O
confirmed O O
AD B-Disease B-Disease
patients O O
across O O
the O O
entire O O
gene O O
region O O
( O O
including O O
> O O
12 O O
Kb O O
on O O
the O O
3 O O
' O O
and O O
5 O O
' O O
flank O O
) O O
revealed O O
limited O O
coding O O
variation O O
, O O
suggesting O O
purifying O O
selection O O
of O O
NGB O O
, O O
but O O
did O O
not O O
identify O O
regulatory O O
or O O
disease O O
associated O O
rare O O
variants O O
. O O

A O O
dinucleotide O O
repeat O O
in O O
intron O O
1 O O
with O O
extensive O O
evidence O O
of O O
functionality O O
showed O O
interesting O O
but O O
inconclusive O O
results O O
, O O
as O O
it O O
was O O
not O O
amenable O O
to O O
further O O
molecular O O
analysis O O
. O O

Enhancer O O
- O O
targeted O O
genome O O
editing O O
selectively O O
blocks O O
innate O O
resistance O O
to O O
oncokinase O O
inhibition O O
. O O

Thousands O O
of O O
putative O O
enhancers O O
are O O
characterized O O
in O O
the O O
human O O
genome O O
, O O
yet O O
few O O
have O O
been O O
shown O O
to O O
have O O
a O O
functional O O
role O O
in O O
cancer B-Disease B-Disease
progression O O
. O O

Inhibiting O O
oncokinases O O
, O O
such O O
as O O
EGFR O O
, O O
ALK O O
, O O
ERBB2 O O
, O O
and O O
BRAF O O
, O O
is O O
a O O
mainstay O O
of O O
current O O
cancer B-Disease B-Disease
therapy O O
but O O
is O O
hindered O O
by O O
innate O O
drug O O
resistance O O
mediated O O
by O O
up O O
- O O
regulation O O
of O O
the O O
HGF O O
receptor O O
, O O
MET O O
. O O

The O O
mechanisms O O
mediating O O
such O O
genomic O O
responses O O
to O O
targeted O O
therapy O O
are O O
unknown O O
. O O

Here O O
, O O
we O O
identify O O
lineage O O
- O O
specific O O
enhancers O O
at O O
the O O
MET O O
locus O O
for O O
multiple O O
common O O
tumor B-Disease B-Disease
types O O
, O O
including O O
a O O
melanoma O B-Disease
lineage O O
- O O
specific O O
enhancer O O
63 O O
kb O O
downstream O O
from O O
the O O
MET O O
TSS O O
. O O
Here O O
, O O
we O O
identify O O
lineage O O
- O O
specific O O
enhancers O O
at O O
the O O
MET O O
locus O O
for O O
multiple O O
common O O
tumor B-Disease B-Disease
types O O
, O O
including O O
a O O
melanoma O B-Disease
lineage O O
- O O
specific O O
enhancer O O
63 O O
kb O O
downstream O O
from O O
the O O
MET O O
TSS O O
. O O

This O O
enhancer O O
displays O O
inducible O O
chromatin O O
looping O O
with O O
the O O
MET O O
promoter O O
to O O
up O O
- O O
regulate O O
MET O O
expression O O
upon O O
BRAF O O
inhibition O O
. O O
This O O
enhancer O O
displays O O
inducible O O
chromatin O O
looping O O
with O O
the O O
MET O O
promoter O O
to O O
up O O
- O O
regulate O O
MET O O
expression O O
upon O O
BRAF O O
inhibition O O
. O O

Epigenomic O O
analysis O O
demonstrated O O
that O O
the O O
melanocyte O O
- O O
specific O O
transcription O O
factor O O
, O O
MITF O O
, O O
mediates O O
this O O
enhancer O O
function O O
. O O

Targeted O O
genomic O O
deletion O O
( O O
< O O
7 O O
bp O O
) O O
of O O
the O O
MITF O O
motif O O
within O O
the O O
MET O O
enhancer O O
suppressed O O
inducible O O
chromatin O O
looping O O
and O O
innate O O
drug O O
resistance O O
, O O
while O O
maintaining O O
MITF O O
- O O
dependent O O
, O O
inhibitor O O
- O O
induced O O
melanoma O O
cell O O
differentiation O O
. O O
Targeted O O
genomic O O
deletion O O
( O O
< O O
7 O O
bp O O
) O O
of O O
the O O
MITF O O
motif O O
within O O
the O O
MET O O
enhancer O O
suppressed O O
inducible O O
chromatin O O
looping O O
and O O
innate O O
drug O O
resistance O O
, O O
while O O
maintaining O O
MITF O O
- O O
dependent O O
, O O
inhibitor O O
- O O
induced O O
melanoma O O
cell O O
differentiation O O
. O O

Epigenomic O O
analysis O O
can O O
thus O O
guide O O
functional O O
disruption O O
of O O
regulatory O O
DNA O O
to O O
decouple O O
pro O O
- O O
and O O
anti O O
- O O
oncogenic O O
functions O O
of O O
a O O
dominant O O
transcription O O
factor O O
and O O
block O O
innate O O
resistance O O
to O O
oncokinase O O
therapy O O
. O O

Human O O
colorectal B-Disease B-Disease
cancer I-Disease I-Disease
- O O
specific O O
CCAT1 O O
- O O
L O O
lncRNA O O
regulates O O
long O O
- O O
range O O
chromatin O O
interactions O O
at O O
the O O
MYC O O
locus O O
. O O

The O O
human O O
8q24 O O
gene O O
desert O O
contains O O
multiple O O
enhancers O O
that O O
form O O
tissue O O
- O O
specific O O
long O O
- O O
range O O
chromatin O O
loops O O
with O O
the O O
MYC O O
oncogene O O
, O O
but O O
how O O
chromatin O O
looping O O
at O O
the O O
MYC O O
locus O O
is O O
regulated O O
remains O O
poorly O O
understood O O
. O O

Here O O
we O O
demonstrate O O
that O O
a O O
long O O
noncoding O O
RNA O O
( O O
lncRNA O O
) O O
, O O
CCAT1 O O
- O O
L O O
, O O
is O O
transcribed O O
specifically O O
in O O
human O O
colorectal B-Disease B-Disease
cancers I-Disease I-Disease
from O O
a O O
locus O O
515 O O
kb O O
upstream O O
of O O
MYC O O
. O O

This O O
lncRNA O O
plays O O
a O O
role O O
in O O
MYC O O
transcriptional O O
regulation O O
and O O
promotes O O
long O O
- O O
range O O
chromatin O O
looping O O
. O O

Importantly O O
, O O
the O O
CCAT1 O O
- O O
L O O
locus O O
is O O
located O O
within O O
a O O
strong O O
super O O
- O O
enhancer O O
and O O
is O O
spatially O O
close O O
to O O
MYC O O
. O O

Knockdown O O
of O O
CCAT1 O O
- O O
L O O
reduced O O
long O O
- O O
range O O
interactions O O
between O O
the O O
MYC O O
promoter O O
and O O
its O O
enhancers O O
. O O
Knockdown O O
of O O
CCAT1 O O
- O O
L O O
reduced O O
long O O
- O O
range O O
interactions O O
between O O
the O O
MYC O O
promoter O O
and O O
its O O
enhancers O O
. O O

In O O
addition O O
, O O
CCAT1 O O
- O O
L O O
interacts O O
with O O
CTCF O O
and O O
modulates O O
chromatin O O
conformation O O
at O O
these O O
loop O O
regions O O
. O O

These O O
results O O
reveal O O
an O O
important O O
role O O
of O O
a O O
previously O O
unannotated O O
lncRNA O O
in O O
gene O O
regulation O O
at O O
the O O
MYC O O
locus O O
. O O

Dlx5 O O
and O O
mef2 O O
regulate O O
a O O
novel O O
runx2 O O
enhancer O O
for O O
osteoblast O O
- O O
specific O O
expression O O
. O O
Runx2 O O
is O O
essential O O
for O O
osteoblast O O
differentiation O O
and O O
chondrocyte O O
maturation O O
. O O
Dlx5 O O
and O O
mef2 O O
regulate O O
a O O
novel O O
runx2 O O
enhancer O O
for O O
osteoblast O O
- O O
specific O O
expression O O
. O O
Runx2 O O
is O O
essential O O
for O O
osteoblast O O
differentiation O O
and O O
chondrocyte O O
maturation O O
. O O

The O O
expression O O
of O O
Runx2 O O
is O O
the O O
first O O
requisite O O
step O O
for O O
the O O
lineage O O
determination O O
from O O
mesenchymal O O
stem O O
cells O O
to O O
osteoblasts O O
. O O

Although O O
the O O
transcript O O
from O O
Runx2 O O
distal O O
promoter O O
is O O
majorly O O
expressed O O
in O O
osteoblasts O O
, O O
the O O
promoter O O
failed O O
to O O
direct O O
green O O
fluorescent O O
protein O O
( O O
GFP O O
) O O
expression O O
to O O
osteoblasts O O
. O O
Although O O
the O O
transcript O O
from O O
Runx2 O O
distal O O
promoter O O
is O O
majorly O O
expressed O O
in O O
osteoblasts O O
, O O
the O O
promoter O O
failed O O
to O O
direct O O
green O O
fluorescent O O
protein O O
( O O
GFP O O
) O O
expression O O
to O O
osteoblasts O O
. O O

To O O
find O O
the O O
regulatory O O
region O O
, O O
we O O
generated O O
GFP O O
reporter O O
mice O O
driven O O
by O O
a O O
bacterial O O
artificial O O
chromosome O O
( O O
BAC O O
) O O
of O O
Runx2 O O
locus O O
, O O
and O O
succeeded O O
in O O
the O O
reproduction O O
of O O
endogenous O O
Runx2 O O
expression O O
. O O

By O O
serially O O
deleting O O
it O O
, O O
we O O
identified O O
a O O
343 O O
- O O
bp O O
enhancer O O
, O O
which O O
directed O O
GFP O O
expression O O
specifically O O
to O O
osteoblasts O O
, O O
about O O
30 O O
kb O O
upstream O O
of O O
the O O
distal O O
promoter O O
. O O
By O O
serially O O
deleting O O
it O O
, O O
we O O
identified O O
a O O
343 O O
- O O
bp O O
enhancer O O
, O O
which O O
directed O O
GFP O O
expression O O
specifically O O
to O O
osteoblasts O O
, O O
about O O
30 O O
kb O O
upstream O O
of O O
the O O
distal O O
promoter O O
. O O

The O O
sequence O O
of O O
the O O
343 O O
- O O
bp O O
enhancer O O
was O O
highly O O
conserved O O
among O O
mouse O O
, O O
human O O
, O O
dog O O
, O O
horse O O
, O O
opossum O O
, O O
and O O
chicken O O
. O O
Dlx5 O O
, O O
Mef2c O O
, O O
Tcf7 O O
, O O
Ctnnb1 O O
, O O
Sp7 O O
, O O
Smad1 O O
, O O
and O O
Sox6 O O
, O O
which O O
localized O O
on O O
the O O
enhancer O O
region O O
in O O
primary O O
osteoblasts O O
, O O
synergistically O O
upregulated O O
the O O
enhancer O O
activity O O
, O O
whereas O O
Msx2 O O
downregulated O O
the O O
activity O O
in O O
mouse O O
osteoblastic O O
MC3T3 O O
- O O
E1 O O
cells O O
. O O
Msx2 O O
was O O
predominantly O O
bound O O
to O O
the O O
enhancer O O
in O O
mouse O O
multipotent O O
mesenchymal O O
C3H10T1 O O
/ O O
2 O O
cells O O
, O O
whereas O O
Dlx5 O O
was O O
predominantly O O
bound O O
to O O
the O O
enhancer O O
in O O
MC3T3 O O
- O O
E1 O O
cells O O
. O O
Dlx5 O O
and O O
Mef2 O O
directly O O
bound O O
to O O
the O O
enhancer O O
, O O
and O O
the O O
binding O O
sites O O
were O O
required O O
for O O
the O O
osteoblast O O
- O O
specific O O
expression O O
in O O
mice O O
, O O
whereas O O
the O O
other O O
factors O O
bound O O
to O O
the O O
enhancer O O
by O O
protein O O
- O O
protein O O
interaction O O
. O O

The O O
enhancer O O
was O O
characterized O O
by O O
the O O
presence O O
of O O
the O O
histone O O
variant O O
H2A O O
. O O
Z O O
, O O
the O O
enrichment O O
of O O
histone O O
H3 O O
mono O O
- O O
and O O
dimethylated O O
at O O
Lys4 O O
and O O
acetylated O O
at O O
Lys18 O O
and O O
Lys27 O O
, O O
but O O
the O O
depletion O O
of O O
histone O O
H3 O O
trimethylated O O
at O O
Lys4 O O
in O O
primary O O
osteoblasts O O
. O O

These O O
findings O O
indicated O O
that O O
the O O
enhancer O O
, O O
which O O
had O O
typical O O
histone O O
modifications O O
for O O
enhancers O O
, O O
contains O O
sufficient O O
elements O O
to O O
direct O O
Runx2 O O
expression O O
to O O
osteoblasts O O
, O O
and O O
that O O
Dlx5 O O
and O O
Mef2 O O
, O O
which O O
formed O O
an O O
enhanceosome O O
with O O
Tcf7 O O
, O O
Ctnnb1 O O
, O O
Sp7 O O
, O O
Smad1 O O
, O O
and O O
Sox6 O O
, O O
play O O
an O O
essential O O
role O O
in O O
the O O
osteoblast O O
- O O
specific O O
activation O O
of O O
the O O
enhancer O O
. O O

2014 O O
American O O
Society O O
for O O
Bone O O
and O O
Mineral O O
Research O O
. O O

A O O
remote O O
GATA2 O O
hematopoietic O O
enhancer O O
drives O O
leukemogenesis O O
in O O
inv O O
( O O
3 O O
) O O
( O O
q21 O O
; O O
q26 O O
) O O
by O O
activating O O
EVI1 O O
expression O O
. O O
A O O
remote O O
GATA2 O O
hematopoietic O O
enhancer O O
drives O O
leukemogenesis O O
in O O
inv O O
( O O
3 O O
) O O
( O O
q21 O O
; O O
q26 O O
) O O
by O O
activating O O
EVI1 O O
expression O O
. O O

Chromosomal O O
inversion O O
between O O
3q21 O O
and O O
3q26 O O
results O O
in O O
high O O
- O O
risk O O
acute B-Disease B-Disease
myeloid I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
AML B-Disease B-Disease
) O O
. O O

In O O
this O O
study O O
, O O
we O O
identified O O
a O O
mechanism O O
whereby O O
a O O
GATA2 O O
distal O O
hematopoietic O O
enhancer O O
( O O
G2DHE O O
or O O
- O O
77 O O
- O O
kb O O
enhancer O O
) O O
is O O
brought O O
into O O
close O O
proximity O O
to O O
the O O
EVI1 O O
gene O O
in O O
inv O O
( O O
3 O O
) O O
( O O
q21 O O
; O O
q26 O O
) O O
inversions O O
, O O
leading O O
to O O
leukemogenesis O O
. O O
In O O
this O O
study O O
, O O
we O O
identified O O
a O O
mechanism O O
whereby O O
a O O
GATA2 O O
distal O O
hematopoietic O O
enhancer O O
( O O
G2DHE O O
or O O
- O O
77 O O
- O O
kb O O
enhancer O O
) O O
is O O
brought O O
into O O
close O O
proximity O O
to O O
the O O
EVI1 O O
gene O O
in O O
inv O O
( O O
3 O O
) O O
( O O
q21 O O
; O O
q26 O O
) O O
inversions O O
, O O
leading O O
to O O
leukemogenesis O O
. O O

We O O
examined O O
the O O
contribution O O
of O O
G2DHE O O
to O O
leukemogenesis O O
by O O
creating O O
a O O
bacterial O O
artificial O O
chromosome O O
( O O
BAC O O
) O O
transgenic O O
model O O
that O O
recapitulates O O
the O O
inv O O
( O O
3 O O
) O O
( O O
q21 O O
; O O
q26 O O
) O O
allele O O
. O O

Transgenic O O
mice O O
harboring O O
a O O
linked O O
BAC O O
developed O O
leukemia B-Disease B-Disease
accompanied O O
by O O
EVI1 O O
overexpression O O
- O O
neoplasia O B-Disease
that O O
was O O
not O O
detected O O
in O O
mice O O
bearing O O
the O O
same O O
transgene O O
but O O
that O O
was O O
missing O O
the O O
GATA2 O O
enhancer O O
. O O
Transgenic O O
mice O O
harboring O O
a O O
linked O O
BAC O O
developed O O
leukemia B-Disease B-Disease
accompanied O O
by O O
EVI1 O O
overexpression O O
- O O
neoplasia O B-Disease
that O O
was O O
not O O
detected O O
in O O
mice O O
bearing O O
the O O
same O O
transgene O O
but O O
that O O
was O O
missing O O
the O O
GATA2 O O
enhancer O O
. O O

These O O
results O O
establish O O
the O O
mechanistic O O
basis O O
underlying O O
the O O
pathogenesis O O
of O O
a O O
severe O O
form O O
of O O
leukemia B-Disease B-Disease
through O O
aberrant O O
expression O O
of O O
the O O
EVI1 O O
proto O O
- O O
oncogene O O
. O O

Identification O O
and O O
characterization O O
of O O
germ O O
cell O O
genes O O
expressed O O
in O O
the O O
F9 O O
testicular O O
teratoma O O
stem O O
cell O O
line O O
. O O

The O O
F9 O O
cell O O
line O O
, O O
which O O
was O O
derived O O
from O O
a O O
mouse O O
testicular B-Disease B-Disease
teratoma I-Disease I-Disease
that O O
originated O O
from O O
pluripotent O O
germ O O
cells O O
, O O
has O O
been O O
used O O
as O O
a O O
model O O
for O O
differentiation O O
. O O

However O O
, O O
it O O
is O O
largely O O
unknown O O
whether O O
F9 O O
cells O O
possess O O
the O O
characteristics O O
of O O
male O O
germ O O
cells O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
spermatogenic O O
stage O O
- O O
and O O
cell O O
type O O
- O O
specific O O
gene O O
expression O O
in O O
F9 O O
cells O O
. O O

Analysis O O
of O O
previous O O
microarray O O
data O O
showed O O
that O O
a O O
large O O
number O O
of O O
stage O O
- O O
regulated O O
germ O O
cell O O
genes O O
are O O
expressed O O
in O O
F9 O O
cells O O
. O O

Specifically O O
, O O
genes O O
that O O
are O O
prominently O O
expressed O O
in O O
spermatogonia O O
and O O
have O O
transcriptional O O
regulatory O O
functions O O
appear O O
to O O
be O O
enriched O O
in O O
F9 O O
cells O O
. O O

Our O O
in O O
silico O O
and O O
in O O
vitro O O
analyses O O
identified O O
several O O
germ O O
cell O O
- O O
specific O O
or O O
- O O
predominant O O
genes O O
that O O
are O O
expressed O O
in O O
F9 O O
cells O O
. O O

Among O O
them O O
, O O
strong O O
promoter O O
activities O O
were O O
observed O O
in O O
the O O
regions O O
upstream O O
of O O
the O O
spermatogonial O O
genes O O
, O O
Dmrt1 O O
( O O
doublesex O O
and O O
mab O O
- O O
3 O O
related O O
transcription O O
factor O O
1 O O
) O O
, O O
Stra8 O O
( O O
stimulated O O
by O O
retinoic O O
acid O O
gene O O
8 O O
) O O
and O O
Tex13 O O
( O O
testis O O
expressed O O
gene O O
13 O O
) O O
, O O
in O O
F9 O O
cells O O
. O O

A O O
detailed O O
analysis O O
of O O
the O O
Tex13 O O
promoter O O
allowed O O
us O O
to O O
identify O O
an O O
enhancer O O
and O O
a O O
region O O
that O O
is O O
implicated O O
in O O
germ O O
cell O O
- O O
specificity O O
. O O
A O O
detailed O O
analysis O O
of O O
the O O
Tex13 O O
promoter O O
allowed O O
us O O
to O O
identify O O
an O O
enhancer O O
and O O
a O O
region O O
that O O
is O O
implicated O O
in O O
germ O O
cell O O
- O O
specificity O O
. O O

We O O
also O O
found O O
that O O
Tex13 O O
expression O O
is O O
regulated O O
by O O
DNA O O
methylation O O
. O O

Finally O O
, O O
analysis O O
of O O
GFP O O
( O O
green O O
fluorescent O O
protein O O
) O O
TEX13 O O
localization O O
revealed O O
that O O
the O O
protein O O
distributes O O
heterogeneously O O
in O O
the O O
cytoplasm O O
and O O
nucleus O O
, O O
suggesting O O
that O O
TEX13 O O
shuttles O O
between O O
these O O
two O O
compartments O O
. O O

Taken O O
together O O
, O O
our O O
results O O
demonstrate O O
that O O
F9 O O
cells O O
express O O
numerous O O
spermatogonial O O
genes O O
and O O
could O O
be O O
used O O
for O O
transcriptional O O
studies O O
focusing O O
on O O
such O O
genes O O
. O O

As O O
an O O
example O O
of O O
this O O
, O O
we O O
use O O
F9 O O
cells O O
to O O
provide O O
comprehensive O O
expressional O O
information O O
about O O
Tex13 O O
, O O
and O O
report O O
that O O
this O O
gene O O
appears O O
to O O
encode O O
a O O
germ O O
cell O O
- O O
specific O O
protein O O
that O O
functions O O
in O O
the O O
nucleus O O
during O O
early O O
spermatogenesis O O
. O O

A O O
NOTCH1 O O
- O O
driven O O
MYC O O
enhancer O O
promotes O O
T O O
cell O O
development O O
, O O
transformation O O
and O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O
A O O
NOTCH1 O O
- O O
driven O O
MYC O O
enhancer O O
promotes O O
T O O
cell O O
development O O
, O O
transformation O O
and O O
acute B-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

Efforts O O
to O O
identify O O
and O O
annotate O O
cancer B-Disease B-Disease
driver O O
genetic O B-Disease
lesions O I-Disease
have O O
been O O
focused O O
primarily O O
on O O
the O O
analysis O O
of O O
protein O O
- O O
coding O O
genes O O
; O O
however O O
, O O
most O O
genetic O B-Disease
abnormalities O I-Disease
found O O
in O O
human O O
cancer B-Disease B-Disease
are O O
located O O
in O O
intergenic O O
regions O O
. O O

Here O O
we O O
identify O O
a O O
new O O
long O O
range O O
- O O
acting O O
MYC O O
enhancer O O
controlled O O
by O O
NOTCH1 O O
that O O
is O O
targeted O O
by O O
recurrent O O
chromosomal O O
duplications O O
in O O
human O O
T B-Disease O
cell I-Disease O
acute I-Disease B-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
T B-Disease B-Disease
- I-Disease I-Disease
ALL I-Disease I-Disease
) O O
. O O
Here O O
we O O
identify O O
a O O
new O O
long O O
range O O
- O O
acting O O
MYC O O
enhancer O O
controlled O O
by O O
NOTCH1 O O
that O O
is O O
targeted O O
by O O
recurrent O O
chromosomal O O
duplications O O
in O O
human O O
T B-Disease B-Disease
cell I-Disease I-Disease
acute I-Disease I-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
T B-Disease B-Disease
- I-Disease I-Disease
ALL I-Disease I-Disease
) O O
. O O

This O O
highly O O
conserved O O
regulatory O O
element O O
, O O
hereby O O
named O O
N O O
- O O
Me O O
for O O
NOTCH O O
MYC O O
enhancer O O
, O O
is O O
located O O
within O O
a O O
broad O O
super O O
- O O
enhancer O O
region O O
+ O O
1 O O
. O O
47 O O
Mb O O
from O O
the O O
MYC O O
transcription O O
initiating O O
site O O
, O O
interacts O O
with O O
the O O
MYC O O
proximal O O
promoter O O
and O O
induces O O
orientation O O
- O O
independent O O
MYC O O
expression O O
in O O
reporter O O
assays O O
. O O
This O O
highly O O
conserved O O
regulatory O O
element O O
, O O
hereby O O
named O O
N O O
- O O
Me O O
for O O
NOTCH O O
MYC O O
enhancer O O
, O O
is O O
located O O
within O O
a O O
broad O O
super O O
- O O
enhancer O O
region O O
+ O O
1 O O
. O O
47 O O
Mb O O
from O O
the O O
MYC O O
transcription O O
initiating O O
site O O
, O O
interacts O O
with O O
the O O
MYC O O
proximal O O
promoter O O
and O O
induces O O
orientation O O
- O O
independent O O
MYC O O
expression O O
in O O
reporter O O
assays O O
. O O

Moreover O O
, O O
analysis O O
of O O
N O O
- O O
Me O O
knockout O O
mice O O
demonstrates O O
a O O
selective O O
and O O
essential O O
role O O
of O O
this O O
regulatory O O
element O O
during O O
thymocyte O O
development O O
and O O
in O O
NOTCH1 O O
- O O
induced O O
T B-Disease B-Disease
- I-Disease I-Disease
ALL I-Disease I-Disease
. O O

Together O O
these O O
results O O
identify O O
N O O
- O O
Me O O
as O O
a O O
long O O
- O O
range O O
oncogenic O O
enhancer O O
implicated O O
directly O O
in O O
the O O
pathogenesis O O
of O O
human O O
leukemia B-Disease B-Disease
and O O
highlight O O
the O O
importance O O
of O O
the O O
NOTCH1 O O
- O O
MYC O O
regulatory O O
axis O O
in O O
T O O
cell O O
transformation O O
and O O
as O O
a O O
therapeutic O O
target O O
in O O
T B-Disease B-Disease
- I-Disease I-Disease
ALL I-Disease I-Disease
. O O

Failed O O
degradation O O
of O O
JunB O O
contributes O O
to O O
overproduction O O
of O O
type O O
I O O
collagen O O
and O O
development O O
of O O
dermal B-Disease O
fibrosis I-Disease O
in O O
patients O O
with O O
systemic B-Disease B-Disease
sclerosis I-Disease I-Disease
. O O

OBJECTIVE O O
: O O
The O O
excessive O O
deposition O O
of O O
extracellular O O
matrix O O
, O O
including O O
type O O
I O O
collagen O O
, O O
is O O
a O O
key O O
aspect O O
in O O
the O O
pathogenesis O O
of O O
connective B-Disease B-Disease
tissue I-Disease I-Disease
diseases I-Disease I-Disease
such O O
as O O
systemic B-Disease B-Disease
sclerosis I-Disease I-Disease
( O O
SSc B-Disease B-Disease
; O O
scleroderma B-Disease B-Disease
) O O
. O O

To O O
further O O
our O O
understanding O O
of O O
the O O
mechanisms O O
governing O O
the O O
dysregulation O O
of O O
type O O
I O O
collagen O O
production O O
in O O
SSc B-Disease B-Disease
, O O
we O O
investigated O O
the O O
role O O
of O O
the O O
activator O O
protein O O
1 O O
( O O
AP O O
- O O
1 O O
) O O
family O O
of O O
transcription O O
factors O O
in O O
regulating O O
COL1A2 O O
transcription O O
. O O

METHODS O O
: O O
The O O
expression O O
and O O
nuclear O O
localization O O
of O O
AP O O
- O O
1 O O
family O O
members O O
( O O
c O O
- O O
Jun O O
, O O
JunB O O
, O O
JunD O O
, O O
Fra O O
- O O
1 O O
, O O
Fra O O
- O O
2 O O
, O O
and O O
c O O
- O O
Fos O O
) O O
were O O
examined O O
by O O
immunohistochemistry O O
and O O
Western O O
blotting O O
in O O
dermal O O
biopsy O O
specimens O O
and O O
explanted O O
skin O O
fibroblasts O O
from O O
patients O O
with O O
diffuse O O
cutaneous B-Disease O
SSc I-Disease B-Disease
and O O
healthy O O
controls O O
. O O

Gene O O
activation O O
was O O
determined O O
by O O
assessing O O
the O O
interaction O O
of O O
transcription O O
factors O O
with O O
the O O
COL1A2 O O
enhancer O O
using O O
transient O O
transfection O O
of O O
reporter O O
gene O O
constructs O O
, O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
chromatin O O
immunoprecipitation O O
analysis O O
, O O
and O O
RNA O O
interference O O
involving O O
knockdown O O
of O O
individual O O
AP O O
- O O
1 O O
family O O
members O O
. O O
Gene O O
activation O O
was O O
determined O O
by O O
assessing O O
the O O
interaction O O
of O O
transcription O O
factors O O
with O O
the O O
COL1A2 O O
enhancer O O
using O O
transient O O
transfection O O
of O O
reporter O O
gene O O
constructs O O
, O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
chromatin O O
immunoprecipitation O O
analysis O O
, O O
and O O
RNA O O
interference O O
involving O O
knockdown O O
of O O
individual O O
AP O O
- O O
1 O O
family O O
members O O
. O O

Inhibition O O
of O O
fibroblast O O
mammalian O O
target O O
of O O
rapamycin O O
( O O
mTOR O O
) O O
, O O
Akt O O
, O O
and O O
glycogen O O
synthase O O
kinase O O
3beta O O
( O O
GSK O O
- O O
3beta O O
) O O
signaling O O
pathways O O
was O O
achieved O O
using O O
small O O
- O O
molecule O O
pharmacologic O O
inhibitors O O
. O O

RESULTS O O
: O O
Binding O O
of O O
JunB O O
to O O
the O O
COL1A2 O O
enhancer O O
was O O
observed O O
, O O
with O O
its O O
coalescence O O
directed O O
by O O
activation O O
of O O
gene O O
transcription O O
through O O
the O O
proximal O O
promoter O O
. O O
RESULTS O O
: O O
Binding O O
of O O
JunB O O
to O O
the O O
COL1A2 O O
enhancer O O
was O O
observed O O
, O O
with O O
its O O
coalescence O O
directed O O
by O O
activation O O
of O O
gene O O
transcription O O
through O O
the O O
proximal O O
promoter O O
. O O

Knockdown O O
of O O
JunB O O
reduced O O
enhancer O O
activation O O
and O O
COL1A2 O O
expression O O
in O O
response O O
to O O
transforming O O
growth O O
factor O O
beta O O
. O O

In O O
SSc B-Disease O
dermal O O
fibroblasts O O
, O O
increased O O
mTOR O O
/ O O
Akt O O
signaling O O
was O O
associated O O
with O O
inactivation O O
of O O
GSK O O
- O O
3beta O O
, O O
leading O O
to O O
blockade O O
of O O
JunB O O
degradation O O
and O O
, O O
thus O O
, O O
constitutively O O
high O O
expression O O
of O O
JunB O O
. O O

CONCLUSION O O
: O O
In O O
patients O O
with O O
SSc B-Disease B-Disease
, O O
the O O
accumulation O O
of O O
JunB O O
resulting O O
from O O
altered O O
mTOR O O
/ O O
Akt O O
signaling O O
and O O
a O O
failure O O
of O O
proteolytic O O
degradation O O
underpins O O
the O O
aberrant O O
overexpression O O
of O O
type O O
I O O
collagen O O
. O O

These O O
findings O O
identify O O
JunB O O
as O O
a O O
potential O O
target O O
for O O
antifibrotic O O
therapy O O
in O O
SSc B-Disease B-Disease
. O O

Long O O
- O O
range O O
enhancer O O
activity O O
determines O O
Myc O O
sensitivity O O
to O O
Notch O O
inhibitors O O
in O O
T B-Disease B-Disease
cell I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

Notch O O
is O O
needed O O
for O O
T O O
- O O
cell O O
development O O
and O O
is O O
a O O
common O O
oncogenic O O
driver O O
in O O
T B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
acute I-Disease I-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

The O O
protooncogene O O
c O O
- O O
Myc O O
( O O
Myc O O
) O O
is O O
a O O
critical O O
target O O
of O O
Notch O O
in O O
normal O O
and O O
malignant O O
pre O O
- O O
T O O
cells O O
, O O
but O O
how O O
Notch O O
regulates O O
Myc O O
is O O
unknown O O
. O O

Here O O
, O O
we O O
identify O O
a O O
distal O O
enhancer O O
located O O
> O O
1 O O
Mb O O
3 O O
' O O
of O O
human O O
and O O
murine O O
Myc O O
that O O
binds O O
Notch O O
transcription O O
complexes O O
and O O
physically O O
interacts O O
with O O
the O O
Myc O O
proximal O O
promoter O O
. O O
Here O O
, O O
we O O
identify O O
a O O
distal O O
enhancer O O
located O O
> O O
1 O O
Mb O O
3 O O
' O O
of O O
human O O
and O O
murine O O
Myc O O
that O O
binds O O
Notch O O
transcription O O
complexes O O
and O O
physically O O
interacts O O
with O O
the O O
Myc O O
proximal O O
promoter O O
. O O

The O O
Notch1 O O
binding O O
element O O
in O O
this O O
region O O
activates O O
reporter O O
genes O O
in O O
a O O
Notch O O
- O O
dependent O O
, O O
cell O O
- O O
context O O
- O O
specific O O
fashion O O
that O O
requires O O
a O O
conserved O O
Notch O O
complex O O
binding O O
site O O
. O O
The O O
Notch1 O O
binding O O
element O O
in O O
this O O
region O O
activates O O
reporter O O
genes O O
in O O
a O O
Notch O O
- O O
dependent O O
, O O
cell O O
- O O
context O O
- O O
specific O O
fashion O O
that O O
requires O O
a O O
conserved O O
Notch O O
complex O O
binding O O
site O O
. O O

Acute O O
changes O O
in O O
Notch O O
activation O O
produce O O
rapid O O
changes O O
in O O
H3K27 O O
acetylation O O
across O O
the O O
entire O O
enhancer O O
( O O
a O O
region O O
spanning O O
> O O
600 O O
kb O O
) O O
that O O
correlate O O
with O O
Myc O O
expression O O
. O O

This O O
broad O O
Notch O O
- O O
influenced O O
region O O
comprises O O
an O O
enhancer O O
region O O
containing O O
multiple O O
domains O O
, O O
recognizable O O
as O O
discrete O O
H3K27 O O
acetylation O O
peaks O O
. O O
Leukemia O O
cells O O
selected O O
for O O
resistance O O
to O O
Notch O O
inhibitors O O
express O O
Myc O O
despite O O
epigenetic O O
silencing O O
of O O
enhancer O O
domains O O
near O O
the O O
Notch O O
transcription O O
complex O O
binding O O
sites O O
. O O

Notch O O
- O O
independent O O
expression O O
of O O
Myc O O
in O O
resistant O O
cells O O
is O O
highly O O
sensitive O O
to O O
inhibitors O O
of O O
bromodomain O O
containing O O
4 O O
( O O
Brd4 O O
) O O
, O O
a O O
change O O
in O O
drug O O
sensitivity O O
that O O
is O O
accompanied O O
by O O
preferential O O
association O O
of O O
the O O
Myc O O
promoter O O
with O O
more O O
3 O O
' O O
enhancer O O
domains O O
that O O
are O O
strongly O O
dependent O O
on O O
Brd4 O O
for O O
function O O
. O O
Notch O O
- O O
independent O O
expression O O
of O O
Myc O O
in O O
resistant O O
cells O O
is O O
highly O O
sensitive O O
to O O
inhibitors O O
of O O
bromodomain O O
containing O O
4 O O
( O O
Brd4 O O
) O O
, O O
a O O
change O O
in O O
drug O O
sensitivity O O
that O O
is O O
accompanied O O
by O O
preferential O O
association O O
of O O
the O O
Myc O O
promoter O O
with O O
more O O
3 O O
' O O
enhancer O O
domains O O
that O O
are O O
strongly O O
dependent O O
on O O
Brd4 O O
for O O
function O O
. O O

These O O
findings O O
indicate O O
that O O
altered O O
long O O
- O O
range O O
enhancer O O
activity O O
can O O
mediate O O
resistance O O
to O O
targeted O O
therapies O O
and O O
provide O O
a O O
mechanistic O O
rationale O O
for O O
combined O O
targeting O O
of O O
Notch O O
and O O
Brd4 O O
in O O
leukemia B-Disease B-Disease
. O O

EWS O O
- O O
FLI1 O O
utilizes O O
divergent O O
chromatin O O
remodeling O O
mechanisms O O
to O O
directly O O
activate O O
or O O
repress O O
enhancer O O
elements O O
in O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
. O O

The O O
aberrant O O
transcription O O
factor O O
EWS O O
- O O
FLI1 O O
drives O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
, O O
but O O
its O O
molecular O O
function O O
is O O
not O O
completely O O
understood O O
. O O

We O O
find O O
that O O
EWS O O
- O O
FLI1 O O
reprograms O O
gene O O
regulatory O O
circuits O O
in O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
by O O
directly O O
inducing O O
or O O
repressing O O
enhancers O O
. O O

At O O
GGAA O O
repeat O O
elements O O
, O O
which O O
lack O O
evolutionary O O
conservation O O
and O O
regulatory O O
potential O O
in O O
other O O
cell O O
types O O
, O O
EWS O O
- O O
FLI1 O O
multimers O O
induce O O
chromatin O O
opening O O
and O O
create O O
de O O
novo O O
enhancers O O
that O O
physically O O
interact O O
with O O
target O O
promoters O O
. O O

Conversely O O
, O O
EWS O O
- O O
FLI1 O O
inactivates O O
conserved O O
enhancers O O
containing O O
canonical O O
ETS O O
motifs O O
by O O
displacing O O
wild O O
- O O
type O O
ETS O O
transcription O O
factors O O
. O O

These O O
divergent O O
chromatin O O
- O O
remodeling O O
patterns O O
repress O O
tumor B-Disease B-Disease
suppressors O O
and O O
mesenchymal O O
lineage O O
regulators O O
while O O
activating O O
oncogenes O O
and O O
potential O O
therapeutic O O
targets O O
, O O
such O O
as O O
the O O
kinase O O
VRK1 O O
. O O

Our O O
findings O O
demonstrate O O
how O O
EWS O O
- O O
FLI1 O O
establishes O O
an O O
oncogenic O O
regulatory O O
program O O
governing O O
both O O
tumor B-Disease B-Disease
survival O O
and O O
differentiation O O
. O O

CRISPR O O
reveals O O
a O O
distal O O
super O O
- O O
enhancer O O
required O O
for O O
Sox2 O O
expression O O
in O O
mouse O O
embryonic O O
stem O O
cells O O
. O O

The O O
pluripotency O O
of O O
embryonic O O
stem O O
cells O O
( O O
ESCs O O
) O O
is O O
maintained O O
by O O
a O O
small O O
group O O
of O O
master O O
transcription O O
factors O O
including O O
Oct4 O O
, O O
Sox2 O O
and O O
Nanog O O
. O O

These O O
core O O
factors O O
form O O
a O O
regulatory O O
circuit O O
controlling O O
the O O
transcription O O
of O O
a O O
number O O
of O O
pluripotency O O
factors O O
including O O
themselves O O
. O O

Although O O
previous O O
studies O O
have O O
identified O O
transcriptional O O
regulators O O
of O O
this O O
core O O
network O O
, O O
the O O
cis O O
- O O
regulatory O O
DNA O O
sequences O O
required O O
for O O
the O O
transcription O O
of O O
these O O
key O O
pluripotency O O
factors O O
remain O O
to O O
be O O
defined O O
. O O

We O O
analyzed O O
epigenomic O O
data O O
within O O
the O O
1 O O
. O O
5 O O
Mb O O
gene O O
- O O
desert O O
regions O O
around O O
the O O
Sox2 O O
gene O O
and O O
identified O O
a O O
13kb O O
- O O
long O O
super O O
- O O
enhancer O O
( O O
SE O O
) O O
located O O
100kb O O
downstream O O
of O O
Sox2 O O
in O O
mouse O O
ESCs O O
. O O
We O O
analyzed O O
epigenomic O O
data O O
within O O
the O O
1 O O
. O O
5 O O
Mb O O
gene O O
- O O
desert O O
regions O O
around O O
the O O
Sox2 O O
gene O O
and O O
identified O O
a O O
13kb O O
- O O
long O O
super O O
- O O
enhancer O O
( O O
SE O O
) O O
located O O
100kb O O
downstream O O
of O O
Sox2 O O
in O O
mouse O O
ESCs O O
. O O

This O O
SE O O
is O O
occupied O O
by O O
Oct4 O O
, O O
Sox2 O O
, O O
Nanog O O
, O O
and O O
the O O
mediator O O
complex O O
, O O
and O O
physically O O
interacts O O
with O O
the O O
Sox2 O O
locus O O
via O O
DNA O O
looping O O
. O O

Using O O
a O O
simple O O
and O O
highly O O
efficient O O
double O O
- O O
CRISPR O O
genome O O
editing O O
strategy O O
we O O
deleted O O
the O O
entire O O
13 O O
- O O
kb O O
SE O O
and O O
characterized O O
transcriptional O O
defects O O
in O O
the O O
resulting O O
monoallelic O O
and O O
biallelic O O
deletion O O
clones O O
with O O
RNA O O
- O O
seq O O
. O O

We O O
showed O O
that O O
the O O
SE O O
is O O
responsible O O
for O O
over O O
90 O O
% O O
of O O
Sox2 O O
expression O O
, O O
and O O
Sox2 O O
is O O
the O O
only O O
target O O
gene O O
along O O
the O O
chromosome O O
. O O

Our O O
results O O
support O O
the O O
functional O O
significance O O
of O O
a O O
SE O O
in O O
maintaining O O
the O O
pluripotency O O
transcription O O
program O O
in O O
mouse O O
ESCs O O
. O O

MyoR O O
modulates O O
cardiac O O
conduction O O
by O O
repressing O O
Gata4 O O
. O O

The O O
cardiac O O
conduction O O
system O O
coordinates O O
electrical O O
activation O O
through O O
a O O
series O O
of O O
interconnected O O
structures O O
, O O
including O O
the O O
atrioventricular O O
node O O
( O O
AVN O O
) O O
, O O
the O O
central O O
connection O O
point O O
that O O
delays O O
impulse O O
propagation O O
to O O
optimize O O
cardiac O O
performance O O
. O O

Although O O
recent O O
studies O O
have O O
uncovered O O
important O O
molecular O O
details O O
of O O
AVN O B-Disease
formation O O
, O O
relatively O O
little O O
is O O
known O O
about O O
the O O
transcriptional O O
mechanisms O O
that O O
regulate O O
AV O O
delay O O
, O O
the O O
primary O O
function O O
of O O
the O O
mature O O
AVN O O
. O O

We O O
identify O O
here O O
MyoR O O
as O O
a O O
novel O O
transcription O O
factor O O
expressed O O
in O O
Cx30 O O
. O O
2 O O
( O O
+ O O
) O O
cells O O
of O O
the O O
AVN O O
. O O

We O O
show O O
that O O
MyoR O O
specifically O O
inhibits O O
a O O
Cx30 O O
. O O
2 O O
enhancer O O
required O O
for O O
AVN O O
- O O
specific O O
gene O O
expression O O
. O O
We O O
show O O
that O O
MyoR O O
specifically O O
inhibits O O
a O O
Cx30 O O
. O O
2 O O
enhancer O O
required O O
for O O
AVN O O
- O O
specific O O
gene O O
expression O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
MyoR O O
interacts O O
directly O O
with O O
Gata4 O O
to O O
mediate O O
transcriptional O O
repression O O
. O O

Our O O
studies O O
reveal O O
that O O
MyoR O O
contains O O
two O O
nonequivalent O O
repression O O
domains O O
. O O

While O O
the O O
MyoR O O
C O O
- O O
terminal O O
repression O O
domain O O
inhibits O O
transcription O O
in O O
a O O
context O O
- O O
dependent O O
manner O O
, O O
the O O
N O O
- O O
terminal O O
repression O O
domain O O
can O O
function O O
in O O
a O O
heterologous O O
context O O
to O O
convert O O
the O O
Hand2 O O
activator O O
into O O
a O O
repressor O O
. O O

In O O
addition O O
, O O
we O O
show O O
that O O
genetic O O
deletion O O
of O O
MyoR O O
in O O
mice O O
increases O O
Cx30 O O
. O O
2 O O
expression O O
by O O
50 O O
% O O
and O O
prolongs O O
AV O O
delay O O
by O O
13 O O
% O O
. O O

Taken O O
together O O
, O O
we O O
conclude O O
that O O
MyoR O O
modulates O O
a O O
Gata4 O O
- O O
dependent O O
regulatory O O
circuit O O
that O O
establishes O O
proper O O
AV O O
delay O O
, O O
and O O
these O O
findings O O
may O O
have O O
wider O O
implications O O
for O O
the O O
variability O O
of O O
cardiac O O
rhythm O O
observed O O
in O O
the O O
general O O
population O O
. O O

Convergence O O
of O O
developmental O O
and O O
oncogenic O O
signaling O O
pathways O O
at O O
transcriptional O O
super O O
- O O
enhancers O O
. O O

Super O O
- O O
enhancers O O
and O O
stretch O O
enhancers O O
( O O
SEs O O
) O O
drive O O
expression O O
of O O
genes O O
that O O
play O O
prominent O O
roles O O
in O O
normal O O
and O O
disease O O
cells O O
, O O
but O O
the O O
functional O O
importance O O
of O O
these O O
clustered O O
enhancer O O
elements O O
is O O
poorly O O
understood O O
, O O
so O O
it O O
is O O
not O O
clear O O
why O O
genes O O
key O O
to O O
cell O O
identity O O
have O O
evolved O O
regulation O O
by O O
such O O
elements O O
. O O

Here O O
, O O
we O O
show O O
that O O
SEs O O
consist O O
of O O
functional O O
constituent O O
units O O
that O O
concentrate O O
multiple O O
developmental O O
signaling O O
pathways O O
at O O
key O O
pluripotency O O
genes O O
in O O
embryonic O O
stem O O
cells O O
and O O
confer O O
enhanced O O
responsiveness O O
to O O
signaling O O
of O O
their O O
associated O O
genes O O
. O O
Cancer O O
cells O O
frequently O O
acquire O O
SEs O O
at O O
genes O O
that O O
promote O O
tumorigenesis O O
, O O
and O O
we O O
show O O
that O O
these O O
genes O O
are O O
especially O O
sensitive O O
to O O
perturbation O O
of O O
oncogenic O O
signaling O O
pathways O O
. O O

Super O O
- O O
enhancers O O
thus O O
provide O O
a O O
platform O O
for O O
signaling O O
pathways O O
to O O
regulate O O
genes O O
that O O
control O O
cell O O
identity O O
during O O
development O O
and O O
tumorigenesis O O
. O O

Nuclear O O
Fractionation O O
Reveals O O
Thousands O O
of O O
Chromatin O O
- O O
Tethered O O
Noncoding O O
RNAs O O
Adjacent O O
to O O
Active O O
Genes O O
. O O

A O O
number O O
of O O
long O O
noncoding O O
RNAs O O
( O O
lncRNAs O O
) O O
have O O
been O O
reported O O
to O O
regulate O O
transcription O O
via O O
recruitment O O
of O O
chromatin O O
modifiers O O
or O O
bridging O O
distal O O
enhancer O O
elements O O
to O O
gene O O
promoters O O
. O O

However O O
, O O
the O O
generality O O
of O O
these O O
modes O O
of O O
regulation O O
and O O
the O O
mechanisms O O
of O O
chromatin O O
attachment O O
for O O
thousands O O
of O O
unstudied O O
human O O
lncRNAs O O
remain O O
unclear O O
. O O

To O O
address O O
these O O
questions O O
, O O
we O O
performed O O
stringent O O
nuclear O O
fractionation O O
coupled O O
to O O
RNA O O
sequencing O O
. O O

We O O
provide O O
genome O O
- O O
wide O O
identification O O
of O O
human O O
chromatin O O
- O O
associated O O
lncRNAs O O
and O O
demonstrate O O
tethering O O
of O O
RNA O O
to O O
chromatin O O
by O O
RNAPII O O
is O O
a O O
pervasive O O
mechanism O O
of O O
attachment O O
. O O

We O O
also O O
uncovered O O
thousands O O
of O O
chromatin O O
- O O
enriched O O
RNAs O O
( O O
cheRNAs O O
) O O
that O O
share O O
molecular O O
properties O O
with O O
known O O
lncRNAs O O
. O O

Although O O
distinct O O
from O O
eRNAs O O
derived O O
from O O
active O O
prototypical O O
enhancers O O
, O O
the O O
production O O
of O O
cheRNAs O O
is O O
strongly O O
correlated O O
with O O
the O O
expression O O
of O O
neighboring O O
protein O O
- O O
coding O O
genes O O
. O O

This O O
work O O
provides O O
an O O
updated O O
framework O O
for O O
nuclear O O
RNA O O
organization O O
that O O
includes O O
a O O
large O O
chromatin O O
- O O
associated O O
transcript O O
population O O
correlated O O
with O O
active O O
genes O O
and O O
may O O
prove O O
useful O O
in O O
de O O
novo O O
enhancer O O
annotation O O
. O O

The O O
DEK O O
Oncoprotein O O
Is O O
a O O
Critical O O
Component O O
of O O
the O O
EKLF O O
/ O O
KLF1 O O
Enhancer O O
in O O
Erythroid O O
Cells O O
. O O
The O O
DEK O O
Oncoprotein O O
Is O O
a O O
Critical O O
Component O O
of O O
the O O
EKLF O O
/ O O
KLF1 O O
Enhancer O O
in O O
Erythroid O O
Cells O O
. O O

Understanding O O
how O O
transcriptional O O
regulators O O
are O O
themselves O O
controlled O O
is O O
important O O
in O O
attaining O O
a O O
complete O O
picture O O
of O O
the O O
intracellular O O
effects O O
that O O
follow O O
signaling O O
cascades O O
during O O
early O O
development O O
and O O
cell O O
- O O
restricted O O
differentiation O O
. O O

We O O
have O O
addressed O O
this O O
issue O O
by O O
focusing O O
on O O
the O O
regulation O O
of O O
EKLF O O
/ O O
KLF1 O O
, O O
a O O
zinc O O
finger O O
transcription O O
factor O O
that O O
plays O O
a O O
necessary O O
role O O
in O O
the O O
global O O
regulation O O
of O O
erythroid O O
gene O O
expression O O
. O O

Using O O
biochemical O O
affinity O O
purification O O
, O O
we O O
have O O
identified O O
the O O
DEK O O
oncoprotein O O
as O O
a O O
critical O O
factor O O
that O O
interacts O O
with O O
an O O
essential O O
upstream O O
enhancer O O
element O O
of O O
the O O
EKLF O O
promoter O O
and O O
exerts O O
a O O
positive O O
effect O O
on O O
EKLF O O
levels O O
. O O
Using O O
biochemical O O
affinity O O
purification O O
, O O
we O O
have O O
identified O O
the O O
DEK O O
oncoprotein O O
as O O
a O O
critical O O
factor O O
that O O
interacts O O
with O O
an O O
essential O O
upstream O O
enhancer O O
element O O
of O O
the O O
EKLF O O
promoter O O
and O O
exerts O O
a O O
positive O O
effect O O
on O O
EKLF O O
levels O O
. O O

This O O
element O O
also O O
binds O O
a O O
core O O
set O O
of O O
erythroid O O
transcription O O
factors O O
, O O
suggesting O O
that O O
DEK O O
is O O
part O O
of O O
a O O
tissue O O
- O O
restricted O O
enhanceosome O O
that O O
contains O O
BMP4 O O
- O O
dependent O O
and O O
- O O
independent O O
components O O
. O O

Together O O
with O O
local O O
enrichment O O
of O O
properly O O
coded O O
histones O O
and O O
an O O
open O O
chromatin O O
domain O O
, O O
optimal O O
transcriptional O O
activation O O
of O O
the O O
EKLF O O
locus O O
can O O
be O O
established O O
. O O

CARMEN O O
, O O
a O O
human O O
super O O
enhancer O O
- O O
associated O O
long O O
noncoding O O
RNA O O
controlling O O
cardiac O O
specification O O
, O O
differentiation O O
and O O
homeostasis O O
. O O

Long O O
noncoding O O
RNAs O O
( O O
lncRNAs O O
) O O
are O O
emerging O O
as O O
important O O
regulators O O
of O O
developmental O O
pathways O O
. O O

However O O
, O O
their O O
roles O O
in O O
human O O
cardiac O O
precursor O O
cell O O
( O O
CPC O O
) O O
remain O O
unexplored O O
. O O

To O O
characterize O O
the O O
long O O
noncoding O O
transcriptome O O
during O O
human O O
CPC O O
cardiac O O
differentiation O O
, O O
we O O
profiled O O
the O O
lncRNA O O
transcriptome O O
in O O
CPCs O O
isolated O O
from O O
the O O
human O O
fetal O O
heart O O
and O O
identified O O
570 O O
lncRNAs O O
that O O
were O O
modulated O O
during O O
cardiac O O
differentiation O O
. O O

Many O O
of O O
these O O
were O O
associated O O
with O O
active O O
cardiac O O
enhancer O O
and O O
super O O
enhancers O O
( O O
SE O O
) O O
with O O
their O O
expression O O
being O O
correlated O O
with O O
proximal O O
cardiac O O
genes O O
. O O

One O O
of O O
the O O
most O O
upregulated O O
lncRNAs O O
was O O
a O O
SE O O
- O O
associated O O
lncRNA O O
that O O
was O O
named O O
CARMEN O O
, O O
( O O
CAR O O
) O O
diac O O
( O O
M O O
) O O
esoderm O O
( O O
E O O
) O O
nhancer O O
- O O
associated O O
( O O
N O O
) O O
oncoding O O
RNA O O
. O O
CARMEN O O
exhibits O O
RNA O O
- O O
dependent O O
enhancing O O
activity O O
and O O
is O O
upstream O O
of O O
the O O
cardiac O O
mesoderm O O
- O O
specifying O O
gene O O
regulatory O O
network O O
. O O

Interestingly O O
, O O
CARMEN O O
interacts O O
with O O
SUZ12 O O
and O O
EZH2 O O
, O O
two O O
components O O
of O O
the O O
polycomb O O
repressive O O
complex O O
2 O O
( O O
PRC2 O O
) O O
. O O

We O O
demonstrate O O
that O O
CARMEN O O
knockdown O O
inhibits O O
cardiac O O
specification O O
and O O
differentiation O O
in O O
cardiac O O
precursor O O
cells O O
independently O O
of O O
MIR O O
- O O
143 O O
and O O
- O O
145 O O
expression O O
, O O
two O O
microRNAs O O
located O O
proximal O O
to O O
the O O
enhancer O O
sequences O O
. O O

Importantly O O
, O O
CARMEN O O
expression O O
was O O
activated O O
during O O
pathological O O
remodeling O O
in O O
the O O
mouse O O
and O O
human O O
hearts O O
, O O
and O O
was O O
necessary O O
for O O
maintaining O O
cardiac O O
identity O O
in O O
differentiated O O
cardiomyocytes O O
. O O

This O O
study O O
demonstrates O O
therefore O O
that O O
CARMEN O O
is O O
a O O
crucial O O
regulator O O
of O O
cardiac O O
cell O O
differentiation O O
and O O
homeostasis O O
. O O

An O O
autoregulatory O O
enhancer O O
controls O O
mammary O O
- O O
specific O O
STAT5 O O
functions O O
. O O

Signal O O
Transducers O O
and O O
Activators O O
of O O
Transcription O O
( O O
STATs O O
) O O
are O O
principal O O
transcription O O
factors O O
downstream O O
of O O
cytokine O O
receptors O O
. O O

Although O O
STAT5A O O
is O O
expressed O O
in O O
most O O
tissues O O
it O O
remains O O
to O O
be O O
understood O O
why O O
its O O
premier O O
, O O
non O O
- O O
redundant O O
functions O O
are O O
restricted O O
to O O
prolactin O O
- O O
induced O O
mammary O O
gland O O
development O O
and O O
function O O
. O O

We O O
report O O
that O O
the O O
ubiquitously O O
expressed O O
Stat5a O O
/ O O
b O O
locus O O
is O O
subject O O
to O O
additional O O
lineage O O
- O O
specific O O
transcriptional O O
control O O
in O O
mammary O O
epithelium O O
. O O

Genome O O
- O O
wide O O
surveys O O
of O O
epigenetic O O
status O O
and O O
transcription O O
factor O O
occupancy O O
uncovered O O
a O O
putative O O
mammary O O
- O O
specific O O
enhancer O O
within O O
the O O
intergenic O O
sequences O O
separating O O
the O O
two O O
Stat5 O O
genes O O
. O O
Genome O O
- O O
wide O O
surveys O O
of O O
epigenetic O O
status O O
and O O
transcription O O
factor O O
occupancy O O
uncovered O O
a O O
putative O O
mammary O O
- O O
specific O O
enhancer O O
within O O
the O O
intergenic O O
sequences O O
separating O O
the O O
two O O
Stat5 O O
genes O O
. O O

This O O
region O O
exhibited O O
several O O
hallmarks O O
of O O
genomic O O
enhancers O O
, O O
including O O
DNaseI O O
hypersensitivity O O
, O O
H3K27 O O
acetylation O O
and O O
binding O O
by O O
GR O O
, O O
NFIB O O
, O O
ELF5 O O
and O O
MED1 O O
. O O

Mammary O O
- O O
specific O O
STAT5 O O
binding O O
was O O
obtained O O
at O O
two O O
canonical O O
STAT5 O O
binding O O
motifs O O
. O O
Mammary O O
- O O
specific O O
STAT5 O O
binding O O
was O O
obtained O O
at O O
two O O
canonical O O
STAT5 O O
binding O O
motifs O O
. O O

CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
genome O O
editing O O
was O O
used O O
to O O
delete O O
these O O
sites O O
in O O
mice O O
and O O
determine O O
their O O
biological O O
function O O
. O O

Mutant O O
animals O O
exhibited O O
an O O
80 O O
% O O
reduction O O
of O O
Stat5 O O
levels O O
in O O
mammary O O
epithelium O O
and O O
a O O
concomitant O O
reduction O O
of O O
STAT5 O O
- O O
dependent O O
gene O O
expression O O
. O O

Transcriptome O O
analysis O O
identified O O
a O O
class O O
of O O
mammary O O
- O O
restricted O O
genes O O
that O O
was O O
particularly O O
dependent O O
on O O
high O O
STAT5 O O
levels O O
as O O
a O O
result O O
of O O
the O O
intergenic O O
enhancer O O
. O O

Taken O O
together O O
, O O
the O O
mammary O O
- O O
specific O O
enhancer O O
enables O O
a O O
positive O O
feedback O O
circuit O O
that O O
contributes O O
to O O
the O O
remarkable O O
abundance O O
of O O
STAT5 O O
and O O
, O O
in O O
turn O O
, O O
to O O
the O O
efficacy O O
of O O
STAT5 O O
- O O
dependent O O
mammary O O
physiology O O
. O O

Identification O O
of O O
the O O
187 O O
bp O O
EphA7 O O
Genomic O O
DNA O O
as O O
the O O
Dorsal O O
Midline O O
- O O
Specific O O
Enhancer O O
of O O
the O O
Diencephalon O O
and O O
Mesencephalon O O
. O O
EphA7 O O
is O O
a O O
key O O
molecule O O
in O O
regulating O O
the O O
development O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
. O O
Identification O O
of O O
the O O
187 O O
bp O O
EphA7 O O
Genomic O O
DNA O O
as O O
the O O
Dorsal O O
Midline O O
- O O
Specific O O
Enhancer O O
of O O
the O O
Diencephalon O O
and O O
Mesencephalon O O
. O O
EphA7 O O
is O O
a O O
key O O
molecule O O
in O O
regulating O O
the O O
development O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
. O O

To O O
get O O
insight O O
into O O
the O O
mechanism O O
of O O
how O O
EphA7 O O
gene O O
expression O O
is O O
regulated O O
during O O
the O O
dorsal O O
specification O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
, O O
we O O
investigated O O
the O O
cis O O
- O O
acting O O
regulatory O O
sequence O O
driving O O
EphA7 O O
to O O
the O O
dorsal O O
midline O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
. O O

Transgenic O O
LacZ O O
reporter O O
analysis O O
, O O
using O O
overlapping O O
EphA7 O O
BACs O O
, O O
was O O
used O O
to O O
narrow O O
down O O
the O O
dorsal O O
midline O O
- O O
specific O O
enhancer O O
, O O
revealing O O
the O O
25 O O
. O O
3 O O
kb O O
genomic O O
region O O
as O O
the O O
enhancer O O
candidate O O
. O O

Strikingly O O
, O O
this O O
genomic O O
DNA O O
was O O
located O O
far O O
downstream O O
of O O
the O O
EphA7 O O
transcription O O
start O O
site O O
, O O
+ O O
302 O O
. O O
6 O O
kb O O
to O O
+ O O
327 O O
. O O
9 O O
kb O O
. O O
Strikingly O O
, O O
this O O
genomic O O
DNA O O
was O O
located O O
far O O
downstream O O
of O O
the O O
EphA7 O O
transcription O O
start O O
site O O
, O O
+ O O
302 O O
. O O
6 O O
kb O O
to O O
+ O O
327 O O
. O O
9 O O
kb O O
. O O

Further O O
enhancer O O
mapping O O
, O O
using O O
comparative O O
genomic O O
analysis O O
and O O
transgenic O O
methods O O
, O O
showed O O
that O O
the O O
187 O O
bp O O
genomic O O
DNA O O
alone O O
, O O
approximately O O
305 O O
kb O O
downstream O O
of O O
the O O
EphA7 O O
transcription O O
start O O
site O O
, O O
was O O
sufficient O O
to O O
act O O
as O O
the O O
dorsal O O
midline O O
- O O
specific O O
enhancer O O
of O O
EphA7 O O
. O O
Further O O
enhancer O O
mapping O O
, O O
using O O
comparative O O
genomic O O
analysis O O
and O O
transgenic O O
methods O O
, O O
showed O O
that O O
the O O
187 O O
bp O O
genomic O O
DNA O O
alone O O
, O O
approximately O O
305 O O
kb O O
downstream O O
of O O
the O O
EphA7 O O
transcription O O
start O O
site O O
, O O
was O O
sufficient O O
to O O
act O O
as O O
the O O
dorsal O O
midline O O
- O O
specific O O
enhancer O O
of O O
EphA7 O O
. O O

Importantly O O
, O O
our O O
results O O
indicate O O
that O O
the O O
187 O O
bp O O
dorsal O O
midline O O
- O O
specific O O
enhancer O O
is O O
critically O O
regulated O O
by O O
homeobox O O
transcription O O
factors O O
during O O
the O O
development O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
. O O
Importantly O O
, O O
our O O
results O O
indicate O O
that O O
the O O
187 O O
bp O O
dorsal O O
midline O O
- O O
specific O O
enhancer O O
is O O
critically O O
regulated O O
by O O
homeobox O O
transcription O O
factors O O
during O O
the O O
development O O
of O O
the O O
dien O O
- O O
and O O
mesencephalon O O
. O O

Stimulus O O
- O O
specific O O
combinatorial O O
functionality O O
of O O
neuronal O O
c O O
- O O
fos O O
enhancers O O
. O O

The O O
c O O
- O O
fos O O
gene O O
( O O
also O O
known O O
as O O
Fos O O
) O O
is O O
induced O O
by O O
a O O
broad O O
range O O
of O O
stimuli O O
and O O
is O O
a O O
reliable O O
marker O O
for O O
neural O O
activity O O
. O O

Its O O
induction O O
mechanism O O
and O O
available O O
reporter O O
mouse O O
lines O O
are O O
based O O
exclusively O O
on O O
c O O
- O O
fos O O
promoter O O
activity O O
. O O
Its O O
induction O O
mechanism O O
and O O
available O O
reporter O O
mouse O O
lines O O
are O O
based O O
exclusively O O
on O O
c O O
- O O
fos O O
promoter O O
activity O O
. O O

Here O O
we O O
demonstrate O O
that O O
multiple O O
enhancers O O
surrounding O O
the O O
c O O
- O O
fos O O
gene O O
are O O
crucial O O
for O O
ensuring O O
robust O O
c O O
- O O
fos O O
response O O
to O O
various O O
stimuli O O
. O O
Here O O
we O O
demonstrate O O
that O O
multiple O O
enhancers O O
surrounding O O
the O O
c O O
- O O
fos O O
gene O O
are O O
crucial O O
for O O
ensuring O O
robust O O
c O O
- O O
fos O O
response O O
to O O
various O O
stimuli O O
. O O

Membrane O O
depolarization O O
, O O
brain O O
- O O
derived O O
neurotrophic O O
factor O O
( O O
BDNF O O
) O O
and O O
forskolin O O
activate O O
distinct O O
subsets O O
of O O
the O O
enhancers O O
to O O
induce O O
c O O
- O O
fos O O
transcription O O
in O O
neurons O O
, O O
suggesting O O
that O O
stimulus O O
- O O
specific O O
combinatorial O O
activation O O
of O O
multiple O O
enhancers O O
underlies O O
the O O
broad O O
inducibility O O
of O O
the O O
c O O
- O O
fos O O
gene O O
. O O

Accordingly O O
, O O
the O O
functional O O
requirement O O
of O O
key O O
transcription O O
factors O O
varies O O
depending O O
on O O
the O O
type O O
of O O
stimulation O O
. O O

Combinatorial O O
enhancer O O
activation O O
also O O
occurs O O
in O O
the O O
brain O O
. O O

Providing O O
a O O
comprehensive O O
picture O O
of O O
the O O
c O O
- O O
fos O O
induction O O
mechanism O O
beyond O O
the O O
minimal O O
promoter O O
, O O
our O O
study O O
should O O
help O O
in O O
understanding O O
the O O
physiological O O
nature O O
of O O
c O O
- O O
fos O O
induction O O
in O O
relation O O
to O O
neural O O
activity O O
and O O
plasticity O O
. O O

Rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
- O O
associated O O
RBPJ O O
polymorphism O O
alters O O
memory O O
CD4 O O
+ O O
T O O
cells O O
. O O

Notch O O
signaling O O
has O O
recently O O
emerged O O
as O O
an O O
important O O
regulator O O
of O O
immune O O
responses O O
in O O
autoimmune B-Disease B-Disease
diseases I-Disease I-Disease
. O O

The O O
recombination O O
signal O O
- O O
binding O O
protein O O
for O O
immunoglobulin O O
kappa O O
J O O
region O O
( O O
RBPJ O O
) O O
is O O
a O O
transcriptional O O
repressor O O
, O O
but O O
converts O O
into O O
a O O
transcriptional O O
activator O O
upon O O
activation O O
of O O
the O O
canonical O O
Notch O O
pathway O O
. O O

Genome O O
- O O
wide O O
association O O
studies O O
of O O
rheumatoid B-Disease B-Disease
arthritis I-Disease I-Disease
( O O
RA B-Disease B-Disease
) O O
identified O O
a O O
susceptibility O O
locus O O
, O O
rs874040 O O
( O O
CC O O
) O O
, O O
which O O
implicated O O
the O O
RBPJ O O
gene O O
. O O

Here O O
, O O
chromatin O O
state O O
mapping O O
generated O O
using O O
the O O
chromHMM O O
algorithm O O
reveals O O
strong O O
enhancer O O
regions O O
containing O O
DNase O O
I O O
hypersensitive O O
sites O O
overlapping O O
the O O
rs874040 O O
linkage O O
disequilibrium O O
block O O
in O O
human O O
memory O O
, O O
but O O
not O O
in O O
naive O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
. O O
Here O O
, O O
chromatin O O
state O O
mapping O O
generated O O
using O O
the O O
chromHMM O O
algorithm O O
reveals O O
strong O O
enhancer O O
regions O O
containing O O
DNase O O
I O O
hypersensitive O O
sites O O
overlapping O O
the O O
rs874040 O O
linkage O O
disequilibrium O O
block O O
in O O
human O O
memory O O
, O O
but O O
not O O
in O O
naive O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
. O O

The O O
rs874040 O O
overlapping O O
this O O
chromatin O O
state O O
was O O
associated O O
with O O
increased O O
RBPJ O O
expression O O
in O O
stimulated O O
memory O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
from O O
healthy O O
subjects O O
homozygous O O
for O O
the O O
risk O O
allele O O
( O O
CC O O
) O O
compared O O
with O O
memory O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
bearing O O
the O O
protective O O
allele O O
( O O
GG O O
) O O
. O O

Transcriptomic O O
analysis O O
of O O
rs874040 O O
( O O
CC O O
) O O
memory O O
T O O
cells O O
showed O O
a O O
repression O O
of O O
canonical O O
Notch O O
target O O
genes O O
IL O O
( O O
interleukin O O
) O O
- O O
9 O O
, O O
IL O O
- O O
17 O O
and O O
interferon O O
( O O
IFN O O
) O O
gamma O O
in O O
the O O
basal O O
state O O
. O O

Interestingly O O
, O O
activation O O
of O O
the O O
Notch O O
pathway O O
using O O
soluble O O
Notch O O
ligand O O
, O O
Jagged2 O O
- O O
Fc O O
, O O
induced O O
IL O O
- O O
9 O O
and O O
IL O O
- O O
17A O O
while O O
delta O O
- O O
like O O
4Fc O O
, O O
another O O
Notch O O
ligand O O
, O O
induced O O
higher O O
IFNgamma O O
expression O O
in O O
the O O
rs874040 O O
( O O
CC O O
) O O
memory O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
compared O O
with O O
their O O
rs874040 O O
( O O
GG O O
) O O
counterparts O O
. O O

In O O
RA B-Disease O
, O O
RBPJ O O
expression O O
is O O
elevated O O
in O O
memory O O
T O O
cells O O
from O O
RA B-Disease B-Disease
patients O O
compared O O
with O O
control O O
subjects O O
, O O
and O O
this O O
was O O
associated O O
with O O
induced O O
inflammatory O O
cytokines O O
IL O O
- O O
9 O O
, O O
IL O O
- O O
17A O O
and O O
IFNgamma O O
in O O
response O O
to O O
Notch O O
ligation O O
in O O
vitro O O
. O O

These O O
findings O O
demonstrate O O
that O O
the O O
rs874040 O O
( O O
CC O O
) O O
allele O O
skews O O
memory O O
T O O
cells O O
toward O O
a O O
pro O O
- O O
inflammatory O O
phenotype O O
involving O O
Notch O O
signaling O O
, O O
thus O O
increasing O O
the O O
susceptibility O O
to O O
develop O O
RA B-Disease B-Disease
. O O

The O O
histone O O
chaperone O O
CAF O O
- O O
1 O O
safeguards O O
somatic O O
cell O O
identity O O
. O O

Cellular O O
differentiation O O
involves O O
profound O O
remodelling O O
of O O
chromatic O O
landscapes O O
, O O
yet O O
the O O
mechanisms O O
by O O
which O O
somatic O O
cell O O
identity O O
is O O
subsequently O O
maintained O O
remain O O
incompletely O O
understood O O
. O O

To O O
further O O
elucidate O O
regulatory O O
pathways O O
that O O
safeguard O O
the O O
somatic O O
state O O
, O O
we O O
performed O O
two O O
comprehensive O O
RNA O O
interference O O
( O O
RNAi O O
) O O
screens O O
targeting O O
chromatin O O
factors O O
during O O
transcription O O
- O O
factor O O
- O O
mediated O O
reprogramming O O
of O O
mouse O O
fibroblasts O O
to O O
induced O O
pluripotent O O
stem O O
cells O O
( O O
iPS O O
cells O O
) O O
. O O

Subunits O O
of O O
the O O
chromatin O O
assembly O O
factor O O
- O O
1 O O
( O O
CAF O O
- O O
1 O O
) O O
complex O O
, O O
including O O
Chaf1a O O
and O O
Chaf1b O O
, O O
emerged O O
as O O
the O O
most O O
prominent O O
hits O O
from O O
both O O
screens O O
, O O
followed O O
by O O
modulators O O
of O O
lysine O O
sumoylation O O
and O O
heterochromatin O O
maintenance O O
. O O

Optimal O O
modulation O O
of O O
both O O
CAF O O
- O O
1 O O
and O O
transcription O O
factor O O
levels O O
increased O O
reprogramming O O
efficiency O O
by O O
several O O
orders O O
of O O
magnitude O O
and O O
facilitated O O
iPS O O
cell O O
formation O O
in O O
as O O
little O O
as O O
4 O O
days O O
. O O

Mechanistically O O
, O O
CAF O O
- O O
1 O O
suppression O O
led O O
to O O
a O O
more O O
accessible O O
chromatin O O
structure O O
at O O
enhancer O O
elements O O
early O O
during O O
reprogramming O O
. O O

These O O
changes O O
were O O
accompanied O O
by O O
a O O
decrease O O
in O O
somatic O O
heterochromatin O O
domains O O
, O O
increased O O
binding O O
of O O
Sox2 O O
to O O
pluripotency O O
- O O
specific O O
targets O O
and O O
activation O O
of O O
associated O O
genes O O
. O O

Notably O O
, O O
suppression O O
of O O
CAF O O
- O O
1 O O
also O O
enhanced O O
the O O
direct O O
conversion O O
of O O
B O O
cells O O
into O O
macrophages O O
and O O
fibroblasts O O
into O O
neurons O O
. O O

Together O O
, O O
our O O
findings O O
reveal O O
the O O
histone O O
chaperone O O
CAF O O
- O O
1 O O
to O O
be O O
a O O
novel O O
regulator O O
of O O
somatic O O
cell O O
identity O O
during O O
transcription O O
- O O
factor O O
- O O
induced O O
cell O O
- O O
fate O O
transitions O O
and O O
provide O O
a O O
potential O O
strategy O O
to O O
modulate O O
cellular O O
plasticity O O
in O O
a O O
regenerative O O
setting O O
. O O

Dynamic O O
Control O O
of O O
Enhancer O O
Repertoires O O
Drives O O
Lineage O O
and O O
Stage O O
- O O
Specific O O
Transcription O O
during O O
Hematopoiesis O O
. O O

Enhancers O O
are O O
the O O
primary O O
determinants O O
of O O
cell O O
identity O O
, O O
but O O
the O O
regulatory O O
components O O
controlling O O
enhancer O O
turnover O O
during O O
lineage O O
commitment O O
remain O O
largely O O
unknown O O
. O O

Here O O
we O O
compare O O
the O O
enhancer O O
landscape O O
, O O
transcriptional O O
factor O O
occupancy O O
, O O
and O O
transcriptomic O O
changes O O
in O O
human O O
fetal O O
and O O
adult O O
hematopoietic O O
stem O O
/ O O
progenitor O O
cells O O
and O O
committed O O
erythroid O O
progenitors O O
. O O

We O O
find O O
that O O
enhancers O O
are O O
modulated O O
pervasively O O
and O O
direct O O
lineage O O
- O O
and O O
stage O O
- O O
specific O O
transcription O O
. O O
GATA2 O O
- O O
to O O
- O O
GATA1 O O
switch O O
is O O
prevalent O O
at O O
dynamic O O
enhancers O O
and O O
drives O O
erythroid O O
enhancer O O
commissioning O O
. O O

Examination O O
of O O
lineage O O
- O O
specific O O
enhancers O O
identifies O O
transcription O O
factors O O
and O O
their O O
combinatorial O O
patterns O O
in O O
enhancer O O
turnover O O
. O O

Importantly O O
, O O
by O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
genomic O O
editing O O
, O O
we O O
uncover O O
functional O O
hierarchy O O
of O O
constituent O O
enhancers O O
within O O
the O O
SLC25A37 O O
super O O
- O O
enhancer O O
. O O
Importantly O O
, O O
by O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
genomic O O
editing O O
, O O
we O O
uncover O O
functional O O
hierarchy O O
of O O
constituent O O
enhancers O O
within O O
the O O
SLC25A37 O O
super O O
- O O
enhancer O O
. O O

Despite O O
indistinguishable O O
chromatin O O
features O O
, O O
we O O
reveal O O
through O O
genomic O O
editing O O
the O O
functional O O
diversity O O
of O O
several O O
GATA O O
switch O O
enhancers O O
in O O
which O O
enhancers O O
with O O
opposing O O
functions O O
cooperate O O
to O O
coordinate O O
transcription O O
. O O

Thus O O
, O O
genome O O
- O O
wide O O
enhancer O O
profiling O O
coupled O O
with O O
in O O
situ O O
enhancer O O
editing O O
provide O O
critical O O
insights O O
into O O
the O O
functional O O
complexity O O
of O O
enhancers O O
during O O
development O O
. O O

Long O O
- O O
range O O
enhancers O O
modulate O O
Foxf1 O O
transcription O O
in O O
blood O O
vessels O O
of O O
pulmonary O O
vascular O O
network O O
. O O

Intimate O O
crosstalk O O
occurs O O
between O O
the O O
pulmonary O O
epithelium O O
and O O
the O O
vascular O O
network O O
during O O
lung O O
development O O
. O O

The O O
transcription O O
factor O O
forkhead O O
box O O
f1 O O
( O O
Foxf1 O O
) O O
is O O
expressed O O
in O O
the O O
lung O O
mesenchyme O O
and O O
plays O O
an O O
indispensable O O
role O O
in O O
pulmonary O O
angiogenesis O O
. O O
Sonic O O
hedgehog O O
( O O
Shh O O
) O O
, O O
a O O
signalling O O
molecule O O
, O O
is O O
expressed O O
in O O
lung O O
epithelium O O
and O O
is O O
required O O
to O O
establish O O
proper O O
angiogenesis O O
. O O

It O O
has O O
been O O
suggested O O
that O O
Foxf1 O O
, O O
a O O
downstream O O
target O O
of O O
the O O
Shh O O
signalling O O
pathway O O
, O O
mediates O O
interaction O O
between O O
angiogenesis O O
and O O
the O O
epithelium O O
in O O
lung O O
. O O

However O O
, O O
there O O
has O O
been O O
no O O
clear O O
evidence O O
showing O O
the O O
mechanism O O
how O O
Foxf1 O O
is O O
regulated O O
by O O
Shh O O
signalling O O
pathway O O
during O O
lung O O
development O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
lung O O
- O O
specific O O
enhancers O O
of O O
Foxf1 O O
and O O
the O O
Gli O O
binding O O
on O O
the O O
enhancers O O
. O O
In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
lung O O
- O O
specific O O
enhancers O O
of O O
Foxf1 O O
and O O
the O O
Gli O O
binding O O
on O O
the O O
enhancers O O
. O O

At O O
first O O
, O O
we O O
found O O
three O O
evolutionarily O O
conserved O O
Foxf1 O O
enhancers O O
, O O
two O O
of O O
which O O
were O O
long O O
- O O
range O O
enhancers O O
. O O
At O O
first O O
, O O
we O O
found O O
three O O
evolutionarily O O
conserved O O
Foxf1 O O
enhancers O O
, O O
two O O
of O O
which O O
were O O
long O O
- O O
range O O
enhancers O O
. O O

Of O O
the O O
long O O
- O O
range O O
enhancers O O
, O O
one O O
demonstrated O O
tissue O O
- O O
specific O O
activity O O
in O O
the O O
proximal O O
and O O
distal O O
pulmonary O O
blood O O
vessels O O
, O O
while O O
the O O
other O O
one O O
demonstrated O O
activity O O
only O O
in O O
distal O O
blood O O
vessels O O
. O O

At O O
analogous O O
positions O O
in O O
human O O
, O O
these O O
long O O
- O O
range O O
enhancers O O
were O O
included O O
in O O
a O O
regulatory O O
region O O
that O O
was O O
reportedly O O
repeatedly O O
deleted O O
in O O
alveolar B-Disease B-Disease
capillary I-Disease I-Disease
dysplasia I-Disease I-Disease
with I-Disease I-Disease
misalignment I-Disease I-Disease
of I-Disease I-Disease
pulmonary I-Disease I-Disease
vein I-Disease I-Disease
patients O O
, O O
which O O
indicates O O
the O O
importance O O
of O O
these O O
enhancers O O
in O O
pulmonary O O
blood O O
vessel O O
formation O O
. O O

We O O
also O O
determined O O
that O O
Gli O O
increased O O
the O O
activity O O
of O O
one O O
of O O
these O O
long O O
- O O
range O O
enhancers O O
, O O
which O O
was O O
specific O O
to O O
distal O O
blood O O
vessel O O
, O O
suggesting O O
that O O
Shh O O
regulates O O
Foxf1 O O
transcription O O
in O O
pulmonary O O
distal O O
blood O O
vessel O O
formation O O
. O O

Single O O
- O O
cell O O
profiling O O
reveals O O
that O O
eRNA O O
accumulation O O
at O O
enhancer O O
- O O
promoter O O
loops O O
is O O
not O O
required O O
to O O
sustain O O
transcription O O
. O O

Enhancers O O
are O O
intergenic O O
DNA O O
elements O O
that O O
regulate O O
the O O
transcription O O
of O O
target O O
genes O O
in O O
response O O
to O O
signaling O O
pathways O O
by O O
interacting O O
with O O
promoters O O
over O O
large O O
genomic O O
distances O O
. O O

Recent O O
studies O O
have O O
revealed O O
that O O
enhancers O O
are O O
bi O O
- O O
directionally O O
transcribed O O
into O O
enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
. O O

Using O O
single O O
- O O
molecule O O
fluorescence O O
in O O
situ O O
hybridization O O
( O O
smFISH O O
) O O
, O O
we O O
investigated O O
the O O
eRNA O O
- O O
mediated O O
regulation O O
of O O
transcription O O
during O O
estrogen O O
induction O O
in O O
MCF O O
- O O
7 O O
cells O O
. O O

We O O
demonstrate O O
that O O
eRNAs O O
are O O
localized O O
exclusively O O
in O O
the O O
nucleus O O
and O O
are O O
induced O O
with O O
similar O O
kinetics O O
as O O
target O O
mRNAs O O
. O O

However O O
, O O
eRNAs O O
are O O
mostly O O
nascent O O
at O O
enhancers O O
and O O
their O O
steady O O
- O O
state O O
levels O O
remain O O
lower O O
than O O
those O O
of O O
their O O
cognate O O
mRNAs O O
. O O

Surprisingly O O
, O O
at O O
the O O
single O O
- O O
allele O O
level O O
, O O
eRNAs O O
are O O
rarely O O
co O O
- O O
expressed O O
with O O
their O O
target O O
loci O O
, O O
demonstrating O O
that O O
active O O
gene O O
transcription O O
does O O
not O O
require O O
the O O
continuous O O
transcription O O
of O O
eRNAs O O
or O O
their O O
accumulation O O
at O O
enhancers O O
. O O

When O O
co O O
- O O
expressed O O
, O O
sub O O
- O O
diffraction O O
distance O O
measurements O O
between O O
nascent O O
mRNA O O
and O O
eRNA O O
signals O O
reveal O O
that O O
co O O
- O O
transcription O O
of O O
eRNAs O O
and O O
mRNAs O O
rarely O O
occurs O O
within O O
closed O O
enhancer O O
- O O
promoter O O
loops O O
. O O

Lastly O O
, O O
basal O O
eRNA O O
transcription O O
at O O
enhancers O O
, O O
but O O
not O O
E2 O O
- O O
induced O O
transcription O O
, O O
is O O
maintained O O
upon O O
depletion O O
of O O
MLL1 O O
and O O
ERalpha O O
, O O
suggesting O O
some O O
degree O O
of O O
chromatin O O
accessibility O O
prior O O
to O O
signal O O
- O O
dependent O O
activation O O
of O O
transcription O O
. O O

Together O O
, O O
our O O
findings O O
suggest O O
that O O
eRNA O O
accumulation O O
at O O
enhancer O O
- O O
promoter O O
loops O O
is O O
not O O
required O O
to O O
sustain O O
target O O
gene O O
transcription O O
. O O

Aberrant O O
activation O O
of O O
the O O
GIMAP O O
enhancer O O
by O O
oncogenic O O
transcription O O
factors O O
in O O
T B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
acute I-Disease I-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
. O O

The O O
transcription O O
factor O O
TAL1 O O
/ O O
SCL O O
is O O
one O O
of O O
the O O
most O O
prevalent O O
oncogenes O O
in O O
T B-Disease B-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
acute I-Disease I-Disease
lymphoblastic I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
T B-Disease B-Disease
- I-Disease I-Disease
ALL I-Disease I-Disease
) O O
, O O
a O O
malignant O O
disorder O O
resulting O O
from O O
leukemic O O
transformation O O
of O O
thymus O O
T O O
- O O
cell O O
precursors O O
. O O
TAL1 O O
is O O
normally O O
expressed O O
in O O
hematopoietic O O
stem O O
cells O O
( O O
HSCs O O
) O O
but O O
is O O
silenced O O
in O O
immature O O
thymocytes O O
. O O

We O O
hypothesize O O
that O O
TAL1 O O
contributes O O
to O O
leukemogenesis O O
by O O
activating O O
genes O O
that O O
are O O
normally O O
repressed O O
in O O
immature O O
thymocytes O O
. O O

Herein O O
, O O
we O O
identified O O
a O O
novel O O
TAL1 O O
- O O
regulated O O
super O O
- O O
enhancer O O
controlling O O
the O O
GIMAP O O
locus O O
, O O
which O O
resides O O
within O O
an O O
insulated O O
chromosomal O O
locus O O
in O O
T O O
- O O
ALL O O
cells O O
. O O
Herein O O
, O O
we O O
identified O O
a O O
novel O O
TAL1 O O
- O O
regulated O O
super O O
- O O
enhancer O O
controlling O O
the O O
GIMAP O O
locus O O
, O O
which O O
resides O O
within O O
an O O
insulated O O
chromosomal O O
locus O O
in O O
T O O
- O O
ALL O O
cells O O
. O O

The O O
GIMAP O O
genes O O
are O O
expressed O O
in O O
HSCs O O
and O O
mature O O
T O O
cells O O
but O O
are O O
downregulated O O
during O O
the O O
immature O O
stage O O
of O O
thymocyte O O
differentiation O O
. O O

The O O
GIMAP O O
enhancer O O
is O O
activated O O
by O O
TAL1 O O
, O O
RUNX1 O O
and O O
GATA3 O O
in O O
human O O
T O O
- O O
ALL O O
cells O O
but O O
is O O
repressed O O
by O O
E O O
- O O
proteins O O
. O O

Overexpression O O
of O O
human O O
GIMAP O O
genes O O
in O O
immature O O
thymocytes O O
alone O O
does O O
not O O
induce O O
tumorigenesis O O
but O O
accelerates O O
leukemia B-Disease B-Disease
development O O
in O O
zebrafish O O
. O O

Our O O
results O O
demonstrate O O
that O O
aberrant O O
activation O O
of O O
the O O
GIMAP O O
enhancer O O
contributes O O
to O O
T O O
- O O
cell O O
leukemogenesis O O
. O O

A O O
novel O O
LSD1 O O
inhibitor O O
NCD38 O O
ameliorates O O
MDS B-Disease B-Disease
- O I-Disease
related O I-Disease
leukemia B-Disease I-Disease
with O O
complex O O
karyotype O O
by O O
attenuating O O
leukemia B-Disease B-Disease
programs O O
via O O
activating O O
super O O
- O O
enhancers O O
. O O
Lysine O O
- O O
specific O O
demethylase O O
1 O O
( O O
LSD1 O O
) O O
regulates O O
gene O O
expression O O
by O O
affecting O O
histone O O
modifications O O
and O O
is O O
a O O
promising O O
target O O
for O O
acute B-Disease B-Disease
myeloid I-Disease I-Disease
leukemia I-Disease I-Disease
( O O
AML B-Disease B-Disease
) O O
with O O
specific O O
genetic O B-Disease
abnormalities O I-Disease
. O O

Novel O O
LSD1 O O
inhibitors O O
, O O
NCD25 O O
and O O
NCD38 O O
, O O
inhibited O O
growth O O
of O O
MLL B-Disease O
- I-Disease O
AF9 I-Disease O
leukemia I-Disease O
as O O
well O O
as O O
erythroleukemia B-Disease B-Disease
, O O
megakaryoblastic B-Disease B-Disease
leukemia I-Disease I-Disease
and O O
myelodysplastic B-Disease B-Disease
syndromes I-Disease I-Disease
( O O
MDSs B-Disease B-Disease
) O O
overt O O
leukemia O O
cells O O
in O O
the O O
concentration O O
range O O
that O O
normal O O
hematopoiesis O O
was O O
spared O O
. O O

NCD25 O O
and O O
NCD38 O O
invoked O O
the O O
myeloid O O
development O O
programs O O
, O O
hindered O O
the O O
MDS B-Disease B-Disease
and O O
AML B-Disease B-Disease
oncogenic O O
programs O O
, O O
and O O
commonly O O
upregulated O O
62 O O
genes O O
in O O
several O O
leukemia O O
cells O O
. O O

NCD38 O O
elevated O O
H3K27ac O O
level O O
on O O
enhancers O O
of O O
these O O
LSD1 O O
signature O O
genes O O
and O O
newly O O
activated O O
~ O O
500 O O
super O O
- O O
enhancers O O
. O O

Upregulated O O
genes O O
with O O
super O O
- O O
enhancer O O
activation O O
in O O
erythroleukemia O O
cells O O
were O O
enriched O O
in O O
leukocyte O O
differentiation O O
. O O

Eleven O O
genes O O
including O O
GFI1 O O
and O O
ERG O O
, O O
but O O
not O O
CEBPA O O
, O O
were O O
identified O O
as O O
the O O
LSD1 O O
signature O O
with O O
super O O
- O O
enhancer O O
activation O O
. O O

Super O O
- O O
enhancers O O
of O O
these O O
genes O O
were O O
activated O O
prior O O
to O O
induction O O
of O O
the O O
transcripts O O
and O O
myeloid O O
differentiation O O
. O O

Depletion O O
of O O
GFI1 O O
attenuated O O
myeloid O O
differentiation O O
by O O
NCD38 O O
. O O

Finally O O
, O O
a O O
single O O
administration O O
of O O
NCD38 O O
causes O O
the O O
in O O
vivo O O
eradication O O
of O O
primary O O
MDS O O
- O O
related O O
leukemia O O
cells O O
with O O
a O O
complex O O
karyotype O O
. O O

Together O O
, O O
NCD38 O O
derepresses O O
super O O
- O O
enhancers O O
of O O
hematopoietic O O
regulators O O
that O O
are O O
silenced O O
abnormally O O
by O O
LSD1 O O
, O O
attenuates O O
leukemogenic O O
programs O O
and O O
consequently O O
exerts O O
anti O O
- O O
leukemic O B-Disease
effect O O
against O O
MDS B-Disease B-Disease
- O I-Disease
related O I-Disease
leukemia B-Disease I-Disease
with O O
adverse O O
outcome O O
. O O

Bisphenol O O
A O O
Induces O O
Sox2 O O
in O O
ER O O
+ O O
Breast O O
Cancer O O
Stem O O
- O O
Like O O
Cells O O
. O O

Bisphenol O O
A O O
( O O
BPA O O
) O O
is O O
an O O
endocrine O O
disrupting O O
compound O O
used O O
in O O
food O O
and O O
beverage O O
plastic O O
containers O O
and O O
has O O
been O O
shown O O
to O O
increase O O
breast B-Disease O
cancer I-Disease O
cellular O O
proliferation O O
. O O

However O O
, O O
the O O
concentrations O O
of O O
BPA O O
used O O
in O O
these O O
experiments O O
are O O
far O O
higher O O
than O O
the O O
physiological O O
levels O O
of O O
BPA O O
detected O O
in O O
the O O
human O O
body O O
. O O

We O O
observed O O
in O O
vitro O O
that O O
exposure O O
of O O
MCF O O
- O O
7 O O
cells O O
to O O
physiological O O
concentrations O O
of O O
BPA O O
failed O O
to O O
increase O O
cell O O
proliferation O O
or O O
to O O
induce O O
canonical O O
estrogen O O
- O O
responsive O O
genes O O
( O O
pS2 O O
and O O
progesterone O O
receptor O O
( O O
PR O O
) O O
) O O
, O O
in O O
contrast O O
to O O
17beta O O
- O O
estradiol O O
( O O
E2 O O
) O O
treatment O O
. O O

However O O
, O O
MCF O O
- O O
7 O O
cells O O
treated O O
with O O
10 O O
nM O O
BPA O O
induced O O
ALDH1 O O
expression O O
, O O
a O O
marker O O
of O O
human O O
mammary O O
stem O O
cells O O
. O O

When O O
treated O O
with O O
10 O O
nM O O
BPA O O
, O O
mammospheres O O
derived O O
either O O
from O O
MCF O O
- O O
7 O O
cells O O
, O O
a O O
patient O O
- O O
derived O O
xenograft O O
, O O
or O O
the O O
normal O O
mouse O O
mammary O O
gland O O
exhibited O O
increased O O
size O O
; O O
however O O
, O O
these O O
effects O O
were O O
not O O
observed O O
in O O
MDA O O
- O O
MB O O
- O O
231 O O
mammospheres O O
. O O

Mechanistically O O
, O O
BPA O O
induced O O
SOX2 O O
mRNA O O
and O O
protein O O
in O O
MCF O O
- O O
7 O O
mammospheres O O
, O O
resulting O O
from O O
enhanced O O
CREB O O
phosphorylation O O
, O O
and O O
subsequent O O
binding O O
of O O
pCREB O O
to O O
a O O
SOX2 O O
downstream O O
enhancer O O
. O O
Mechanistically O O
, O O
BPA O O
induced O O
SOX2 O O
mRNA O O
and O O
protein O O
in O O
MCF O O
- O O
7 O O
mammospheres O O
, O O
resulting O O
from O O
enhanced O O
CREB O O
phosphorylation O O
, O O
and O O
subsequent O O
binding O O
of O O
pCREB O O
to O O
a O O
SOX2 O O
downstream O O
enhancer O O
. O O

These O O
findings O O
suggest O O
that O O
physiological O O
levels O O
of O O
BPA O O
increase O O
estrogen B-Disease O
receptor I-Disease O
- I-Disease O
positive I-Disease O
breast I-Disease B-Disease
cancer I-Disease I-Disease
tumor B-Disease I-Disease
maintenance O O
through O O
enhanced O O
cancer O O
stem O O
- O O
like O O
cell O O
activity O O
via O O
direct O O
regulation O O
of O O
SOX2 O O
transcription O O
. O O

MAPK O O
Signaling O O
and O O
Inflammation O O
Link O O
Melanoma B-Disease B-Disease
Phenotype O O
Switching O O
to O O
Induction O O
of O O
CD73 O O
during O O
Immunotherapy O O
. O O

Evolution O O
of O O
tumor O O
cell O O
phenotypes O O
promotes O O
heterogeneity O O
and O O
therapy O O
resistance O O
. O O

Here O O
we O O
found O O
that O O
induction O O
of O O
CD73 O O
, O O
the O O
enzyme O O
that O O
generates O O
immunosuppressive O O
adenosine O O
, O O
is O O
linked O O
to O O
melanoma B-Disease B-Disease
phenotype O O
switching O O
. O O

Activating O O
MAPK O O
mutations O O
and O O
growth O O
factors O O
drove O O
CD73 O O
expression O O
, O O
which O O
marked O O
both O O
nascent O O
and O O
full O O
activation O O
of O O
a O O
mesenchymal O O
- O O
like O O
melanoma O O
cell O O
state O O
program O O
. O O

Proinflammatory O O
cytokines O O
like O O
TNFalpha O O
cooperated O O
with O O
MAPK O O
signaling O O
through O O
the O O
c O O
- O O
Jun O O
/ O O
AP O O
- O O
1 O O
transcription O O
factor O O
complex O O
to O O
activate O O
CD73 O O
transcription O O
by O O
binding O O
to O O
an O O
intronic O O
enhancer O O
. O O

In O O
a O O
mouse O O
model O O
of O O
T O O
- O O
cell O O
immunotherapy O O
, O O
CD73 O O
was O O
induced O O
in O O
relapse O O
melanomas B-Disease B-Disease
, O O
which O O
acquired O O
a O O
mesenchymal O O
- O O
like O O
phenotype O O
. O O

We O O
also O O
detected O O
CD73 O O
upregulation O O
in O O
melanoma B-Disease B-Disease
patients O O
progressing O O
under O O
adoptive O O
T O O
- O O
cell O O
transfer O O
or O O
immune O O
checkpoint O O
blockade O O
, O O
arguing O O
for O O
an O O
adaptive O O
resistance O O
mechanism O O
. O O

Our O O
work O O
substantiates O O
CD73 O O
as O O
a O O
target O O
to O O
combine O O
with O O
current O O
immunotherapies O O
, O O
but O O
its O O
dynamic O O
regulation O O
suggests O O
limited O O
value O O
of O O
CD73 O O
pretreatment O O
expression O O
as O O
a O O
biomarker O O
to O O
stratify O O
melanoma B-Disease B-Disease
patients O O
. O O
Cancer B-Disease O
Res O O
; O O
77 O O
( O O
17 O O
) O O
; O O
4697 O O
- O O
709 O O
. O O

2017 O O
AACR O O
. O O

Super O O
- O O
enhancers O O
define O O
a O O
proliferative O O
PGC O O
- O O
1alpha O O
- O O
expressing O O
melanoma B-Disease B-Disease
subgroup O O
sensitive O O
to O O
BET O O
inhibition O O
. O O

Metabolic O O
changes O O
are O O
linked O O
to O O
epigenetic O O
reprogramming O O
and O O
play O O
important O O
roles O O
in O O
several O O
tumor B-Disease B-Disease
types O O
. O O
PGC O O
- O O
1alpha O O
is O O
a O O
transcriptional O O
coactivator O O
controlling O O
mitochondrial O O
biogenesis O O
and O O
is O O
linked O O
to O O
oxidative O O
phosphorylation O O
. O O

We O O
provide O O
evidence O O
that O O
melanoma B-Disease B-Disease
models O O
with O O
elevated O O
PGC O O
- O O
1alpha O O
levels O O
are O O
characteristic O O
of O O
the O O
proliferative O O
phenotype O O
and O O
are O O
sensitive O O
to O O
bromodomain O O
and O O
extra O O
- O O
terminal O O
domain O O
( O O
BET O O
) O O
inhibitor O O
treatment O O
. O O

A O O
super O O
- O O
enhancer O O
region O O
highly O O
occupied O O
by O O
the O O
BET O O
family O O
member O O
BRD4 O O
was O O
identified O O
for O O
the O O
PGC O O
- O O
1alpha O O
gene O O
. O O

BET O O
inhibitor O O
treatment O O
prevented O O
this O O
interaction O O
, O O
leading O O
to O O
a O O
dramatic O O
reduction O O
of O O
PGC O O
- O O
1alpha O O
expression O O
. O O

Accordingly O O
, O O
BET O O
inhibition O O
diminished O O
respiration O O
and O O
mitochondrial O O
function O O
in O O
cells O O
. O O

In O O
vivo O O
, O O
melanoma B-Disease B-Disease
models O O
with O O
high O O
PGC O O
- O O
1alpha O O
expression O O
strongly O O
responded O O
to O O
BET O O
inhibition O O
by O O
reduction O O
of O O
PGC O O
- O O
1alpha O O
and O O
impaired O O
tumor B-Disease B-Disease
growth O O
. O O

Altogether O O
, O O
our O O
findings O O
identify O O
epigenetic O O
regulatory O O
elements O O
that O O
define O O
a O O
subset O O
of O O
melanomas B-Disease B-Disease
with O O
high O O
sensitivity O O
to O O
BET O O
inhibition O O
, O O
which O O
opens O O
up O O
the O O
opportunity O O
to O O
define O O
melanoma B-Disease B-Disease
patients O O
most O O
likely O O
to O O
respond O O
to O O
this O O
treatment O O
, O O
depending O O
on O O
their O O
tumor B-Disease B-Disease
characteristics O O
. O O

A O O
DNA O O
Contact O O
Map O O
for O O
the O O
Mouse O O
Runx1 O O
Gene O O
Identifies O O
Novel O O
Haematopoietic O O
Enhancers O O
. O O

The O O
transcription O O
factor O O
Runx1 O O
is O O
essential O O
for O O
definitive O O
haematopoiesis O O
, O O
and O O
the O O
RUNX1 O O
gene O O
is O O
frequently O O
translocated O O
or O O
mutated O O
in O O
leukaemia B-Disease B-Disease
. O O
Runx1 O O
is O O
transcribed O O
from O O
two O O
promoters O O
, O O
P1 O O
and O O
P2 O O
, O O
to O O
give O O
rise O O
to O O
different O O
protein O O
isoforms O O
. O O

Although O O
the O O
expression O O
of O O
Runx1 O O
must O O
be O O
tightly O O
regulated O O
for O O
normal O O
blood O O
development O O
, O O
the O O
mechanisms O O
that O O
regulate O O
Runx1 O O
isoform O O
expression O O
during O O
haematopoiesis O O
remain O O
poorly O O
understood O O
. O O

Gene O O
regulatory O O
elements O O
located O O
in O O
non O O
- O O
coding O O
DNA O O
are O O
likely O O
to O O
be O O
important O O
for O O
Runx1 O O
transcription O O
. O O

Here O O
we O O
use O O
circular O O
chromosome O O
conformation O O
capture O O
sequencing O O
to O O
identify O O
DNA O O
interactions O O
with O O
the O O
P1 O O
and O O
P2 O O
promoters O O
of O O
Runx1 O O
, O O
and O O
the O O
previously O O
identified O O
+ O O
24 O O
enhancer O O
, O O
in O O
the O O
mouse O O
multipotent O O
haematopoietic O O
progenitor O O
cell O O
line O O
HPC O O
- O O
7 O O
. O O
Here O O
we O O
use O O
circular O O
chromosome O O
conformation O O
capture O O
sequencing O O
to O O
identify O O
DNA O O
interactions O O
with O O
the O O
P1 O O
and O O
P2 O O
promoters O O
of O O
Runx1 O O
, O O
and O O
the O O
previously O O
identified O O
+ O O
24 O O
enhancer O O
, O O
in O O
the O O
mouse O O
multipotent O O
haematopoietic O O
progenitor O O
cell O O
line O O
HPC O O
- O O
7 O O
. O O

The O O
active O O
promoter O O
, O O
P1 O O
, O O
interacts O O
with O O
nine O O
non O O
- O O
coding O O
regions O O
that O O
are O O
occupied O O
by O O
transcription O O
factors O O
within O O
a O O
1 O O
Mb O O
topologically O O
associated O O
domain O O
. O O
Eight O O
of O O
nine O O
regions O O
function O O
as O O
blood O O
- O O
specific O O
enhancers O O
in O O
zebrafish O O
, O O
of O O
which O O
two O O
were O O
previously O O
shown O O
to O O
harbour O O
blood O O
- O O
specific O O
enhancer O O
activity O O
in O O
mice O O
. O O
The O O
active O O
promoter O O
, O O
P1 O O
, O O
interacts O O
with O O
nine O O
non O O
- O O
coding O O
regions O O
that O O
are O O
occupied O O
by O O
transcription O O
factors O O
within O O
a O O
1 O O
Mb O O
topologically O O
associated O O
domain O O
. O O
Eight O O
of O O
nine O O
regions O O
function O O
as O O
blood O O
- O O
specific O O
enhancers O O
in O O
zebrafish O O
, O O
of O O
which O O
two O O
were O O
previously O O
shown O O
to O O
harbour O O
blood O O
- O O
specific O O
enhancer O O
activity O O
in O O
mice O O
. O O

Interestingly O O
, O O
the O O
+ O O
24 O O
enhancer O O
interacted O O
with O O
multiple O O
distant O O
regions O O
on O O
chromosome O O
16 O O
, O O
suggesting O O
it O O
may O O
regulate O O
the O O
expression O O
of O O
additional O O
genes O O
. O O

The O O
Runx1 O O
DNA O O
contact O O
map O O
identifies O O
connections O O
with O O
multiple O O
novel O O
and O O
known O O
haematopoietic O O
enhancers O O
that O O
are O O
likely O O
to O O
be O O
involved O O
in O O
regulating O O
Runx1 O O
expression O O
in O O
haematopoietic O O
progenitor O O
cells O O
. O O

Dynamic O O
transcriptional O O
control O O
of O O
macrophage O O
miRNA O O
signature O O
via O O
inflammation O O
responsive O O
enhancers O O
revealed O O
using O O
a O O
combination O O
of O O
next O O
generation O O
sequencing O O
- O O
based O O
approaches O O
. O O

MicroRNAs O O
are O O
important O O
components O O
of O O
the O O
post O O
- O O
transcriptional O O
fine O O
- O O
tuning O O
of O O
macrophage O O
gene O O
expression O O
in O O
physiological O O
and O O
pathological O O
conditions O O
. O O

However O O
, O O
the O O
mechanistic O O
underpinnings O O
and O O
the O O
cis O O
- O O
acting O O
genomic O O
factors O O
of O O
how O O
macrophage O O
polarizing O O
signals O O
induce O O
miRNA O O
expression O O
changes O O
are O O
not O O
well O O
characterized O O
. O O

Therefore O O
, O O
we O O
systematically O O
evaluated O O
the O O
transcriptional O O
basis O O
underlying O O
the O O
inflammation O O
- O O
mediated O O
regulation O O
of O O
macrophage O O
microRNome O O
using O O
the O O
combination O O
of O O
different O O
next O O
generation O O
sequencing O O
datasets O O
. O O

We O O
investigated O O
the O O
LPS O O
- O O
induced O O
expression O O
changes O O
at O O
mature O O
miRNA O O
and O O
pri O O
- O O
miRNA O O
levels O O
in O O
mouse O O
macrophages O O
utilizing O O
a O O
small O O
RNA O O
- O O
seq O O
method O O
and O O
publicly O O
available O O
GRO O O
- O O
seq O O
dataset O O
, O O
respectively O O
. O O

Next O O
, O O
we O O
identified O O
an O O
enhancer O O
set O O
associated O O
with O O
LPS O O
- O O
responsive O O
pri O O
- O O
miRNAs O O
based O O
on O O
publicly O O
available O O
H3K4 O O
mono O O
- O O
methylation O O
- O O
specific O O
ChIP O O
- O O
seq O O
and O O
GRO O O
- O O
seq O O
datasets O O
. O O

This O O
enhancer O O
set O O
was O O
further O O
characterized O O
by O O
the O O
combination O O
of O O
publicly O O
available O O
ChIP O O
and O O
ATAC O O
- O O
seq O O
datasets O O
. O O

Finally O O
, O O
direct O O
interactions O O
between O O
the O O
miR O O
- O O
155 O O
- O O
coding O O
genomic O O
region O O
and O O
its O O
distal O O
regulatory O O
elements O O
were O O
identified O O
using O O
a O O
3C O O
- O O
seq O O
approach O O
. O O

Our O O
analysis O O
revealed O O
15 O O
robustly O O
LPS O O
- O O
regulated O O
miRNAs O O
at O O
the O O
transcriptional O O
level O O
. O O

In O O
addition O O
, O O
we O O
found O O
that O O
these O O
miRNA O O
genes O O
are O O
associated O O
with O O
an O O
inflammation O O
- O O
responsive O O
enhancer O O
network O O
. O O

Based O O
on O O
NFkappaB O O
- O O
p65 O O
and O O
JunB O O
transcription O O
factor O O
binding O O
, O O
we O O
showed O O
two O O
distinct O O
enhancer O O
subsets O O
associated O O
with O O
LPS O O
- O O
activated O O
miRNAs O O
that O O
possess O O
distinct O O
epigenetic O O
characteristics O O
and O O
LPS O O
- O O
responsiveness O O
. O O

Finally O O
, O O
our O O
3C O O
- O O
seq O O
analysis O O
revealed O O
the O O
LPS O O
- O O
induced O O
extensive O O
reorganization O O
of O O
the O O
pri O O
- O O
miR O O
- O O
155 O O
- O O
associated O O
functional O O
chromatin O O
domain O O
as O O
well O O
as O O
chromatin O O
loop O O
formation O O
between O O
LPS O O
- O O
responsive O O
enhancers O O
and O O
the O O
promoter O O
region O O
. O O

Our O O
genomic O O
approach O O
successfully O O
combines O O
various O O
genome O O
- O O
wide O O
datasets O O
and O O
allows O O
the O O
identification O O
of O O
the O O
putative O O
regulatory O O
elements O O
controlling O O
miRNA O O
expression O O
in O O
classically O O
activated O O
macrophages O O
. O O

STAT3 O O
controls O O
COL1A2 O O
enhancer O O
activation O O
cooperatively O O
with O O
JunB O O
, O O
regulates O O
type O O
I O O
collagen O O
synthesis O O
posttranscriptionally O O
, O O
and O O
is O O
essential O O
for O O
lung O O
myofibroblast O O
differentiation O O
. O O
Fibroblast O O
differentiation O O
is O O
a O O
key O O
cellular O O
process O O
that O O
underlies O O
the O O
process O O
of O O
fibrosis B-Disease O
, O O
a O O
deadly O O
complication O O
of O O
fibrotic B-Disease B-Disease
diseases I-Disease I-Disease
like O O
scleroderma B-Disease B-Disease
( O O
SSc B-Disease B-Disease
) O O
. O O
STAT3 O O
controls O O
COL1A2 O O
enhancer O O
activation O O
cooperatively O O
with O O
JunB O O
, O O
regulates O O
type O O
I O O
collagen O O
synthesis O O
posttranscriptionally O O
, O O
and O O
is O O
essential O O
for O O
lung O O
myofibroblast O O
differentiation O O
. O O
Fibroblast O O
differentiation O O
is O O
a O O
key O O
cellular O O
process O O
that O O
underlies O O
the O O
process O O
of O O
fibrosis B-Disease O
, O O
a O O
deadly O O
complication O O
of O O
fibrotic B-Disease B-Disease
diseases I-Disease I-Disease
like O O
scleroderma B-Disease B-Disease
( O O
SSc B-Disease B-Disease
) O O
. O O

This O O
transition O O
coincides O O
with O O
the O O
overproduction O O
of O O
collagen O O
type O O
I O O
( O O
COL1 O O
) O O
and O O
other O O
extracellular O O
matrix O O
proteins O O
. O O

High O O
- O O
level O O
expression O O
of O O
the O O
collagen O O
type O O
1alpha2 O O
subunit O O
( O O
COL1A2 O O
) O O
, O O
requires O O
the O O
engagement O O
of O O
a O O
far O O
- O O
upstream O O
enhancer O O
, O O
whose O O
activation O O
is O O
strongly O O
dependent O O
on O O
the O O
AP1 O O
factor O O
JunB O O
. O O

We O O
now O O
report O O
that O O
STAT3 O O
also O O
binds O O
the O O
COL1A2 O O
enhancer O O
and O O
is O O
essential O O
for O O
RNA O O
polymerase O O
recruitment O O
, O O
without O O
affecting O O
JunB O O
binding O O
. O O
STAT3 O O
is O O
required O O
for O O
the O O
increased O O
COL1A2 O O
expression O O
observed O O
in O O
myofibroblasts O O
. O O
We O O
now O O
report O O
that O O
STAT3 O O
also O O
binds O O
the O O
COL1A2 O O
enhancer O O
and O O
is O O
essential O O
for O O
RNA O O
polymerase O O
recruitment O O
, O O
without O O
affecting O O
JunB O O
binding O O
. O O
STAT3 O O
is O O
required O O
for O O
the O O
increased O O
COL1A2 O O
expression O O
observed O O
in O O
myofibroblasts O O
. O O

We O O
also O O
report O O
that O O
TGFbeta O O
partially O O
activates O O
STAT3 O O
and O O
show O O
that O O
inhibiting O O
STAT3 O O
potently O O
blocks O O
TGFbeta O O
signaling O O
, O O
matrix O O
remodeling O O
, O O
and O O
TGFbeta O O
- O O
induced O O
myofibroblast O O
differentiation O O
. O O

Activation O O
of O O
STAT3 O O
with O O
IL6 O O
transsignaling O O
alone O O
, O O
however O O
, O O
only O O
increased O O
COL1A2 O O
protein O O
expression O O
, O O
leaving O O
COL1A2 O O
mRNA O O
levels O O
unchanged O O
. O O

Our O O
results O O
suggest O O
that O O
activated O O
STAT3 O O
is O O
not O O
the O O
limiting O O
factor O O
for O O
collagen O O
enhancer O O
activation O O
in O O
human O O
lung O O
fibroblasts O O
. O O

Yet O O
, O O
a O O
certain O O
threshold O O
level O O
of O O
STAT3 O O
activity O O
is O O
essential O O
to O O
support O O
activation O O
of O O
the O O
COL1A2 O O
enhancer O O
and O O
TGFbeta O O
signaling O O
in O O
fibroblasts O O
. O O
Yet O O
, O O
a O O
certain O O
threshold O O
level O O
of O O
STAT3 O O
activity O O
is O O
essential O O
to O O
support O O
activation O O
of O O
the O O
COL1A2 O O
enhancer O O
and O O
TGFbeta O O
signaling O O
in O O
fibroblasts O O
. O O

We O O
propose O O
that O O
STAT3 O O
operates O O
at O O
the O O
posttranscriptional O O
as O O
well O O
as O O
the O O
transcriptional O O
level O O
. O O

Coordinated O O
d O O
- O O
cyclin O O
/ O O
Foxd1 O O
activation O O
drives O O
mitogenic O O
activity O O
of O O
the O O
Sonic O O
Hedgehog O O
signaling O O
pathway O O
. O O
Sonic O O
Hedgehog O O
( O O
Shh O O
) O O
signaling O O
plays O O
key O O
regulatory O O
roles O O
in O O
embryonic O O
development O O
and O O
postnatal O O
homeostasis O O
and O O
repair O O
. O O

Modulation O O
of O O
the O O
Shh O O
pathway O O
is O O
known O O
to O O
cause O O
malformations B-Disease O
and O O
malignancies B-Disease O
associated O O
with O O
dysregulated O O
tissue O O
growth O O
. O O

However O O
, O O
our O O
understanding O O
of O O
the O O
molecular O O
mechanisms O O
by O O
which O O
Shh O O
regulates O O
cellular O O
proliferation O O
is O O
incomplete O O
. O O

Here O O
, O O
using O O
mouse O O
embryonic O O
fibroblasts O O
, O O
we O O
demonstrate O O
that O O
the O O
Forkhead O O
box O O
gene O O
Foxd1 O O
is O O
transcriptionally O O
regulated O O
by O O
canonical O O
Shh O O
signaling O O
and O O
required O O
for O O
downstream O O
proliferative O O
activity O O
. O O

We O O
show O O
that O O
Foxd1 O O
deletion O O
abrogates O O
the O O
proliferative O O
response O O
to O O
SHH O O
ligand O O
while O O
FOXD1 O O
overexpression O O
alone O O
is O O
sufficient O O
to O O
induce O O
cellular O O
proliferation O O
. O O

The O O
proliferative O O
response O O
to O O
both O O
SHH O O
ligand O O
and O O
FOXD1 O O
overexpression O O
was O O
blocked O O
by O O
pharmacologic O O
inhibition O O
of O O
cyclin O O
- O O
dependent O O
kinase O O
signaling O O
. O O

Time O O
- O O
course O O
experiments O O
revealed O O
that O O
Shh O O
pathway O O
activation O O
of O O
Foxd1 O O
is O O
followed O O
by O O
downregulation O O
of O O
Cdkn1c O O
, O O
which O O
encodes O O
a O O
cyclin O O
- O O
dependent O O
kinase O O
inhibitor O O
. O O

Consistent O O
with O O
a O O
direct O O
transcriptional O O
regulation O O
mechanism O O
, O O
we O O
found O O
that O O
FOXD1 O O
reduces O O
reporter O O
activity O O
of O O
a O O
Fox O O
enhancer O O
sequence O O
in O O
the O O
second O O
intron O O
of O O
Cdkn1c O O
. O O
Consistent O O
with O O
a O O
direct O O
transcriptional O O
regulation O O
mechanism O O
, O O
we O O
found O O
that O O
FOXD1 O O
reduces O O
reporter O O
activity O O
of O O
a O O
Fox O O
enhancer O O
sequence O O
in O O
the O O
second O O
intron O O
of O O
Cdkn1c O O
. O O

Supporting O O
the O O
applicability O O
of O O
these O O
findings O O
to O O
specific O O
biological O O
contexts O O
, O O
we O O
show O O
that O O
Shh O O
regulation O O
of O O
Foxd1 O O
and O O
Cdkn1c O O
is O O
recapitulated O O
in O O
cranial O O
neural O O
crest O O
cells O O
and O O
provide O O
evidence O O
that O O
this O O
mechanism O O
is O O
operational O O
during O O
upper O O
lip O O
morphogenesis O O
. O O

These O O
results O O
reveal O O
a O O
novel O O
Shh O O
- O O
Foxd1 O O
- O O
Cdkn1c O O
regulatory O O
circuit O O
that O O
drives O O
the O O
mitogenic O O
action O O
of O O
Shh O O
signaling O O
and O O
may O O
have O O
broad O O
implications O O
in O O
development O O
and O O
disease O O
. O O

A O O
Myc O O
enhancer O O
cluster O O
regulates O O
normal O O
and O O
leukaemic O O
haematopoietic O O
stem O O
cell O O
hierarchies O O
. O O
A O O
Myc O O
enhancer O O
cluster O O
regulates O O
normal O O
and O O
leukaemic O O
haematopoietic O O
stem O O
cell O O
hierarchies O O
. O O

The O O
transcription O O
factor O O
Myc O O
is O O
essential O O
for O O
the O O
regulation O O
of O O
haematopoietic O O
stem O O
cells O O
and O O
progenitors O O
and O O
has O O
a O O
critical O O
function O O
in O O
haematopoietic B-Disease B-Disease
malignancies I-Disease I-Disease
. O O

Here O O
we O O
show O O
that O O
an O O
evolutionarily O O
conserved O O
region O O
located O O
1 O O
. O O
7 O O
megabases O O
downstream O O
of O O
the O O
Myc O O
gene O O
that O O
has O O
previously O O
been O O
labelled O O
as O O
a O O
' O O
super O O
- O O
enhancer O O
' O O
is O O
essential O O
for O O
the O O
regulation O O
of O O
Myc O O
expression O O
levels O O
in O O
both O O
normal O O
haematopoietic O O
and O O
leukaemic O O
stem O O
cell O O
hierarchies O O
in O O
mice O O
and O O
humans O O
. O O
Here O O
we O O
show O O
that O O
an O O
evolutionarily O O
conserved O O
region O O
located O O
1 O O
. O O
7 O O
megabases O O
downstream O O
of O O
the O O
Myc O O
gene O O
that O O
has O O
previously O O
been O O
labelled O O
as O O
a O O
' O O
super O O
- O O
enhancer O O
' O O
is O O
essential O O
for O O
the O O
regulation O O
of O O
Myc O O
expression O O
levels O O
in O O
both O O
normal O O
haematopoietic O O
and O O
leukaemic O O
stem O O
cell O O
hierarchies O O
in O O
mice O O
and O O
humans O O
. O O

Deletion O O
of O O
this O O
region O O
in O O
mice O O
leads O O
to O O
a O O
complete O O
loss O O
of O O
Myc O O
expression O O
in O O
haematopoietic O O
stem O O
cells O O
and O O
progenitors O O
. O O

This O O
caused O O
an O O
accumulation O O
of O O
differentiation O O
- O O
arrested O O
multipotent O O
progenitors O O
and O O
loss O O
of O O
myeloid O O
and O O
B O O
cells O O
, O O
mimicking O O
the O O
phenotype O O
caused O O
by O O
Mx1 O O
- O O
Cre O O
- O O
mediated O O
conditional O O
deletion O O
of O O
the O O
Myc O O
gene O O
in O O
haematopoietic O O
stem O O
cells O O
. O O

This O O
super O O
- O O
enhancer O O
comprises O O
multiple O O
enhancer O O
modules O O
with O O
selective O O
activity O O
that O O
recruits O O
a O O
compendium O O
of O O
transcription O O
factors O O
, O O
including O O
GFI1b O O
, O O
RUNX1 O O
and O O
MYB O O
. O O

Analysis O O
of O O
mice O O
carrying O O
deletions O O
of O O
individual O O
enhancer O O
modules O O
suggests O O
that O O
specific O O
Myc O O
expression O O
levels O O
throughout O O
most O O
of O O
the O O
haematopoietic O O
hierarchy O O
are O O
controlled O O
by O O
the O O
combinatorial O O
and O O
additive O O
activity O O
of O O
individual O O
enhancer O O
modules O O
, O O
which O O
collectively O O
function O O
as O O
a O O
' O O
blood O O
enhancer O O
cluster O O
' O O
( O O
BENC O O
) O O
. O O
Analysis O O
of O O
mice O O
carrying O O
deletions O O
of O O
individual O O
enhancer O O
modules O O
suggests O O
that O O
specific O O
Myc O O
expression O O
levels O O
throughout O O
most O O
of O O
the O O
haematopoietic O O
hierarchy O O
are O O
controlled O O
by O O
the O O
combinatorial O O
and O O
additive O O
activity O O
of O O
individual O O
enhancer O O
modules O O
, O O
which O O
collectively O O
function O O
as O O
a O O
' O O
blood O O
enhancer O O
cluster O O
' O O
( O O
BENC O O
) O O
. O O

We O O
show O O
that O O
BENC O O
is O O
also O O
essential O O
for O O
the O O
maintenance O O
of O O
MLL O O
- O O
AF9 O O
- O O
driven O O
leukaemia B-Disease B-Disease
in O O
mice O O
. O O

Furthermore O O
, O O
a O O
BENC O O
module O O
, O O
which O O
controls O O
Myc O O
expression O O
in O O
mouse O O
haematopoietic O O
stem O O
cells O O
and O O
progenitors O O
, O O
shows O O
increased O O
chromatin O O
accessibility O O
in O O
human O O
acute B-Disease O
myeloid I-Disease O
leukaemia I-Disease O
stem O O
cells O O
compared O O
to O O
blasts O O
. O O

This O O
difference O O
correlates O O
with O O
MYC O O
expression O O
and O O
patient O O
outcome O O
. O O

We O O
propose O O
that O O
clusters O O
of O O
enhancers O O
, O O
such O O
as O O
BENC O O
, O O
form O O
highly O O
combinatorial O O
systems O O
that O O
allow O O
precise O O
control O O
of O O
gene O O
expression O O
across O O
normal O O
cellular O O
hierarchies O O
and O O
which O O
also O O
can O O
be O O
hijacked O O
in O O
malignancies B-Disease O
. O O

Robust O O
diagnosis O O
of O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
by O O
immunohistochemical O O
detection O O
of O O
super O O
- O O
enhancer O O
- O O
driven O O
EWSR1 O O
- O O
ETS O O
targets O O
. O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
is O O
an O O
undifferentiated O O
small B-Disease B-Disease
- I-Disease I-Disease
round I-Disease I-Disease
- I-Disease I-Disease
cell I-Disease I-Disease
sarcoma I-Disease I-Disease
. O O

Although O O
molecular O O
detection O O
of O O
pathognomonic O O
EWSR1 O O
- O O
ETS O O
fusions O O
such O O
as O O
EWSR1 O O
- O O
FLI1 O O
enables O O
definitive O O
diagnosis O O
, O O
substantial O O
confusion O O
can O O
arise O O
if O O
molecular O O
diagnostics O O
are O O
unavailable O O
. O O

Diagnosis O O
based O O
on O O
the O O
conventional O O
immunohistochemical O O
marker O O
CD99 O O
is O O
unreliable O O
due O O
to O O
its O O
abundant O O
expression O O
in O O
morphological O O
mimics O O
. O O

To O O
identify O O
novel O O
diagnostic O O
immunohistochemical O O
markers O O
for O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
, O O
we O O
performed O O
comparative O O
expression O O
analyses O O
in O O
768 O O
tumors B-Disease B-Disease
representing O O
21 O O
entities O O
including O O
Ewing B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
sarcomas I-Disease I-Disease
, O O
which O O
confirmed O O
that O O
CIC O O
- O O
DUX4 O O
- O O
, O O
BCOR O O
- O O
CCNB3 O O
- O O
, O O
EWSR1 O O
- O O
NFATc2 O O
- O O
, O O
and O O
EWSR1 O O
- O O
ETS O O
- O O
translocated O O
sarcomas B-Disease B-Disease
are O O
distinct O O
entities O O
, O O
and O O
revealed O O
that O O
ATP1A1 O O
, O O
BCL11B O O
, O O
and O O
GLG1 O O
constitute O O
specific O O
markers O O
for O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
. O O

Their O O
high O O
expression O O
was O O
validated O O
by O O
immunohistochemistry O O
and O O
proved O O
to O O
depend O O
on O O
EWSR1 O O
- O O
FLI1 O O
- O O
binding O O
to O O
highly O O
active O O
proximal O O
super O O
- O O
enhancers O O
. O O

Automated O O
cut O O
- O O
off O O
- O O
finding O O
and O O
combination O O
- O O
testing O O
in O O
a O O
tissue O O
- O O
microarray O O
comprising O O
174 O O
samples O O
demonstrated O O
that O O
detection O O
of O O
high O O
BCL11B O O
and O O
/ O O
or O O
GLG1 O O
expression O O
is O O
sufficient O O
to O O
reach O O
96 O O
% O O
specificity O O
for O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
. O O

While O O
88 O O
% O O
of O O
tested O O
Ewing B-Disease B-Disease
- I-Disease I-Disease
like I-Disease I-Disease
sarcomas I-Disease I-Disease
displayed O O
strong O O
CD99 O O
- O O
immunoreactivity O O
, O O
none O O
displayed O O
combined O O
strong O O
BCL11B O O
- O O
and O O
GLG1 O O
- O O
immunoreactivity O O
. O O

Collectively O O
, O O
we O O
show O O
that O O
ATP1A1 O O
, O O
BCL11B O O
, O O
and O O
GLG1 O O
are O O
EWSR1 O O
- O O
FLI1 O O
targets O O
, O O
of O O
which O O
BCL11B O O
and O O
GLG1 O O
offer O O
a O O
fast O O
, O O
simple O O
, O O
and O O
cost O O
- O O
efficient O O
way O O
to O O
diagnose O O
Ewing B-Disease B-Disease
sarcoma I-Disease I-Disease
by O O
immunohistochemistry O O
. O O

These O O
markers O O
may O O
significantly O O
reduce O O
the O O
number O O
of O O
misdiagnosed O O
patients O O
, O O
and O O
thus O O
improve O O
patient O O
care O O
. O O

Transcription O O
Factor O O
IRF8 O O
Governs O O
Enhancer O O
Landscape O O
Dynamics O O
in O O
Mononuclear O O
Phagocyte O O
Progenitors O O
. O O
Monocytes O O
and O O
dendritic O O
cells O O
( O O
DCs O O
) O O
, O O
mononuclear O O
phagocytes O O
essential O O
for O O
immune O O
responses O O
, O O
develop O O
from O O
hematopoietic O O
stem O O
cells O O
via O O
monocyte O O
- O O
DC O O
progenitors O O
( O O
MDPs O O
) O O
. O O

The O O
molecular O O
basis O O
of O O
their O O
development O O
remains O O
unclear O O
. O O

Because O O
promoter O O
- O O
distal O O
enhancers O O
are O O
key O O
to O O
cell O O
fate O O
decisions O O
, O O
we O O
analyzed O O
enhancer O O
landscapes O O
during O O
mononuclear O O
phagocyte O O
development O O
in O O
vivo O O
. O O
Monocyte O O
- O O
and O O
DC O O
- O O
specific O O
enhancers O O
were O O
gradually O O
established O O
at O O
progenitor O O
stages O O
before O O
the O O
expression O O
of O O
associated O O
genes O O
. O O

Of O O
the O O
transcription O O
factors O O
predicted O O
to O O
bind O O
to O O
these O O
enhancers O O
, O O
IRF8 O O
, O O
essential O O
for O O
monocyte O O
and O O
DC O O
development O O
, O O
was O O
found O O
to O O
be O O
required O O
for O O
the O O
establishment O O
of O O
these O O
enhancers O O
, O O
particularly O O
those O O
common O O
to O O
both O O
monocyte O O
and O O
DC O O
lineages O O
. O O

Although O O
Irf8 O O
- O O
/ O O
- O O
mononuclear O O
phagocyte O O
progenitors O O
, O O
including O O
MDPs O O
, O O
displayed O O
grossly O O
normal O O
gene O O
expression O O
patterns O O
, O O
their O O
enhancer O O
landscapes O O
resembled O O
that O O
of O O
an O O
upstream O O
progenitor O O
population O O
. O O

Our O O
results O O
illustrate O O
the O O
dynamic O O
process O O
by O O
which O O
key O O
transcription O O
factors O O
regulate O O
enhancer O O
formation O O
and O O
, O O
therefore O O
, O O
direct O O
future O O
gene O O
expression O O
to O O
achieve O O
mononuclear O O
phagocyte O O
development O O
. O O

A O O
Novel O O
Distal O O
Enhancer O O
Mediates O O
Inflammation O O
- O O
, O O
PTH O O
- O O
, O O
and O O
Early O O
Onset O O
Murine O B-Disease
Kidney B-Disease I-Disease
Disease I-Disease I-Disease
- O O
Induced O O
Expression O O
of O O
the O O
Mouse O O
Fgf23 O O
Gene O O
. O O
Fibroblast O O
growth O O
factor O O
23 O O
( O O
FGF23 O O
) O O
production O O
is O O
regulated O O
by O O
both O O
calciotropic O O
hormones O O
and O O
inflammation O O
. O O

Consistent O O
with O O
this O O
, O O
elevated O O
FGF23 O O
levels O O
are O O
associated O O
with O O
inflammatory O O
markers O O
as O O
well O O
as O O
parathyroid O O
hormone O O
( O O
PTH O O
) O O
in O O
various O O
disease O O
states O O
, O O
including O O
chronic B-Disease B-Disease
kidney I-Disease I-Disease
disease I-Disease I-Disease
( O O
CKD B-Disease B-Disease
) O O
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
underpinning O O
Fgf23 O O
transcription O O
in O O
response O O
to O O
these O O
regulators O O
are O O
largely O O
unknown O O
. O O

We O O
therefore O O
utilized O O
chromatin O O
immunoprecipitation O O
followed O O
by O O
DNA O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
data O O
from O O
an O O
osteocyte O O
cell O O
line O O
to O O
identify O O
potential O O
regulatory O O
regions O O
of O O
the O O
Fgf23 O O
gene O O
. O O

Based O O
on O O
ChIP O O
- O O
seq O O
analysis O O
of O O
enhancer O O
- O O
associated O O
histone O O
modifications O O
, O O
including O O
H3K4 O O
methylation O O
and O O
H3K9 O O
acetylation O O
, O O
we O O
discovered O O
several O O
potential O O
enhancers O O
for O O
Fgf23 O O
, O O
one O O
of O O
which O O
was O O
located O O
16kb O O
upstream O O
of O O
the O O
gene O O
' O O
s O O
transcriptional O O
start O O
site O O
. O O
Based O O
on O O
ChIP O O
- O O
seq O O
analysis O O
of O O
enhancer O O
- O O
associated O O
histone O O
modifications O O
, O O
including O O
H3K4 O O
methylation O O
and O O
H3K9 O O
acetylation O O
, O O
we O O
discovered O O
several O O
potential O O
enhancers O O
for O O
Fgf23 O O
, O O
one O O
of O O
which O O
was O O
located O O
16kb O O
upstream O O
of O O
the O O
gene O O
' O O
s O O
transcriptional O O
start O O
site O O
. O O

Deletion O O
of O O
this O O
putative O O
enhancer O O
from O O
the O O
mouse O O
genome O O
using O O
CRISPR O O
- O O
Cas9 O O
technology O O
led O O
to O O
lower O O
bone O O
, O O
thymus O O
, O O
and O O
spleen O O
expression O O
of O O
Fgf23 O O
mRNA O O
without O O
altering O O
circulating O O
levels O O
of O O
the O O
intact O O
hormone O O
, O O
although O O
as O O
previously O O
reported O O
, O O
only O O
bone O O
displayed O O
significant O O
basal O O
expression O O
. O O

Nevertheless O O
, O O
lack O O
of O O
the O O
- O O
16kb O O
enhancer O O
blunted O O
FGF23 O O
upregulation O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
by O O
the O O
acute O O
inflammatory O O
inducers O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
interleukin O O
- O O
1 O O
- O O
beta O O
( O O
IL O O
- O O
1beta O O
) O O
, O O
and O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNFalpha O O
) O O
in O O
bone O O
, O O
non O O
- O O
osseous O O
tissues O O
, O O
and O O
in O O
circulation O O
. O O

Lack O O
of O O
the O O
- O O
16kb O O
enhancer O O
also O O
inhibited O O
PTH O O
- O O
induced O O
bone O O
Fgf23 O O
mRNA O O
. O O

Moreover O O
, O O
the O O
absence O O
of O O
this O O
Fgf23 O O
enhancer O O
in O O
an O O
oxalate O O
diet O O
- O O
induced O O
murine O O
CKD B-Disease B-Disease
model O O
prevented O O
the O O
early O O
onset O O
induction O O
of O O
osseous O O
, O O
renal O O
, O O
and O O
thymic O O
Fgf23 O O
mRNA O O
levels O O
and O O
led O O
to O O
a O O
significant O O
blunting O O
of O O
elevated O O
circulating O O
intact O O
FGF23 O O
levels O O
. O O
Moreover O O
, O O
the O O
absence O O
of O O
this O O
Fgf23 O O
enhancer O O
in O O
an O O
oxalate O O
diet O O
- O O
induced O O
murine O O
CKD B-Disease B-Disease
model O O
prevented O O
the O O
early O O
onset O O
induction O O
of O O
osseous O O
, O O
renal O O
, O O
and O O
thymic O O
Fgf23 O O
mRNA O O
levels O O
and O O
led O O
to O O
a O O
significant O O
blunting O O
of O O
elevated O O
circulating O O
intact O O
FGF23 O O
levels O O
. O O

These O O
results O O
suggest O O
that O O
- O O
16kb O O
enhancer O O
mediates O O
the O O
induction O O
of O O
Fgf23 O O
by O O
inflammation O O
and O O
PTH O O
and O O
facilitates O O
the O O
increase O O
in O O
FGF23 O O
expression O O
in O O
a O O
murine O O
model O O
of O O
CKD B-Disease B-Disease
. O O

As O O
exemplified O O
herein O O
, O O
these O O
Fgf23 O O
enhancer O O
- O O
deleted O O
mice O O
will O O
provide O O
a O O
unique O O
model O O
in O O
which O O
to O O
study O O
the O O
role O O
of O O
FGF23 O O
expression O O
in O O
inflammatory B-Disease B-Disease
diseases I-Disease I-Disease
. O O
As O O
exemplified O O
herein O O
, O O
these O O
Fgf23 O O
enhancer O O
- O O
deleted O O
mice O O
will O O
provide O O
a O O
unique O O
model O O
in O O
which O O
to O O
study O O
the O O
role O O
of O O
FGF23 O O
expression O O
in O O
inflammatory B-Disease B-Disease
diseases I-Disease I-Disease
. O O

A O O
Muscle O O
- O O
Specific O O
Enhancer O O
RNA O O
Mediates O O
Cohesin O O
Recruitment O O
and O O
Regulates O O
Transcription O O
In O O
trans O O
. O O
A O O
Muscle O O
- O O
Specific O O
Enhancer O O
RNA O O
Mediates O O
Cohesin O O
Recruitment O O
and O O
Regulates O O
Transcription O O
In O O
trans O O
. O O

The O O
enhancer O O
regions O O
of O O
the O O
myogenic O O
master O O
regulator O O
MyoD O O
give O O
rise O O
to O O
at O O
least O O
two O O
enhancer O O
RNAs O O
. O O
Core O O
enhancer O O
eRNA O O
( O O
CEeRNA O O
) O O
regulates O O
transcription O O
of O O
the O O
adjacent O O
MyoD O O
gene O O
, O O
whereas O O
DRReRNA O O
affects O O
expression O O
of O O
Myogenin O O
in O O
trans O O
. O O
The O O
enhancer O O
regions O O
of O O
the O O
myogenic O O
master O O
regulator O O
MyoD O O
give O O
rise O O
to O O
at O O
least O O
two O O
enhancer O O
RNAs O O
. O O
Core O O
enhancer O O
eRNA O O
( O O
CEeRNA O O
) O O
regulates O O
transcription O O
of O O
the O O
adjacent O O
MyoD O O
gene O O
, O O
whereas O O
DRReRNA O O
affects O O
expression O O
of O O
Myogenin O O
in O O
trans O O
. O O

We O O
found O O
that O O
DRReRNA O O
is O O
recruited O O
at O O
the O O
Myogenin O O
locus O O
, O O
where O O
it O O
colocalizes O O
with O O
Myogenin O O
nascent O O
transcripts O O
. O O
DRReRNA O O
associates O O
with O O
the O O
cohesin O O
complex O O
, O O
and O O
this O O
association O O
correlates O O
with O O
its O O
transactivating O O
properties O O
. O O

Despite O O
being O O
expressed O O
in O O
undifferentiated O O
cells O O
, O O
cohesin O O
is O O
not O O
loaded O O
on O O
Myogenin O O
until O O
the O O
cells O O
start O O
expressing O O
DRReRNA O O
, O O
which O O
is O O
then O O
required O O
for O O
cohesin O O
chromatin O O
recruitment O O
and O O
maintenance O O
. O O

Functionally O O
, O O
depletion O O
of O O
either O O
cohesin O O
or O O
DRReRNA O O
reduces O O
chromatin O O
accessibility O O
, O O
prevents O O
Myogenin O O
activation O O
, O O
and O O
hinders O O
muscle O O
cell O O
differentiation O O
. O O

Thus O O
, O O
DRReRNA O O
ensures O O
spatially O O
appropriate O O
cohesin O O
loading O O
in O O
trans O O
to O O
regulate O O
gene O O
expression O O
. O O

Identification O O
of O O
Novel O O
Gata3 O O
Distal O O
Enhancers O O
Active O O
in O O
Mouse O O
Embryonic O O
Lens O O
. O O
Identification O O
of O O
Novel O O
Gata3 O O
Distal O O
Enhancers O O
Active O O
in O O
Mouse O O
Embryonic O O
Lens O O
. O O

BACKGROUND O O
: O O
The O O
tissue O O
- O O
specific O O
transcriptional O O
programs O O
during O O
normal O O
development O O
require O O
tight O O
control O O
by O O
distal O O
cis O O
- O O
regulatory O O
elements O O
, O O
such O O
as O O
enhancers O O
, O O
with O O
specific O O
DNA O O
sequences O O
recognized O O
by O O
transcription O O
factors O O
, O O
coactivators O O
, O O
and O O
chromatin O O
remodeling O O
enzymes O O
. O O
Gata3 O O
is O O
a O O
sequence O O
- O O
specific O O
DNA O O
- O O
binding O O
transcription O O
factor O O
that O O
regulates O O
formation O O
of O O
multiple O O
tissues O O
and O O
organs O O
, O O
including O O
inner O O
ear O O
, O O
lens O O
, O O
mammary O O
gland O O
, O O
T O O
- O O
cells O O
, O O
urogenital O O
system O O
, O O
and O O
thyroid O O
gland O O
. O O

In O O
the O O
eye O O
, O O
Gata3 O O
has O O
a O O
highly O O
restricted O O
expression O O
domain O O
in O O
the O O
posterior O O
part O O
of O O
the O O
lens O O
vesicle O O
; O O
however O O
, O O
the O O
underlying O O
regulatory O O
mechanisms O O
are O O
unknown O O
. O O

RESULTS O O
: O O
Here O O
we O O
describe O O
the O O
identification O O
of O O
a O O
novel O O
bipartite O O
Gata3 O O
lens O O
- O O
specific O O
enhancer O O
located O O
~ O O
18 O O
kb O O
upstream O O
from O O
its O O
transcriptional O O
start O O
site O O
. O O
RESULTS O O
: O O
Here O O
we O O
describe O O
the O O
identification O O
of O O
a O O
novel O O
bipartite O O
Gata3 O O
lens O O
- O O
specific O O
enhancer O O
located O O
~ O O
18 O O
kb O O
upstream O O
from O O
its O O
transcriptional O O
start O O
site O O
. O O

We O O
also O O
found O O
that O O
a O O
5 O O
- O O
kb O O
Gata3 O O
promoter O O
possesses O O
low O O
activity O O
in O O
the O O
lens O O
. O O
We O O
also O O
found O O
that O O
a O O
5 O O
- O O
kb O O
Gata3 O O
promoter O O
possesses O O
low O O
activity O O
in O O
the O O
lens O O
. O O

The O O
bipartite O O
enhancer O O
contains O O
arrays O O
of O O
AP O O
- O O
1 O O
, O O
Ets O O
- O O
, O O
and O O
Smad1 O O
/ O O
5 O O
- O O
binding O O
sites O O
as O O
well O O
as O O
binding O O
sites O O
for O O
lens O O
- O O
associated O O
DNA O O
- O O
binding O O
factors O O
. O O
The O O
bipartite O O
enhancer O O
contains O O
arrays O O
of O O
AP O O
- O O
1 O O
, O O
Ets O O
- O O
, O O
and O O
Smad1 O O
/ O O
5 O O
- O O
binding O O
sites O O
as O O
well O O
as O O
binding O O
sites O O
for O O
lens O O
- O O
associated O O
DNA O O
- O O
binding O O
factors O O
. O O

Transient O O
transfection O O
studies O O
of O O
the O O
promoter O O
with O O
the O O
bipartite O O
enhancer O O
showed O O
enhanced O O
activation O O
by O O
BMP4 O O
and O O
FGF2 O O
. O O

CONCLUSIONS O O
: O O
These O O
studies O O
identify O O
a O O
novel O O
distal O O
enhancer O O
of O O
Gata3 O O
with O O
high O O
activity O O
in O O
lens O O
and O O
indicate O O
that O O
BMP O O
and O O
FGF O O
signaling O O
can O O
up O O
- O O
regulate O O
expression O O
of O O
Gata3 O O
in O O
differentiating O O
lens O O
fiber O O
cells O O
through O O
the O O
identified O O
Gata3 O O
enhancer O O
and O O
promoter O O
elements O O
. O O
CONCLUSIONS O O
: O O
These O O
studies O O
identify O O
a O O
novel O O
distal O O
enhancer O O
of O O
Gata3 O O
with O O
high O O
activity O O
in O O
lens O O
and O O
indicate O O
that O O
BMP O O
and O O
FGF O O
signaling O O
can O O
up O O
- O O
regulate O O
expression O O
of O O
Gata3 O O
in O O
differentiating O O
lens O O
fiber O O
cells O O
through O O
the O O
identified O O
Gata3 O O
enhancer O O
and O O
promoter O O
elements O O
. O O

Developmental O O
Dynamics O O
247 O O
: O O
1186 O O
- O O
1198 O O
, O O
2018 O O
. O O

2018 O O
The O O
Authors O O
. O O

Developmental O O
Dynamics O O
published O O
by O O
Wiley O O
Periodicals O O
, O O
Inc O O
. O O
on O O
behalf O O
of O O
American O O
Association O O
of O O
Anatomists O O
. O O

